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Abstract 
Background: Direct reprogramming of human somatic cells to pluripotent 
embryonic stem (ES) cell -like cells, termed induced pluripotent stem (iPS) cells, 
can be achieved by expression of defined transcription factors. The potential 
use of iPS cells derived from the urinary tract provides a substantial opportunity 
in developing new disease models, drug screening and tissue engineering. We 
aimed to generate, for the first time, human induced pluripotent stem cells 
derived from the urinary tract (UT-iPS) cells and to assess capacity for directed 
differentiation into bladder lineages.  
Methods: Human primary culture cells derived from benign bladder and ureters 
were transduced with OCT4, SOX2, KLF4 and C-MYC genes to generate 
human UT-iPS cells. Generated cells were characterised using RT-PCR and 
immunofluorescence. Differentiation capacity was evaluated by embryoid body 
formation in vitro and teratoma assay in vivo. Established co-culture based 
directed differentiation into bladder cells was assessed in comparison with 
classical skin-derived iPS cells. 
Results: We demonstrated successful re-programming of adult urinary tract 
cells from both bladder and ureter into human UT-iPS cells. Most of the clones 
showed efficient transgene silencing and maintained a normal diploid karyotype. 
Specifically, we showed expression of ES cell markers and functional 
pluripotency by the generation of endodermal, ectodermal and mesodermal 
lineages. Differentiation into bladder lineages was demonstrated by expression 
of urothelial-specific markers, uroplakins (UPIb, UPII, UPIIIa, and UPIIIb), 
claudins (CLD1 and CLD5) and cytokeratin (CK7); and stromal smooth muscle 
markers a-SMA, calponin, and desmin. Human UT-iPS cells were shown to be 
more efficient than skin-derived iPS cells in undergoing bladder differentiation, 
underlining the importance of the origin of the parent cell for re-programming.  
Conclusions: We demonstrated that the induction of human urinary tract cells 
into iPS cells is possible, offering a new exciting opportunity for tissue 
engineering and for the study of bladder disease. 
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1 Chapter 1. Introduction 
1.1 Clinical need for bladder reconstruction 
The normal function of the bladder and associated structures of the lower 
urinary tract may be diseased for many reasons and people from all races, ages 
and ethnic groups suffer from poor quality of life even with access to the best 
medical care. Some conditions are primary congenital abnormalities and 
become lifelong health concerns of the genitourinary system. The most 
common birth abnormalities include hypospadias, where the urethral opening 
develops inferior to its normal location, and bladder exstrophy, where the 
bladder develops on the outer surface of the abdomen. These conditions have a 
considerable impact on social and psychological development. Secondary 
conditions are much more common and create acute and chronic medical 
problems such as bladder malignancies, trauma and neuropathy (Atala, 2008; 
Ferlay et al., 2008) and are a leading cause of urinary symptoms (including 
incontinence), kidney failure, pelvic pain, urinary tract infection and death.  
In particular, carcinoma of the bladder is a significant clinical problem that is a 
common and a serious healthcare problem throughout the world. Recent 
statistics estimate that over 380,000 persons are diagnosed with the disease 
worldwide each year (Ferlay J, 2010). In the UK, bladder cancer ranks as the 
fourth and eleventh most frequently diagnosed cancer in men and women, 
respectively. It is estimated that about 10,300 cases are diagnosed each year, 
and 4,500 patients die annually, that is around 96 people every week (CRUK-
CancerStats, 2010). Bladder cancer is typically seen in people over 65, with an 
incidence nearly four times higher in men than in women. Histologically, the 
majority of bladder cancer patients present with transitional cell carcinoma 
(TCC, 90%), whilst 5% present with squamous cell carcinoma (SCC) and less 
than 2% with adenocarcinoma (Bladder cancer statistics July 2008 ). To 
determine the stage of bladder cancer, many factors must be considered; how 
deeply the tumour is and whether it has invaded the bladder wall (T-staging) 
(Figure  1-1), the presence of tumour in the lymph nodes (N-staging), and 
whether there are any metastases (M-staging) (Barentsz et al., 1993; MacVicar, 
2000). TCC presents as non-muscle invasive disease (superficial), i.e. (stage 
Tis, Ta, T1) in nearly 80% of patients, and as muscle invasive (stage T2) or 
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extravesical bladder invasive (stage T3-4) in the remaining 20% (Kirkali et al., 
2005; Said and Theodorescu, 2009). Approximately 80% of patients with 
superficial transitional cell malignancy survive the disease for at least five years 
after diagnosis, however, with invasive tumours, the overall survival rate is 
approximately 50% even when aggressive multimodal treatments are combined 
(Crawford et al., 1991; de Wit, 2003). The verities of health problems associated 
with the bladder highlights the urgent need to expand bladder health-related 
research and to develop better management, and treatment of bladder 
diseases.  
 
 
 
Figure  1-1: Stages of Urinary Bladder Cancer. Tis: Carcinoma in situ, Ta: 
cancer is just in the innermost layer of the bladder lining, T1: cancer limited to 
lamina propria, T2: cancer invades the muscle, T3: cancer has grown through 
the muscle into the fat layer, T4: cancer has spread outside the bladder. 
Modified from (Bladder cancer stage and grade, 2013) 
 
Currently, using gastrointestinal segments of the patient’s own intestine, also 
termed Enterocystoplasty is the most commonly performed procedure for 
bladder replacement or repair (Bolland and Southgate, 2008). However, 
because the bladder and intestine have different functions, this procedure has 
been associated with multiple complications such as infection, stone formation, 
metabolic disturbances, and malignancy (Atala et al., 1993; Ali-El-Dein et al., 
2002). Therefore, new regenerative methods and also new models (human 
specific tools that accurately reflect normal physiology) to study disease 
initiation and progression are required.  
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1.2 Embryology of the lower urinary tract 
To better understand normal and pathologic function of the lower urinary tract it 
is important to understand its embryology. In human development, the 
blastocyst, a structure containing an inner cell mass (ICM) and formed five days 
after fertilisation, gives rise to all three germ layers of the embryo (Figure  1-2). 
By the second week of gestation, the ectoderm and the endoderm are 
developed from the ICM and by week three, a third layer called mesoderm 
develops in between the previous two layers (Sadler, 1985). It is from the 
mesoderm and endoderm germ layers that the bladder develops. 
 
 
Figure  1-2: Schematic diagram showing the development of the germ layers. By 
the second week of gestation the inner cell mass differentiates to form two cell 
layers: ectoderm (green) and endoderm (red). During the 3rd week of gestation, 
a third layer, mesoderm (blue) develops in between the ectoderm and 
endoderm. 
 
3.1.1 Development of the bladder 
The cloacal membrane is formed at the caudal end of the embryo, differential 
growth of the mesenchyme near the cloacal membrane leads to the generation 
of the cloaca, which is a chamber formed by folding the caudal end of the 
embryo onto itself. Between the 4th and the 7th week of gestation, the urorectal 
septum grows caudally dividing the cloacal membrane into the urogenital 
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membrane and the anal membrane, and the cloaca into the urogenital sinus 
and the rectum. From this point the urogenital sinus can be divided on 
morphological basis into three sections. The first and largest section will form 
the urinary bladder. The second and pelvic section will form the prostatic and 
membranous urethra in males and the third section will form the urethra and the 
external genitalia (Figure  1-3) (Stephens, 1963; Schick, 2008). The 
mesonephric duct develops from the mesoderm adjacent to the coelom, called 
the primitive peritoneum. Once the mesonephric duct extends caudally to reach 
the urogenital sinus, a diverticulum grows cranially from the mesonephric duct 
forming the ureteric bud. The excretory duct is formed from stretching the 
mesonephric duct and merge together to form the primitive trigone. However, it 
has been suggested that the trigone may be formed through vitamin A-mediated 
apoptosis of the common nephric duct rather than fusion of the mesonephric 
ducts but (Batourina et al., 2005; Viana et al., 2007) other reports also 
suggested the endodermal origin of the trigone rather than the mesodermal 
origin (Oswald et al., 2006; Tanaka et al., 2010). 
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Figure  1-3: Schematic diagram showing the development of the bladder. During 
gestational week 4, the urorectal septum divides the cloaca into the urogenital 
sinus and the rectum. During gestational week 7, the urogenital sinus can be 
further subdivided into three sections. The first and largest section will form the 
urinary bladder. The second and pelvic section will form the prostatic and 
membranous urethra in males and the third section will form the urethra and the 
external genitalia. 
 
Around the 6th week of gestation, the urogenital sinus expands cranially to form 
the primitive bladder and caudally to form the future prostate, urethra, and 
external genitalia. At this stage, the bladder wall is composed primarily of 
connective tissue. However, by the 17th week of gestation, the bladder has 
three muscle layers: inner and outer longitudinal layers, and a middle circular 
layer. The urothelium also undergoes extensive development during this time. 
21 
 
The urothelium of the bladder wall, excluding the trigone and the urethra is 
thought to be derived from the endodermal layer, while the urothelium of the 
renal pelvis, ureter, and trigone region of the bladder (the area of the bladder 
that forms a triangle between the insertion of the two ureters and the point 
where the urethra begins) is derived from the mesodermal layer. However, 
histologically, the urothelium derived from mesoderm is indistinguishable from 
that derived from endoderm. In addition, no significant cellular, structural and 
functional differences are found among the urothelial cells of different regions of 
the urinary tract (Staack et al., 2005). The urothelium differentiates gradually 
starting from a simple cuboidal epithelium with smooth luminal surface and 
continues to end with a stratified transitional epithelium with asymmetric unit 
membrane plaques and mature fusiform vesicles (Staack et al., 2005; Ersoy et 
al., 2006).  
3.1.2 Anatomy of the post-natal human bladder 
The lower urinary tract (LUT) consists of two ureters, the bladder, and the 
urethra and is responsible for the storage and evacuation of the urine. Urine 
comes from the kidneys through two ureters which measure from 25 to 30 cm in 
length and have a tubular structure that begin at the renal pelvis, pierce the 
posterior wall of the bladder, and run indirectly through it for about 2 cm at the 
level of the vesico–ureteral junction. Crossing the bladder wall obliquely is 
believed to work as a valve mechanism, and prevents the ureteric reflux during 
increases in bladder pressure. The wall of the ureter has two distinct layers of 
smooth muscle: an inner, longitudinal and an outer, circular layer. The bladder 
is a balloon-like organ that stores and expels urine. The normal capacity of the 
bladder is about 400ml of urine. When the bladder is filled, it sends a signal 
through the nerves to the brain that the bladder is getting full. When the signal 
comes back from the brain to void, the detrusor muscle in the bladder contracts 
and the sphincter relaxes to push the urine through the urethra and out of the 
body. From an inside view, three distinct orifices in the bladder wall that delimit 
the trigonal region of the bladder can be observed: two ureteral orifices and the 
internal urethral orifice (Lang et al., 2006; Drake, 2007; Clare J. Fowler, 2008). 
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I. The detrusor muscle 
Functionally, the bladder has a complex imbrication of smooth muscle fibres for 
efficient bladder emptying and elasticity that permits low-pressure urine storage. 
Anatomically, the wall of the bladder consists of three smooth muscular layers 
called the detrusor muscle. The lumen of the bladder is covered by a layer of 
transitional epithelium, called the urothelium. Deep to this, a thick layer of 
connective tissue traversed by numerous capillaries, lymph vessels, and nerves 
called lamina propria lies between the urothelium and the detrusor muscle. This 
layer provides the bladder with a highly variable shape and allows it to expand 
and collapse during filling and emptying (Haab F, 2001; Schick, 2008). 
II. The urothelium  
The majority of the urinary tract, including the renal pelvis, ureters, bladder, and 
proximal urethra is lined by transitional epithelium that occurs nowhere else in 
the body, also known as “Urothelium”. The urothelium consists of a basal, 
intermediate, and a superficial cell layer (Lewis, 2000). Although similar to 
epithelial cells in other type of tissues, the urothelium has unique properties. In 
addition to its role as a highly effective barrier between the urine and the 
underlying connective tissue, the urothelium  modulates the movement of ions, 
solutes, and water across the mucosal surface of the bladder, and protects the 
underlying tissue from pathogens (Hicks, 1975; Marceau, 1990; Limas, 1993; 
Baskin et al., 1997; Apodaca, 2004). Furthermore, it has been reported that the 
smooth muscle layers under the urothelium need an epithelial signal to 
differentiate from the mesenchyme (Baskin et al., 1996; Cao et al., 2008). 
3.1.3 Urothelial histology 
Typically, the urothelium is composed of three cell layers: basal, intermediate, 
and umbrella superficial cell layer (Figure  1-4) (Lewis, 2000; Apodaca, 2004). 
The basal layer is found immediately above the basement membrane and 
consists of a single layer of small (with diameters of ~10μm) and polygonal 
cells. The intermediate cells are pyriform (10–25 μm in diameter) and can form 
numerous cell layers. The luminal surface of the bladder is lined by a single 
layer of cuboidal, large (25–250 μm in diameter), occasionally multi-nucleated, 
and terminally differentiated cells (known as umbrella or superficial cells) with 
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distinct apical and basolateral membrane domains demarcated by tight 
junctions. The morphology and size of these cells are changed according to the 
filling condition of the bladder. In empty bladders, umbrella cells are roughly 
cuboidal, whilst in filled bladders, these cells become stretched (Truschel et al., 
2002; Acharya et al., 2004; Varley et al., 2006; Khandelwal et al., 2009).  
The scalloped appearance of the apical surface of umbrella cells which 
comprises of raised hinges (also called micro-plicae) and intervening regions 
called plaques are considered one of the most identifiable features of umbrella 
cells (Hicks, 1965; Kachar et al., 1999). Urothelial plaques provide the 
urothelium with a very high transepithelial electrical resistance making the 
urothelium a very constant permeability barrier with inherent flexibility to 
accommodate significant changes in surface area (Lewis and de Moura, 1982; 
Wu et al., 2009; Ho et al., 2012). In the plaque regions, the luminal leaflet of the 
plasma membrane is twice as thick as the cytoplasmic leaflet, forming an 
asymmetric unit membrane (AUM) (Porter et al., 1967; Romih et al., 2005). 
These AUM plaques are formed mainly by the interactions between a family of 
transmembrane proteins called uroplakins (UPs) (Wu et al., 1990; Wu and Sun, 
1993; Southgate et al., 1994; Wu et al., 1994; Southgate et al., 1999a; Truschel 
et al., 1999).  
The intermediate cell layer exists directly under the umbrella cell layer and 
comprises of variable cell layers of pear-shaped cells. These cells are 
connected to each other, to the upper layer, and to the basal cell layer by 
desmosomes (Hicks, 1975; Jost et al., 1989). Notably, the intermediate cells 
just below the superficial cells are partially differentiated, can also express UPs 
and have the ability to rapidly differentiate in case of the loss of the superficial 
cells (Martin, 1972; Hicks, 1975). The basal cell layer includes a single layer of 
mononucleate cells connected to a continuous basement membrane by 
hemidesmosomes (Southgate et al., 1994; Jones, 2001; Southgate et al., 2007; 
Khandelwal et al., 2009; Wu et al., 2009) 
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 Figure  1-4: Diagram showing that the urothelium expands to cover the renal 
pelvis, ureters, and bladder (red). Bladder urothelium: A three-layered 
epithelium is apparent, consisting of large, binucleated superficial cells overlying 
an intermediate and a basal cell layer. This is separated by a basement 
membrane from a suburothelial layer that contains blood vessels, nerves and 
myofibroblasts. 
 
3.1.4 The urothelium differentiation  
The urothelium expresses various types of cytokeratins (CKs) (Moll et al., 1988; 
Schaafsma et al., 1989; Southgate et al., 1999b; Romih et al., 2005). 
Immunohistochemical analysis of normal human urothelium has shown that 
cytokeratin 13 is expressed in both intermediate and basal layers, whereas 
cytokeratin 5, 10, and 17 are only expressed by the basal cells (Figure  1-5). All 
urothelial layers express cytokeratin 7, 8, 18, and 19, whereas cytokeratin 20 is 
restricted to the fully differentiated umbrella cells (Moll et al., 1988; Southgate et 
al., 1999a; Southgate et al., 1999b; Romih et al., 2005; Varley et al., 2006; 
Southgate et al., 2007).  
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 Figure  1-5: Distribution of various types of CKs in the urothelium layers 
 
Another panel of urothelial differentiation markers are the UPs, a group of 
integral transmembrane proteins that design AUM plaques. As mentioned 
before, five types of UPs (UPIa, UPIb, UPII, UPIIIa, and UPIIIb) have been 
described and their expression provides excellent markers for studying the 
urothelial differentiation as they are only expressed in urothelial cells during 
advanced stages of differentiation (Wu et al., 1994; Yu et al., 1994; Olsburgh et 
al., 2003; Romih et al., 2005; Wu et al., 2009).  
The UP proteins have many functions, contributing towards the barrier and 
permeability to enable solute and water to flow across the apical membrane (Hu 
et al., 2002). UPs are also targets of bacterial and fungal toxins (Zhou et al., 
2001). In normal human urothelium UPIa, UPII, UPIIIa, and UPIIIb are only 
expressed in umbrella cells (Figure  1-6); while UPIb is found in intermediate 
cells suggesting that UPIb expression might be correlated with less 
differentiation (Lobban et al., 1998; Olsburgh et al., 2003).  
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 Figure  1-6: Distribution of selected uroplakins in the normal urothelium. 
 
The paracellular barrier function of the urothelium is controlled by intercellular 
tight junctions located between juxtaposed umbrella cells. These tight junctions 
consist of cytoplasmic plaque proteins, the zonular occludens (ZO), that 
connect the tight junction to the cytoskeleton and integral transmembrane 
proteins, such as occludins, junctional adhesion molecule (JAM) and claudins 
(Varley and Southgate, 2008).  
Claudins are a group of 24 proteins, which regulate the paracellular transport 
and are involved in the structure of the tight junctions of all epithelial cells 
(Kiuchi-Saishin et al., 2002). In 2006, Varley et al (Varley et al., 2006) examined 
the expression of claudins in human urothelium using probes for claudin-1 to -
10 and found that human ureteric urothelium expressed claudin-3, 4, 5, and 7, 
whilst the basolateral surface of the umbrella cells layer expressed claudin-5. 
Also, claudin-4 was distributed at the intercellular borders of all urothelial cell 
layers (Figure  1-7).  
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 Figure  1-7: Distribution of various types of claudins in the urothelium layers. 
 
1.3 Urinary bladder replacement and tissue engineering strategies  
Diseased urinary tract may require either replacement or augmentation, usually 
with bowel segments as the current mainstay of treatment. Although this 
procedure can improve bladder capacity and continence, incorporating bowel 
into the urinary tract can be associated with several relatively common and 
potentially serious complications such as low grade bacteriuria, stone formation, 
and malignant transformation (Bolland and Southgate, 2008) as the intestinal 
lining is not adapted to prolonged contact with urine (Turner et al., 2011). 
Experimental animal models have shown that even augmentation with de-
epithelialised bowel segments is associated with fibrosis and shrinkage (Bolland 
and Southgate, 2008). These observations suggest that the ideal material would 
be the use of urothelium and the compliance afforded by its associated stroma 
containing smooth muscle. The use of native cells has been explored in a 
number of experimental approaches involving ex vivo expansion of autologous 
cells that would avoid rejection. The main strategies include engraftment of 
urothelium onto de-epithelialised bowel (composite enterocystoplasty) or 
engraftment of both urothelial and smooth muscle stromal cells into acellular 
biomaterials such as for reconstruction (Turner et al., 2011).  
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3.1.5 Composite enterocystoplasty: 
Composite enterocystoplasty is a cell engineering approach in which the bowel 
epithelium is replaced with an in vitro -generated autologous urothelium 
therefore enabling utilisation of the available vascularised and compliant smooth 
muscle of the bowel. However, preclinical models of composite 
enterocystoplasty show that this technique can be compromised by graft 
contraction and poor urothelial coverage (Fraser et al., 2004). 
3.1.6 Biomaterials and Cell-seeded constructs 
Biomaterials can be either natural or synthetic (Grise, 2002). The outcomes of 
the incorporation of synthetic materials such as polyglycolic acid (PGA), 
polyethylene and polyvinyl into the bladder have been unfavorable due to 
biomechanical failure or biological incompatibility resulting in recurrent infection, 
scar generation and urinary stone formation (Elbahnasy et al., 1998). Natural 
tissue matrices derived from various types of tissue, including small intestinal 
submucosa (SIS), porcine dermis (Kimuli et al., 2004), and the urinary bladder 
itself have been developed and investigated in both in vitro and in vivo settings. 
In animal models, using SIS bioscaffold for bladder regeneration resulted in 
rapid cellular infiltration with the resultant tissue similar to that of the native 
organ. However, the level of the bladder damage appears to affect the success 
of bladder reconstruction using SIS (Zhang et al., 2006).  Bladder acellular matrix 
grafts (BAMG) are naturally derived from dissected split thickness bladders and 
also from full-thickness bladders. Previous studies using BAMG in animal 
bladder studies have demonstrated their bladder regeneration potential. 
However, the use of this matrix has been associated with many problems 
including poor vascularisation, graft shrinkage and incomplete or disorganised 
smooth muscle development (Bolland and Southgate, 2008). In 2006, Atala and 
colleagues reported the first human clinical trial with engineered bladders, using 
autologous cells onto biomaterials (Atala et al., 2006). However, these 
strategies rely on ex vivo cell culture to generate sufficient quantities and quality 
of autologous cells and patients with tissue loss and end-organ cellular damage 
are not ideal candidates. Although even small biopsies of normal urothelium can 
be readily expanded before undergoing senescence, this is significantly 
restricted in diseased tissue (Subramaniam et al., 2011). Moreover, the use of 
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this material may be inherently compromised by the disease itself and in the 
case of malignancy the use of macroscopically normal urothelium would be of 
concern due to genetically primed field-characterisation affecting the entire 
bladder (Jones et al., 2005). Given the limitations described, increasing 
attention has focussed on the use of stem cells that may provide a more readily 
expandable source of cells with their ability for sustained self-renewal (Becker 
and Jakse, 2007). 
1.4 Stem cells and urinary bladder tissue regeneration  
3.1.7 Stem cells 
The ability to continually self-renew through mitosis and to specialize to a 
certain tissue makes stem cells unique. Based on their ability to grow and their 
potential to generate differentiated cell types, stem cells can be classified as: (a) 
totipotent stem cells, which exist at the earliest stage of organism development 
(fertilized egg, zygote and the first 2, 4, 8, 16 blastomeres from the early 
embryo), and are capable to form all three major germ layers required for 
embryo development (ectoderm, endoderm, and mesoderm) as well as the 
extra-embryonic tissues, such as the placenta, (b) pluripotent stem cells derived 
from the ICM of the blastocyst and have the potential to generate any of the 
three germ layers, but they are unable to produce extra-embryonic tissues,(c) 
multipotent stem cells are observed later in development and have the ability to 
form a small number of tissues, multipotent stem cells are necessary for tissue 
renewal and believed to exist in all adult tissue and (d) unipotent stem cells 
which reside in adult organisms and give rise to just one cell type under normal 
conditions (Wagers and Weissman, 2004). Based on their source of origin, stem 
cells are also categorized into embryonic or adult stem cells. 
1.4.1.1 Stem cells derived from early embryos  
Embryonic stem (ES) cell research began with the study of spontaneous 
tumours that occur in the testes or ovaries of certain strains of mice and arise 
from the germ cells, known as teratocarcinomas. Histological analyses revealed 
a mixture of tissues derived from the three embryo germ layers such as bone, 
skin, and muscles. In the 1970s, Stevens found that embryos from the 
blastocyst grafted into ectopic sites in host mice could also form spontaneous 
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teratocarcinomas (Stevens, 1970). These spontaneous tumours contain many 
kinds of embryonic, immature, and adult tissues. They realized that the small 
population of undifferentiated cells in the tumour mass termed embryonal 
carcinoma (EC) cells were mainly responsible for growth of teratocarcinomas. 
These cells are pluripotent stem cells that can proliferate indefinitely and 
differentiate in culture into derivatives of the three germ layers even after serial 
transplantation (Stevens, 1970; Martin, 1981). Although EC cells could 
contribute to the development of completely normal adult mice when introduced 
into blastocyst-stage embryos (Brinster, 1974; Papaioannou et al., 1975), these 
cells maintained a tumour generating phenotype and showed phenotypic and 
chromosomal aberrations (Solter et al., 1970). A need for non-cancer derived, 
pluripotent cells that could be used for developmental studies and clinical 
applications was necessary. In 1981, pluripotent cells were successfully isolated 
directly from the ICM of pre-implantation mouse embryos by two independent 
laboratories. These cells were termed mouse embryonic stem (ES) cells to 
distinguish their origin from EC cells derived from teratocarcinomas (Evans and 
Kaufman, 1981; Martin, 1981).  
Like mouse ES cells, human ES cell lines were first isolated from the ICM of 
pre-implantation embryos in 1998 (Thomson and Marshall, 1998). Significantly, 
in the unmanipulated embryo, cells from the ICM function as precursor cells, but 
not as stem cells as they have limited life-spans before they become committed 
to form the primary germinal layers. However, these cells can maintain their 
features and self-renew as undifferentiated cells when maintained in optimal 
conditions (Martin, 1981; Thomson and Marshall, 1998).  
Human ES cell lines have also been derived from parthenogenetic embryos (Lin 
et al., 2007), single- cell blastomeres (Chung et al., 2006) earlier stage embryos 
(morula) (Strelchenko et al., 2004) and later blastocyst embryos (Stojkovic et 
al., 2004). The ability of transplanted gonadal ridges to form teratocarcinomas 
suggested that ES–like cells could be isolated from primordial germ cells before 
they differentiated to specialized gametes. Subsequently, embryonic germ (EG) 
cell lines were derived from murine (Matsui et al., 1992; Resnick et al., 1992) 
and human (Shamblott et al., 1998) primordial germ cells prior to their migration 
in gastrulating embryos or following their arrival in the genital ridges. Like ES 
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cells, these pluripotent cell lines have the ability to differentiate in vitro and in 
vitro (Rohwedel et al., 1996), as well as the ability to contribute to the germ line 
of chimeric mice (Stewart et al., 1994). These observations indicate that the 
germline lineage maintains the capacity to establish pluripotent cells. Indeed, 
pluripotent stem cells were isolated from spermatogonial cells of newborn and 
adult mice. Analysis of mouse spermatogonial stem cells demonstrated that 
they have the morphology of ES-like cells, express the pluripotency marker 
genes, induce mature teratomas after transplantation into nude mice and form 
germline chimeras in vivo (Kanatsu-Shinohara et al., 2004; Guan et al., 2006).  
1.4.1.2 Adult stem cells 
Adult stem cells (or somatic stem cells) are undifferentiated cells that are found 
in a differentiated tissue. Adult stem cells are mostly multipotent cells, and tend 
to be tissue specific. Their primary function is to maintain and repair the organ 
system in which they exist because they are able to renew themselves during 
the lifetime of the organism and to generate differentiated daughter cells. Of 
these, the most studied are haematopoietic stem cells isolated from bone 
marrow (de Haan, 2002), and mesenchymal stem cells isolated from bone 
marrow stroma (Kim and Cho, 2013). Within the last decade many other types 
of tissue-specific stem cells have been identified and studied in detail such as 
retina (Tropepe et al., 2000), brain (Okano, 2002), skin (Watt, 2001), pancreas 
(Ramiya et al., 2000), and prostate (Bhatt et al., 2003; Richardson et al., 2004). 
Adult stem cells can be found in a specific microenvironment in each organ 
known as the “niche” which has been proposed to regulate their behaviour. 
Unfortunately, only low numbers of adult stem cells can be found in each tissue 
and once removed from their normal cellular environment they lose their 
capacity to divide continually (Yoshida et al., 2007); the reason why propagation 
of adult stem cells in culture is still challenging. Typically, adult stem cells 
generate intermediate cell types (precursor or progenitor cells) which in turn 
divide and give rise to fully differentiated cells (Marcus and Woodbury, 2008). In 
most tissues, adult stem cells may remain in a metabolically quiescent state for 
long periods of time before they are triggered by tissue injury. However, even in 
normal situations they constantly generate new cells to maintain tissues. 
Isolation and characterization of tissue-specific stem cells has been possible 
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through the use of a variety of methods to track cell fate in vivo or in vitro. Of 
these, the most fundamental tools are fluorescence-activated cell sorting 
(FACS) and monoclonal antibody production (Spangrude et al., 1988; Baum et 
al., 1992), while methods of in vivo lineage tracing include the incorporation of 
DNA nucleoside analogs and cellular marking through genetic reporter 
strategies. 
The classification into embryonic or adult stem cells is very important due to the 
ethical issues associated with the destruction of an embryo to harvest cells and 
to use in research. Although adult stem cells are identified to be restricted in 
their potency by the tissue from which they arose, there is a hot debate in the 
literature about this idea. During the last decade, it has been suggested that 
these cells are inherently plastic, purporting that under certain conditions, adult 
stem cells may be much more flexible than previously envisioned and they 
could cross boundaries to differentiate into cells of unrelated tissue. This 
phenomenon is referred to as trans-differentiation and has been reported for a 
variety of cell types. For example, neural stem cells isolated from cloned mice 
show the ability to differentiate into all cell types of haematopoietic lineage 
(Bjornson et al., 1999), and haematopoietic stem cells can differentiate into liver 
cells (Petersen et al., 1999). Haematopoietic stem cells and mesenchymal stem 
cells have also been reported to possess the ability to give rise to non-
haematopoietic cells such as muscle, liver, and lung (Quesenberry et al., 2010). 
More recently, other studies have suggested that this process is a result of 
fusion between implanted cells and host somatic/precursor cells instead of 
actual trans-differentiation. Hence, the exact molecular mechanisms 
responsible for this phenomenon are poorly understood (Nygren et al., 2004; 
Gruh and Martin, 2009; Jopling et al., 2011; Peran et al., 2011).  
Although adult stem cells do not require the destruction of an embryo and can 
be used in autologous therapies, there are challenges involved in employing 
them in a wider field. Principally, these cells are usually present in a very limited 
numbers within the adult organs and isolating and purifying them has also 
proven to be quite challenging (Mimeault and Batra, 2008). In addition, great 
difficulty has been encountered in maintaining and expanding long term 
cultures. 
33 
 
1.4.1.3 Bladder urothelial stem cell 
Urology is lagging behind other fields in terms of stem cell research. While the 
characteristics and location of stem cells in other organs and tissues have been 
well known for years, and those cells have been cultured, expanded, and even 
differentiated, the isolation, morphological and biochemical characterization of 
urinary tract stem cells has not yet been possible. In the case of the urothelium, 
this may be due to the fact that it is a poorly understood epithelium: very few 
biochemical markers of differentiation have been found, and the growth 
regulation mechanisms are not known. It is only recently that research has 
explored the possible applications of stem cells in the urology field  and a 
number of studies now support the existence of urothelial stem cells (Pastor-
Navarro et al., 2010).  
The mature urothelium renews itself very slowly with turnover interval being 
estimated as up to 12-24 weeks (Jost, 1989; Khandelwal et al., 2009). However, 
the urothelium shows remarkable ability to proliferate and regenerate itself 
following injury or pathological damage resulting in its very rapid and full 
restoration (Kreft et al., 2005; Mysorekar et al., 2009). Furthermore, several 
studies report the plasticity of urothelial cells to undergo different patterns of 
differentiation (Kvist et al., 1992; Staack et al., 2005). Overall, the presence of 
resident committed urothelial progenitor or stem cell populations has been 
suggested. 
Epithelial stem cells have been found to reside in a specialized and well-
protected geographical niche that may reduce their exposure to trauma. For 
example, corneal stem cells are found to reside in the basal layer of the limbus, 
sequestered in the peripheral cornea (Cotsarelis et al., 1989; Pellegrini et al., 
2001; Majo et al., 2008). In the epidermis, stem cells are found at the bottom of 
the hair follicles in area called ’the bulge’ (Oshima et al., 2001; Morris et al., 
2004). However, in the case of the urothelium, the exact location of urothelial 
stem cells has not been identified. 
A particularly powerful method to identify the location of stem cells takes 
advantage of their slow-cycling characteristics (Potten and Morris, 1988; 
Terskikh et al., 2012). Once stem cells are exposed to labelled nucleosides, 
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such as 3H-thymidine or 5-bromo-2'-deoxyuridine (BrdU), they retain that label 
for a long period of time, while the more rapidly-cycling cells incorporate the 
label faster, mature, and die. Thus, these slowly cycling cells known as label 
retaining cells (LRC) are thought to represent the stem cell subpopulation. 
Using this technique, stem cells have been identified in the bulge region of the 
hair follicle (Watt et al., 2006), the limbus of the cornea, the endometrium of the 
uterus, the crypts of intestine, and the proximal region of prostatic ducts 
(Bickenbach, 1981; Chan and Gargett, 2006). Recently, Kurzrock et al have 
adapted this technique and pulse-chased labelled rats with BrdU (Kurzrock et 
al., 2008). One year after the administration of BrdU, 9% of bladder urothelium 
basal cells retained the label. Further analyses of this bladder LRC population 
indicated that these cells are characterized by small size (5–10 µM), low 
granularity, high β4 integrin expression and superior clonogenic and 
proliferative ability compared with unlabelled epithelial cells. Furthermore, these 
cells specifically expressed cytokeratin 5 and 6, which are basal cell-specific 
markers in the lung, prostate, and other epithelia cells. However, the ability of 
these LRC to differentiate into urothelial cells remains to be proven.  
Consistent with this result, Gaisa et al. used naturally occurring mitochrondrial 
DNA mutations as markers of clonal expansion in an attempt to identify the 
location of the urothelial stem cell niche in humans. In this study, the authors 
identified patches of intermediate and umbrella cells that had been extended 
from monoclonal proliferative units originated in basal cells. However, 
superficial cells could not be identified in all monoclonal proliferative units 
(Gaisa et al., 2011). Moreover, in vivo lineage tracing studies in mice suggested 
that basal cells of the urothelium may contain stem cells that can give rise to all 
other layers (Shin et al., 2011). These data from rodents and humans support 
the urothelial stem cell to localise within the basal layer. However, controversial 
data have recently been obtained using LRC method with a different synthetic 
nucleoside-5-ethynyl-2- deoxyuridine (EdU) to identify potential stem cells in 
neonatal rat bladders. In this study, the distribution of the LRC in the urothelium 
was mostly random with no clear preferential labelling of basal cells (Zhang et 
al., 2012). One possible explanation could be the differences in labelling 
efficiency and chase period. Also the identification of BrdU – label retaining cells 
is technically challenging and thus prone to error. In addition, finding that 
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umbrella cells are capable to divide suggested that they may represent another 
pool of stem cells in the urothelium (English et al., 1987; Evans and Chandler, 
1987).  
One such study by Signoretti et al. used the p63-/- mouse as a tool to study 
urothelial development. p63, also known as transformation-related protein 63 is 
a well-documented marker of basal and intermediate cell layers of bladder 
urothelium (Yang et al., 1998). In this study, bladders of p63 deficient chimera 
only contained umbrella cells suggesting that functional p63 basal cells are not 
required for the development of umbrella cells (Signoretti et al., 2005). Further 
support to the hypothesis that basal cells are not the only origin of urothelial 
stem cells that can give rise to mature urothelial cells came from another study 
which reported the development of abnormal urothelium containing only 
umbrella cells in adult bladders of p63-null mice. Notably, these cells were 
positive for uroplakin II expression (Karni-Schmidt et al., 2011; Ho et al., 2012). 
An original study by Nguyen et al. (Nguyen et al., 2007) demonstrated that cells 
harvested from rat caudal bladder segments have significantly higher colony-
forming efficiency than those from cephalic bladder segments, suggesting that 
more clonogenic cells exist in the lower bladder. On the other hand, Ki-67 
staining showed no geographical difference in cell proliferation under normal 
homeostatic in vivo conditions. Although these data demonstrated that 
progenitor cells distribution pertains to a region, the authors argued that this 
does not necessarily reflect a stem cell niche and the proliferative capacity 
presented in vitro might be caused by transit amplifying population, which is still 
undefined in the urothelium.  
Further evidence for the existence of urothelial stem cells comes from in vivo 
studies that have characterized a population of spheroids obtained from human 
bladder specimens with self-replicative potential, termed bladder spheres. 
Spheroids were mechanically dissociated into single cells and re-plated to 
produce secondary cultures. This procedure was repeated every week for 2 
months and most of the cultures maintained a good proliferation rate implying 
that they might represent a stem cell population in the bladder (Fierabracci et 
al., 2007). Zhang et al have recently described the isolation of a progenitor cell 
population (About 0.2%) from urine specimens, termed urine-derived progenitor 
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cells (UPCs) (Zhang et al., 2008). These UPCs can be induced to undergo 
multilineage differentiation into urothelial, smooth muscle and even endothelial 
and interstitial cells. In addition, these UPCs express stem/progenitor cell 
markers, such as c-Kit (interstitial stem cell marker), and SSEA4 an ES cell 
marker. In vitro, UPCs gave rise to multiple lineages that express cell markers 
of urothelium, endothelial, smooth muscle, and interstitial. These UPCs 
expressed CD44 (a marker for cells developed from the basal layer) and CK13 
(an intracellular protein marker for basal cell) suggesting that UPCs are most 
likely derived from basal cells of the urothelium. In addition, karyotype analysis 
was performed to test the chromosomal stability of urine derived cells after 
serial subcultures and all passages exhibited a normal diploid complement of 
autosomes. However, the exact source of these cells is still undetermined. 
 
3.1.8 Tissue engineering of urinary bladder using stem cells  
Over the past decade, an increased number of studies have investigated the 
utility of stem cells such as MSCs, ES cells, EG cells, and amniotic fluid-derived 
stem cells in the field of regenerative urology (Yu and Estrada, 2010). In 
addition, several differentiation protocols have been utilized to direct stem cell 
differentiation to bladder tissue. However, the most powerful described method 
utilises tissue recombinant xenografts of embryonic bladder mesenchyme 
(EBLM) (Baskin et al., 1996; Oottamasathien et al., 2006; Oottamasathien et al., 
2007). Interesting results have been achieved using ES cells. Oottamasathien 
et al, showed that mouse ES cells can differentiate to bladder cells when 
associated with embryonic rat bladder mesenchyme and implanted under the 
kidney capsule for up to 42 days. The endodermal markers of Foxa1 and 
Foxa2, but not uroplakin were first detected at day 7 after grafting. By 42 days, 
optimized number of cells resulted in pure urothelial cells with mature bladder 
tissues derived from the ES cells that was evident by hematoxylin and eosin 
staining. Maturation was evident based on expression of uroplakin, a selective 
marker for urothelial cell differentiation and the basal cell marker p63, whereas 
smooth muscle α-actin (SMA); was used as a marker to identify smooth muscle 
cells (SMCs) (Oottamasathien et al., 2006; Oottamasathien et al., 2007).  
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However, there are ethical and immunological debates about using this 
procedure in humans. In addition, the differences observed between murine ES 
cells and human ES cells regarding molecular and developmental properties 
may represent an obstacle for direct translation to humans. Therefore, 
increasing attention has been paid to the use of adult stem cells which are less 
controversial, but equally promising cells in particular MSCs due to their 
versatility and their ability to differentiate into wide range of adult tissue cell 
types (Caplan, 2007; da Silva Meirelles et al., 2008), including muscle (Luttun et 
al., 2006; Crisan et al., 2008), liver (Mimeault and Batra, 2008), lungs (Nolen-
Walston et al., 2008), neuronal (Duan et al., 2007) and gut tissue (Jiang et al., 
2002). Utilizing the same model, Anumanthan and his colleagues used a 
recombinant xenograft of MSCs with EBLM to differentiate mouse MSCs toward 
mature bladder cells. Histological examination showed a bladder tissue 
structure with expression of uroplakin, SMA and desmin (Oottamasathien et al., 
2007). MSCs and human EG cell-derived cells seeded on porcine small 
intestinal submucosa grafts were also found to enhance bladder reconstitution 
in animal models. Three months after augmentation, only the stem cell seeded 
biohybrid displayed normal bladder structure with both urothelial and SMCs  
exhibiting gene expression levels similar to those of sham-operated animals 
(Chung et al., 2005; Frimberger et al., 2005). However, cytotoxic effects of the 
commercially available small intestinal submucosa (SIS) on urothelial cells have 
been reported (Feil et al., 2006).  
Tian et al. reported that bone marrow mesenchymal stem cells (BMSCs) can be 
differentiated into urothelial cells and SMCs in vitro and in vivo when co-cultured 
with bladder cells or conditioned media derived from bladder cell culture (Tian et 
al., 2010b). Later, the same group published that BMSCs could be induced to 
differentiate into bladder SMCs and urothelial cells when seeded on a highly 
porous PLLA scaffold and treated with several key growth factors including 
platelet-derived growth factor BB (PDGF-BB) and transforming growth factor β1 
(TGF-β1) (Tian et al., 2010a; Petrovic et al., 2011). However the clinical utility of 
BMSC is currently limited mainly because of their extremely low frequency, the 
intricacy and pain of the process, and difficulty in maintaining them in culture 
(Arai et al., 2002).  
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Another source of autologous adult stem cells has been obtained from stromal 
elements of adipose tissue (referred to as adipose-derived stem cells ,ADSC) 
and have been successfully used to tissue engineer the smooth muscle of the 
urinary bladder in rat (Zuk et al., 2001; Jack et al., 2009).  
In an attempt to overcome problems concerning appropriate cells sources for 
tissue regeneration of the bladder, Drewa at al showed that stem cells from rat 
hair follicle seeded on a bladder acellular matrix (BAM) scaffold and grafted into 
a surgically created defect within the anterior bladder wall were able to 
reconstruct both the urothelial and the muscle layers into surgically created 
defects. However, they did not demonstrate any uroplakin expression and the 
urothelial cells showed incomplete differentiation with weak expression of CK7. 
Most importantly, they couldn’t control the differentiation of the hair follicle stem 
cells after transplantation. Muscle layers were thick in bladders reconstructed 
with cell-seeded grafts and very thin in acellular grafts. Again, obtaining 
sufficient cell numbers posed a major challenge regarding the use of these cells 
(Drewa, 2008; Petrovic et al., 2011).  
Recently, Zhang et al. isolated a subpopulation of cells with progenitor cell 
characteristics from urine samples. These cells showed the ability to 
differentiate in vitro into multiple lineages that expressed cell markers of 
urothelial, endothelial, smooth muscle, and interstitial cells and maintained 
normal karyotype even after several passages (Zhang et al., 2008).  
Although many trials documented great therapeutic potential of adult stem cells, 
experimental studies reported that adult stem cells are able to form other cell 
types by fusion with them rather than trans-differentiation which might produce 
cells with karyotypic abnormalities (Terada et al., 2002; Ying et al., 2002; 
Sievert et al., 2007). Alternatively, pluripotent stem cells by their ability to 
proliferate indefinitely and to differentiate into any of the cell types in the body 
represent a serious alternative and major avenue in the regenerative medicine 
An exciting and recent advancement in stem cell research involves that of viral 
overexpression of specific transcriptional factors OCT4, SOX2, KLF4, and C-
MYC which can reprogram the differentiated cells back to pluripotency termed 
induced pluripotent stem (iPS) cells (Takahashi and Yamanaka, 2006; 
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Takahashi et al., 2007). These iPS cells exhibit embryonic stem cell 
characteristics and can differentiate into all 3 embryonic germ layers. Disease-
specific and patient-specific iPS cells have also been generated, thus providing 
a new method to evaluate potential therapeutics and to gain mechanistic insight 
into a variety of diseases (Park et al., 2008). Because production of iPS cells 
doesn’t involve the use of embryos or oocytes, they overcome the ethical 
restrictions that clearly obstruct the isolation, study, and use of ES cells, 
therefore they hold the general promise of ES cells, that is, pluripotency, and 
thus the ability to form any desired tissue (Yu and Estrada, 2010; Robinton and 
Daley, 2012). In this project, we aim to generate iPS cells from adult human 
urinary tract cells by lentiviral transduction. Such cells have great application 
potential for tissue engineering, understanding the mechanisms of bladder 
disease and drug screening.  
1.5 Pluripotent stem cell characteristics 
Irrespective of the cell origin, all pluripotent stem cells have the same main 
biological characteristics which considerably differ from those of normal somatic 
cells: the ability to proliferate indefinitely and the ability to differentiate into 
multiple somatic and germ cells in vitro and in vivo (Murry and Keller, 2008).  
1.1.1 Pluripotent stem cells morphology and cell cycle  
In culture, undifferentiated pluripotent stem cells grow in relatively flat, compact 
colonies with defined edges containing cells with a high ratio of nucleus to 
cytoplasm and prominent nucleoli (Thomson et al., 1995; Thomson and 
Marshall, 1998). Currently, the  majority of human ES cell lines are maintained 
on a feeder layer of mouse embryonic fibroblasts (MEFs), in medium that lacks 
serum but includes other exogenous peptide growth factors (Thomson and 
Marshall, 1998). However, the use of feeder layers and animal serum products 
can produce variable and heterogeneous results and precludes clinical 
applications (Sakamoto et al., 2007). Great progress in the culture systems of 
human ES cells has been recently achieved by Amit et al. who reported long-
term culture of  human ES cells under serum-free conditions (Amit et al., 2000), 
Richard el al. who replaced MEFs with human feeder layers (Richards et al., 
2002), and Xu et al. who reported the first attempt to produced feeder-free 
40 
 
cultures of human ES cells using Matrigel, or laminin substrates in medium 
conditioned by MEFs (Xu et al., 2001). In addition, iPS and ES cell lines have 
been successfully established using a number of serum and feeder replacement 
media formulations including KnockOut Serum replacement, defined serum-free 
media (Cheng et al., 2004), and mTeSR as specific media which  provides 
serum-free and feeder-free conditions to culture human iPS and ES cells 
(Ludwig et al., 2006). A very common method for monitoring ES cells culture is 
visual observation. Observation of ES cell morphology may give an indication of 
the state of differentiation in routine cultures (Thomson et al., 1995; Thomson 
and Marshall, 1998). Despite limitations in terms of quantification and 
sensitivity, this approach is one of the most effective and inexpensive means to 
reveal any changes in the undifferentiated cells in culture (Schatten et al., 
2005). Pluripotent stem cells have rapid growth supported by brief G1 cell cycle 
phase whilst cells remain in S-phase for most of the cell cycle (Becker et al., 
2006). 
1.1.2 Pluripotent stem cells gene expression and epigenetics 
All pluripotent stem cell lines share similar gene expression patterns, which 
significantly distinguish them from other cells with lower developmental potency. 
These cells express a panel of protein markers that has been commonly used 
to characterize them in cultures such as stage-specific embryonic antigens 3 
and 4 (SSEA-3 and SSEA-4), high molecular weight glycoproteins TRA-1-60 
and TRA-1-81, and alkaline phosphatase (Draper et al., 2002; Henderson et al., 
2002). They also express a number of genes that have now been found to be 
closely associated with the pluripotent state including Pou5F1/OCT3/4 (POU 
domain, class 5, transcription factor 1/Octamer binding transcription factor 3/4), 
SOX2, NANOG, teratocarcinoma-derived growth factor-1 (TDGF-1), DNMT3B, 
and growth and differentiation factor 3 (GDF3), together with the lack of 
differentiation markers. Furthermore, pluripotent stem cells have long telomeres 
due to high telomerase activity, an enzyme associated with immortal cell lines 
(Thomson et al., 1995; Thomson and Marshall, 1998; Adewumi et al., 2007). 
Telomerase is a ribonucleoprotein responsible for the maintenance of 
chromosome length by adding telomere repeats to chromosome ends. The high 
telomerase activity expressed by the ES cells provides them with long 
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replicative life span and long-term maintenance in culture and as the cell 
differentiates the telomerase activity is reduced (Marion and Blasco, 2010).  
The International Stem Cell Initiative has analyzed 59 human ES cell lines 
obtained and maintained in 17 laboratories worldwide for expression of different 
potential markers of the undifferentiated stem cells. They found that all of these 
ES cell lines expressed a specific set of marker antigens and genes that can 
generally be used to screen pluripotent stem cells (Adewumi et al., 2007).  
Epigenetically, ES cells also have distinct chromatin signatures consisting of 
bivalent domains. These regions harbour both a “repressive” and an “activating” 
chromatin modification and function to silence developmental genes in ES cells 
while keeping them poised for induction upon initiation of specific 
developmental pathways (Bernstein et al., 2006).  
 
1.1.3 Functional assays of pluripotency 
I. In vitro differentiation potential of pluripotent stem cells  
Several tests have been developed to characterise pluripotent cell lines. The 
pluripotency of ES cells in vitro can be evaluated by the ability of these cells to 
generate embryoid bodies (EBs) comprising cells that represent the three germ 
layers. When cultivated in suspension, both mouse and human ES cells form 
multicellular aggregates which have been termed “embryoid bodies” (EBs) , and 
upon further differentiation on adherent culture the EBs produce a wide range of 
cell types derived from all three embryonic germ layers However, EBs do not 
exactly simulate the structural design perceived in the embryo. Several studies 
have routinely used this assay to test pluripotency in vitro (Martin, 1981; 
Itskovitz-Eldor et al., 2000). Direct differentiation of ES cells to form the lineage 
of interest can also be used to test their ability to generate cells that represent 
each embryonic layer (Trounson, 2006). In these protocols, cells are transfected 
with ubiquitously expressing transcription factors, co-cultured with cell types 
capable of lineage induction or exposed to specific culture conditions and 
selected growth factors to enhance the differentiation towards a specific 
lineage.  
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II. In vivo differentiation potential of pluripotent stem cells  
The most convincing proof for pluripotency can be achieved by demonstrating 
the ability of stem cells to give rise to all three embryonic germ layers, including 
germ cells, in chimeras formed by mixing ES cells with mouse blastomeres or 
blastocysts (Nagy et al., 1993). However, because chimera formation is 
unethical using human ES cells, this has only been successfully established 
with mouse ES cells. For testing human ES cells, the most irrevocable test 
available is to demonstrate their ability to produce benign teratomas containing 
differentiated cells representing all three embryonic germ layers in 
immunodeficient mice (Thomson and Marshall, 1998; Gertow et al., 2004). 
Teratomas are generated by the introduction of the cells into immunodeficient 
mice beneath the testis or kidney capsules (Thomson and Marshall, 1998), 
intramuscularly (Tzukerman et al., 2003), subcutaneously (Levenberg et al., 
2002), or in the liver (Cooke et al., 2006).  
1.6 Signalling pathways to maintain pluripotency 
The first isolated mouse ES cells were cultured onto a feeder layer of mitotically 
inactivated mouse primary embryonic fibroblasts using media conditioned by 
teratocarcinoma cells supplemented with foetal bovine serum and exogenous 
proteins. Until recently, this was the most effective system for derivation, 
propagation, and expansion of ES cell lines of different species (Martin, 1981). 
The feeder layer supports ES cell growth and prevents spontaneous 
differentiation of ES cells during culture. In the absence of feeder layers, 
conditioned medium (CM) collected from embryonic fibroblasts was found to 
support undifferentiated mouse ES cell culture (Smith and Hooper, 1983). Smith 
and Williams analysed the CM collected from embryonic fibroblasts and found 
that the key factor to inhibit the differentiation was leukemia inhibitory factor 
(LIF) (Smith et al., 1988; Williams et al., 1988). LIF enhanced the expression of 
specific target genes important for sustaining the undifferentiated state of the 
mouse ES cell by activating the Jak/Stat3 signalling pathways (Burdon et al., 
2002). Subsequently, other extrinsic factors involved in self-renewal and 
pluripotency of ES cells have been detected. Animal sera such as foetal bovine 
serum (FBS) provide all of these extrinsic factors, except LIF.  
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The bone morphogenetic protein (BMP) signalling pathway was found to 
cooperate with LIF to maintain self-renewal of mouse ES cells and activate 
differentiation inhibitor genes in serum-free culture conditions (Ying et al., 
2003). More recently, a combination of LIF and small-molecule inhibitors of ERK 
has been reported to repress the differentiation proteins and enhance the 
proliferation of the ES cell propagation (Ying et al., 2008). Other factors such as 
vitamin A (Chen and Khillan, 2010), threonine (Wang et al., 2009), and a 
decreased oxidation state (Yanes et al., 2010) have also been reported to 
maintain undifferentiated mouse ES cells.  
Although human and mouse ES cells are similar with respect to their self-
renewal and differentiation capacity, growth factor requirements for maintaining 
mouse ES cell culture were unable to support long-term self-renewal of human 
ES cell lines (Bongso et al., 1994; Xu et al., 2002). For instance, human ES 
cells do not require LIF signalling for their derivation or propagation. Indeed, the 
LIF-JAK-STAT3 signalling is not active in human ES cells (Brandenberger et al., 
2004) but is essential for self-renewal of mouse ES cells. Further confirmation 
of the fundamental differences between mouse and human ES cells comes 
from studies by Xu et al. In this work, the authors found that BMP-4 signalling 
pathways which have been shown to enhance the self-renewal of mouse ES 
cells, could stimulate human ES cells to differentiate into trophoblast cells or 
mesodermal precursors (Xu et al., 2002; Pera et al., 2004).  
In contrast, human ES cells require elevated basic fibroblast growth factor 
(bFGF) in the culture medium to maintain their pluripotency and undifferentiated 
state in the absence of fibroblasts or fibroblast-conditioned medium (Vallier et 
al., 2005; Xu et al., 2005a; Xu et al., 2005b). A study by Wang et al. 
demonstrated for the first time that a combination of BMP antagonist and high 
concentrations of bFGF can help to maintain the pluripotency of human ES cells 
in the absence of feeder layers (Wang et al., 2005). However, in mouse ES 
cells, FGF signalling cascades have been shown to promote differentiation by 
stimulation of ERK1/2 signalling (Mayshar et al., 2008).  
Other essential factors in combination with bFGF are likely to be involved in 
growth enhancement and preserve the undifferentiated state of human ES cells 
such as transforming growth factor β (TGFβ), activin and Nodal (Beattie et al., 
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2005; James et al., 2005). It has been suggested that the TGFβ/Activin/Nodal 
and BMP/GDF/MIS subfamilies control the cell fate of human ES cell through 
the Smad pathway. In human ES cells, the activity of Smad1/5/8 pathway is 
repressed and Smad2/3 pathway is stimulated whereas upon differentiation 
Smad 2/3 pathway is repressed and Smad 1/5/8 pathway is stimulated 
(Miyazawa et al., 2002; Shi and Massague, 2003). The ERK, PI3K/Akt and 
Nuclear Factor Kappa-lightchain- enhancer of activated B cells (NFκB) 
pathways have also been suggested to have a role in the maintenance of 
human ES cells (Armstrong et al., 2006). Inhibition of the ERK and PI3K/Akt 
pathways has been shown to enhance the differentiation and induce the 
apoptosis in human ES cells (Li et al., 2007b). Similarly, the inhibition of NFκB 
pathway induces differentiation and increases cell death in human ES cells 
(Armstrong et al., 2006).  
Activation of Wnt signalling is sufficient to maintain and support the growth of 
mouse and human ES cells (Sato et al., 2004). Wnt, a biological inhibitor of 
Gsk3β, is endogenously activated in both mouse (Nordin et al., 2008) and 
human (Okoye et al., 2008) ES cells. A previous study by Sato et al, reported 
that the activation of Wnt pathway maintained the expression of pluripotency 
markers OCT4, REX-1 and NANOG and promoted self-renewal in both types of 
ES cells whilst the usual differentiation program could be induced by removing 
the compound (Sato et al., 2004). However, contradictory results have been 
reported by Dravid et al. in 2005, using either Wnt3a or Wnt antagonists. They 
found that Wnt activation could enhance the proliferation of human ES cells but 
was not sufficient to maintain and expand their undifferentiated state (Dravid et 
al., 2005). On the other hand, Wnt signalling is also required to promote the 
differentiation of mouse (Lindsley et al., 2006), and human ES cells (Wang and 
Nakayama, 2009). Therefore, further research is required to understand the 
precise roles of Wnts on ES cell proliferation and maintenance. 
1.7 Transcriptional network for maintenance of pluripotency 
Cellular pluripotency is governed by specific molecular signalling pathways as 
well as maintained by specific gene expression patterns that are characterized 
by activation of genes that support and sustain an undifferentiated cellular state 
and repression of those that promote differentiation. Several transcription 
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factors have been recognized as key regulators of cell pluripotency. Amongst 
them, OCT4, SOX2, and NANOG are proposed to form a core regulatory 
circuitry regulating pluripotency and self-renewal in human (Boyer et al., 2005), 
and mouse (Chen et al., 2008) ES cells. However, the reprogramming of  
mouse and human somatic cells to a pluripotent state using just four 
transcription factors OCT4, SOX2, C-MYC and KLF4 (Takahashi and 
Yamanaka, 2006; Takahashi et al., 2007) or OCT4, SOX2, NANOG and LIN28 
(Yu et al., 2007) endorsed the central roles of these genes in regulating cell 
pluripotency.  
OCT4: 
OCT4 (octamer-binding transcription factor 4), also known as POU5F1 is the 
master regulator of the pluripotent state of germ cells, EG, and ES cells. OCT4 
is an octamer-binding homeobox transcriptional factor that belongs to the class 
V family of transcription factors containing the POU DNA binding domain. In the 
mouse embryo, OCT4 protein is only expressed in the ICM cells after cavitation 
whilst it’s downregulated in the differentiated trophectoderm (TE). Therefore, 
OCT4 is essential marker for stem cell pluripotency. In vitro, OCT4 is expressed 
in undifferentiated EC, EG and ES cell lines (Niwa et al., 2000; Takahashi and 
Yamanaka, 2006). OCT4-deficient embryos fail to form the ICM and die shortly 
at pre implantation stage. In vitro culture of OCT4-negative embryos produced 
non-pluripotent ICM cells (Nichols et al., 1998), suggesting that OCT4 function 
is an absolute requirement for the establishment of the ICM pluripotency and it’s 
necessary to maintain self-renewal of pluripotent ES cells. Furthermore, OCT4 
can directly repress the main regulators of trophectoderm differentiation Cdx2, 
Eomes and hCG. Hence, a component of OCT4’s role is as a gatekeeper that 
blocks the differentiation into the trophectoderm lineage and maintains the 
pluripotency in the ICM (Liu et al., 1997; Niwa et al., 2000). Importantly, a 
precise level of OCT4 seems to be critical for the fate decisions of ES cells. In 
support of this, previous studies have demonstrated that overexpression of 
OCT4 resulted in differentiation into primitive endoderm and mesoderm, In 
contrast, reduction in OCT4 levels result in dedifferentiation to trophectoderm 
(Niwa et al., 2000; Zeineddine et al., 2006). 
 
46 
 
SOX2:  
In mouse embryo, SOX2 expression is found in epiblast, and germ cells. Unlike 
OCT4, SOX2 expression is also persistent in multipotent cells of extra-
embryonic ectoderm. Knockout of SOX2 in mice resulted in embryonic lethality 
after implantation due to defects in epiblast formation (Avilion et al., 2003). In 
vitro, SOX2 expression is detected in pluripotent ES cells and neural progenitor 
cells (Li et al., 1998). SiRNA-mediated knockdown of SOX2 results in the 
differentiation of ES cells into trophoectoderm. However, forced expression of 
OCT4 can successfully rescue SOX2-null pluripotent cells indicating that the 
essential function of SOX2 is related to the transcriptional activation of OCT4. 
SOX2 represents an important binding partner for OCT4 to enhance the 
expression of most pluripotency-associated genes, including FGF4, UTF1, 
Fbxo15, Lefty1, and NANOG. Furthermore, the OCT–SOX enhancers can 
stimulate the expression of OCT4 and SOX2 through a positive-feedback loop 
(Kuroda et al., 2005; Masui et al., 2007).  
NANOG: 
The homeodomain transcription factor NANOG is another important 
pluripotency-related factor in mouse and human pluripotent and 
teratocarcinoma cells. Similar to OCT4, the in vivo expression of NANOG is 
specific to the ICM, epiblast and germ cells. In vitro, NANOG is expressed in 
both mouse and human pluripotent cell lines (Chambers et al., 2003). Mouse 
embryos lacking NANOG fail to form ICM and die shortly after implantation. 
Similarly, removing NANOG from mouse (Mitsui et al., 2003) and human 
(Hyslop et al., 2005) ES cells has been shown to incite differentiation to multi-
lineage cells, while elevated levels of NANOG can enhance the self-renewal 
and prevent the differentiation of human ES cells (Darr et al., 2006), and mouse 
ES cells in the absence of LIF, or even in the presence of LIF antagonists 
(Chambers et al., 2003). Notably, NANOG expression failed to maintain the 
pluripotency of mouse ES cells in the absence of OCT4 (Mitsui et al., 2003; Hart 
et al., 2004). NANOG is also found to interact in concert with OCT4 and SOX2 
in the maintenance of pluripotency of mouse and human ES cells (Chen et al., 
2008). In this aspect OCT4, SOX2, and NANOG together can also form 
interconnected autoregulatory and feedforward loops by binding to the 
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promoters of their own genes (Boyer et al., 2005; Wang et al., 2006). In 
addition, these transcription factors interact with several other genes to repress 
the differentiation of ICM into extra-embryonic lineages–trophoblast and extra-
embryonic endoderm (Niwa et al., 2009). A recent study by Chambers et al. 
(2007) suggested a different view where the authors reported that NANOG-null 
ES cells maintain the expression of pluripotency markers and the ability to 
differentiate to multi-lineage cells in vitro and in vivo (Chambers et al., 2007). 
Collectively, NANOG appears to play a significant role in regulating pluripotency 
but unlike OCT4 and SOX2, it is not critical in the transcriptional housekeeping 
machinery of pluripotency. 
KLF4: 
KLF4 belongs to the Krüppel-like factor family of zinc finger transcription factors. 
It has been found that overexpression of OCT4, SOX2 and C-MYC, KLF4 can 
reprogram somatic cells back to an embryonic-like state (Takahashi and 
Yamanaka, 2006; Takahashi et al., 2007). In mouse, KLF4 overexpression was 
found to block the differentiation of ES cells into erythroid progenitors (Li et al., 
2005). KLF4 knockout mice preserved their pluripotent stem cell populations. 
Similarly, siRNA-mediated knockdown of KLF4 doesn’t affect the general 
phenotype of mouse ES cells which might be due to the functional corporation 
among other KLF family members in ES cells. Indeed, triple knockdown of 
KLF2, KLF4 and KLF45 induced differentiation in mouse ES cells and caused 
more changes in expression compared to single or double knockdown (Jiang et 
al., 2008). Moreover, somatic cells were successfully reprogramed after 
replacing KLF4 with other KLF family members such as KLF1, KLF2 and KLF5 
(Nakagawa et al., 2008). However, successful generation of iPS cells without 
using KLF4 suggested that KLF4 acts as a supporter rather than an essential 
factor in the reprogramming process (Yu et al., 2007). The requirement for LIF 
to maintain pluripotency can be sufficiently replaced by artificial expression of 
KLF4 or Tbx3. Remarkably, in the absence of LIF, overexpression of NANOG 
supports self-renewal of mouse ES cells while sustaining the OCT4 activity 
even without KLF4 and Tbx3 activity (Niwa et al., 2009). In human ES cells, 
KLF4 expression was found to prevent differentiation by activating the NANOG 
promoter (Chan et al., 2009b). 
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LIN28 
LIN28 encodes a cytoplasmic RNA binding protein that was identified as a key 
regulator of developmental timing in Caenorhabditis elegans (Polesskaya et al., 
2007). Overexpression of LIN28 was associated with very rapid cell proliferation 
in mouse ES cells (Xu et al., 2009a) while it seemed to decrease cell 
proliferation in human ES cells (Darr and Benvenisty, 2009). Indeed at present, 
the exact role of LIN28 in human and mouse ES cell is still intriguing. Although 
LIN28 was used together with OCT4, SOX2 and NANOG to reprogram human 
somatic cells back to a pluripotent state (Yu et al., 2007), its role was not critical 
for reprogramming and it can even be replaced by other factors, suggesting that 
it may not be an essential factor in maintaining pluripotency but rather, serves 
as a secondary factor to enhance pluripotency, much like KLF4 (Takahashi et 
al., 2007). 
C-MYC: 
MYC is a proto-oncogene whose overexpression is frequently observed in 
human tumours and is involved in transformation and tumorigenesis (Kendall et 
al., 2006). Overexpression of C-MYC is reported during the blastocyst stage 
and several studies have demonstrated the central role of C-MYC in early 
mouse and human embryo (Paria et al., 1992; Naz et al., 1994). 
Overexpression of C-MYC in mouse ES cells has been found to prevent 
differentiation while downregulation of C-MYC antagonized self-renewal and 
caused differentiation (Cartwright et al., 2005). On the other hand, 
overexpression of C-MYC in human ES cells resulted in apoptosis and 
differentiation into extraembryonic endoderm and trophectoderm. To explain the 
conflicting roles of C-MYC in both proliferation and apoptosis, the “dual signal” 
model has been proposed in which C-MYC is  involved in both proliferation and 
growth arrest pathways (Pucci et al., 2000). Although C-MYC was one of the 
four factors that Yamanaka used to reprogram both mouse and human somatic 
cells (Takahashi and Yamanaka, 2006; Takahashi et al., 2007), subsequent 
studies have reported the generation of iPS cells without using C-MYC. 
However, the efficiency was significantly reduced (Nakagawa et al., 2008; 
Wernig et al., 2008b) Indeed, several studies have suggested a different role for 
C-MYC in comparison to other pluripotency factors. During the reprogramming 
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process, C-MYC was proposed to mainly down-regulate somatic gene 
expressions rather than activate that of pluripotency regulators (Sridharan et al., 
2009). C-MYC is also proposed to support the self-renewal of stem cells by 
inducing a cell cycle program and enhancing cell proliferation (Vermeulen et al., 
2003).  
In conclusion, pluripotency cannot simply be characterized by just the 
expression of a particular set of genes or signalling pathways. Instead, multiple 
signalling pathways and transcriptional networks interact together to maintain 
ES cell pluripotency (Figure  1-8). 
 
Figure  1-8: Signalling pathways involved in pluripotency and self-renewal. 
Modified from: (http://www.pharmatutor.org/articles/molecules-involved-in-
regulation-of-stem-cell-differentiation). 
1.8 Reprogramming and induced pluripotency  
Despite their immense potential for differentiation and expansion, the 
application of human ES cells in research, clinical therapies, and pharma-
screening is still controversial due to the destruction of human embryos, 
immunologic rejection of allogeneic ES cell-derived grafts and the unavailability 
of patient-specific cells (Johnson, 2008). Adult stem cells have also gained 
serious interest as they circumvent some of the ethical and immunologic issues 
of human ES cells, but, they have a rather limited differentiation and expansion 
potential (Wagers et al., 2002; Murry et al., 2004). Consequently, great effort 
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has gone into developing functional equivalents of human ES cells without 
using embryonic material. In particular, research has focused on generating 
pluripotent stem cells directly from somatic cells which finally led in 2006 to the 
ground breaking work by Shinya Yamanaka who demonstrated the induction of 
pluripotency in differentiated cells. These cells are called induced pluripotent 
stem (iPS) cells and are generated from a patient’s own cells, thus bypassing 
the immune rejection and the ethical issues associated with the use of human 
embryos (Takahashi and Yamanaka, 2006). Reversal of the differentiated state 
to a state of developmental pluripotency is defined as “reprogramming.” A 
number of techniques have been established over the years to reprogram 
somatic cells to a pluripotent state including cloning or somatic cell nuclear 
transfer (SCNT), cellular fusion, cell extracts or defined media, and direct 
reprogramming using exogenous factors (Figure  1-9).  
1.1.4 Somatic cell nuclear transfer (SCNT) 
SCNT is a pioneering technique first used by John Gurdon to generate Dolly the 
sheep, the first mammal to be cloned, whereby he transferred the somatic cell 
nucleus into an enucleated oocyte arrested at metaphase II stage (Gurdon and 
Melton, 2008). Upon transfer, the epigenome of the somatic cell is 
reprogrammed by the cellular factors in the egg. The resultant entity is assumed 
to have the same developmental potential as a fertilized zygote and can give 
rise to a cloned organism (Wilmut et al., 1997). Hereby this work constituted the 
first evidence that the differentiation process is not a permanent change and 
that the somatic cell can be reprogrammed to an embryonic-like stage and more 
importantly acquires all genetic materials required to create a mature organism 
(Hanley et al., 2010). Following Dolly, other animals including mouse (Tsunoda 
et al., 1987), cow (Prather et al., 1987), goat (Willadsen, 1986), pig (Prather et 
al., 1989), cat (Imsoonthornruksa et al., 2012) and rabbit (Matsuda et al., 2002) 
were successfully generated by SCNT. 
SCNT bestowed a powerful tool to study the molecular mechanisms controlling 
early development and raised the possibility of using them for autologous 
transplantation without the risk of immunologic rejection. There are two types of 
cloning, reproductive and therapeutic cloning. Reproductive cloning is used to 
create genetically identical embryo to the donor nucleus. Then this embryo is 
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grown into the uterus to generate an infant that is a clone of the donor. 
However, the application of this type of cloning for humans is denied in most 
countries. The other type of cloning is therapeutic cloning which has also been 
called somatic cell nuclear transfer. This type is also used to form blastocysts 
from an embryo that has identical genetic material to its cell origin. However, 
blastocysts are cultured in vitro with the goal of generating an autologous ES 
cell line (Kawase et al., 2000; Hochedlinger and Jaenisch, 2003; Byrne et al., 
2007). Importantly, these cell lines are similar to normal ES cell lines with 
respect to morphology and gene expression profile (Brambrink et al., 2006). 
The pluripotency of ES cells derived from SCNT was confirmed by their ability 
to form teratomas after injection into immunocompromised mice (Munsie et al., 
2000), and their ability to contribute to mouse diploid chimeras, suggesting that 
they can be used as an alternative source of transplantable cells that are 
identical to the patient’s own cells (Hochedlinger and Jaenisch, 2002). The 
therapeutic effects of nuclear transfer derived ES cells have been reported in 
mouse models of severe combined immunodeficiency (Rideout et al., 2002), 
and Parkinson’s disease (Barberi et al., 2003). Most recently, SCNT human 
blastocysts were produced for the first time using somatic adult donor nuclei 
reprogrammed by human oocytes (French et al., 2008). Nevertheless the 
efficiency of generating ES cell lines from nuclear-transferred embryos is 
significantly low where very few clones survive after implantation, and even 
those have severe malformations (Ogonuki et al., 2002; Byrne et al., 2007; 
Atala, 2011).  
Interestingly, cloning with a less differentiated somatic cell as a nuclear donor is 
significantly more efficient than with terminally differentiated somatic cells 
(Blelloch et al., 2006). Consistently, skin stem cells and neural stem cells create 
cloned animals more easily than do keratinocytes and neurons, respectively 
(Inoue et al., 2007; Li et al., 2007a). Donor cell cycle stage has also been 
reported to impact the efficiency of SCNT (Cibelli et al., 1998). Following SCNT, 
histone modifications and DNA demethylation seem to be essential for 
developmental potential of cloned embryos (Dean et al., 2001). DNA 
methylation and histone acetylation are also directly involved in X chromosome 
inactivation in female SCNT embryos (Xiong et al., 2005). Bortvin at al reported 
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that the failure of deriving cloned embryos is often correlated to an incomplete 
reactivation of genes functioning in the pluripotent cells of the preimplantation 
embryo, in particular, OCT4 which is only expressed in pluripotent cells of the 
early embryo and the germline (Bortvin et al., 2003). Although this approach 
has recently been expanded to other mammals (Gurdon and Melton, 2008), the 
use of SCNT in research and therapy however is hampered by many technical 
limits associated with the cloning process including low efficiency, incomplete 
remodelling, high percentage of abnormalities and low birth rate, and ethical 
limits surrounding the use of human eggs (Gurdon and Melton, 2008). 
Nevertheless, SCNT trials provide the proof-of-concept that paved the way to 
identify the main key factors required for nuclear reprogramming.  
1.1.5 Cellular fusion  
Cellular fusion has been used previously to study the plasticity of differentiated 
cells (Blau and Blakely, 1999). In a pioneering study, mouse EC cells were 
fused with thymocytes and the resultant pluripotent hybrid cells showed the 
ability to induce teratomas upon injection into immunocomprimised mice (Miller 
and Ruddle, 1976). More recent research has revealed that ES and EG cells 
also possess the ability to reprogram somatic cells (Han and Sidhu, 2008). 
Matveeva et al. reported for the first time the ability of mouse ES cells to 
reprogram somatic cells. In this work, hybrid cells with pluripotent properties 
were obtained by fusion of mouse ES cells with the spleen cells of an adult 
female mouse (Matveeva et al., 1998). Reactivation of OCT4–enhanced green 
fluorescent protein (EGFP) transgene and silencing of X chromosome were 
detected in the ES hybrid cells (Tada et al., 2001). Microarray analysis showed 
that a mouse embryonic fibroblast /ES cell hybrid contains unique expression 
profiles that are similar to normal ES cells (Ambrosi et al., 2007). Similarly, 
Eggan’s group artificially fused human ES cells with human fibroblasts through 
the merging of their membranes to form a stable cell hybrid. The resultant cell 
contained both the somatic and human ES cell chromosomes in a single 
nucleus, had a phenotype similar to the parental ES cell, and grew in 
appearance similar to a human ES cell. Reprogramming of the somatic genome 
in hybrid cells to an embryonic state is demonstrated  by the silencing of the 
somatic-specific genes, demethylation and reactivation of several pluripotency 
genes including OCT4, NANOG, and REX1, reactivation of the inactive X 
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chromosome in fused female somatic cells and the ability to differentiate into all 
three germ layers in vitro and in vivo (Cowan et al., 2005). Comparable results 
have been obtained with human ES cells and haematopoietic cells. The 
resultant hybrid cells showed reactivation of OCT4–EGFP and expression of ES 
cell-specific genes at a level comparable to that in diploid human ES cells. 
Furthermore, the hybrid cells had the ability to form the three germ layers 
suggesting functional nuclear reprogramming (Yu et al., 2006). However, this 
approach is still limited by technical and ethical barriers that have restricted the 
use of ES cells in research including low efficiency and chromosomal and 
genetic instability of the hybrid which can lead to malignant transformation 
(Vasilkova et al., 2007; Nowak-Imialek et al., 2010). Furthermore, although the 
somatic cell genome is reprogrammed, the tetraploid DNA content presents an 
additional technical hurdle before this process could be used in customized cell 
therapy as transplanting these tetraploid hybrids into the somatic donor will 
probably result in immune rejection caused by the existence of the foreign 
genome. 
1.1.6 Cell extracts and defined media 
Based on observations from SCNT and fusion experiment, it has been 
suggested that reprogramming may be induced by incubation of somatic cells 
with ES nuclear and cytoplasmic extracts (Taranger et al., 2005). Xenopus egg 
extract has been used to reprogram human lymphocytes. Egg extract-treated 
cells showed increased expression of endogenous pluripotent gene OCT4 
whilst somatic genes were inhibited (Hansis et al., 2004). Similarly, exposing 
293Tand NIH3T3 cells to extracts of mouse EC or ES cells resulted in 
demethylation of OCT4 and NANOG promoters concomitant with down 
regulation of differentiation genes. Moreover, generated cells exhibited the 
ability to differentiate towards several cell lineages including neurogenic, 
adipogenic, osteogenic, and endothelial lineage (Taranger et al., 2005; Freberg 
et al., 2007). However, employing this technique is hindered by the instability of 
the reprogramming outcomes which may lead to cancer development and the 
very low yield of extracts even with large numbers of oocytes. 
 Another technique to produce reprogrammed cells is based on exposing cells 
in vitro to a specific mixture of growth factors. Under standard ES cell culture 
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conditions, adult testis cells can gain ES cell characteristics (Guan et al., 2006). 
Cellular dedifferentiation of murine C2C12 myoblasts can also be induced using 
A2,6-disubstituted purine, reversine (Chen et al., 2004). To date the 
mechanisms by which these defined factors function are still elusive. 
1.1.7 Direct reprogramming using exogenous factors 
In 2006, Shinya Yamanaka and his team presented a new concept of 
reprogramming mouse somatic cells using retroviral-mediated overexpression 
of key transcription factors (Takahashi and Yamanaka, 2006). The generated 
cells called induced pluripotent stem (iPS) cells are almost identical to ES cells 
in terms of morphology, molecular characteristics, and teratoma formation 
ability. These results were later reproduced on human adult fibroblasts to 
generate human iPS cells that would serve as another source of patient-specific 
pluripotent stem cells that circumvent some of the problems associated with ES 
cells, hence bear promise to advance biomedical research and regenerative 
medicine (Takahashi et al., 2007; Yu et al., 2007).  
 
 
Figure  1-9: Mechanisms to induce nuclear reprogramming. 
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1.8.1.1 Induction of pluripotent stem cells from murine fibroblasts  
The induction of pluripotent stem cells from murine fibroblasts by Shinya 
Yamanaka and Kazutoshi Takahashi represents a hallmark in stem cell 
research (Takahashi and Yamanaka, 2006). They first selected a combination 
of 24 candidate genes due to their suggested role in production and 
maintenance of the ICM in the blastocyst and also in maintaining the pluripotent 
state of ES cells (Figure  1-10). These factors were delivered as a pool by 
retroviral transduction to MEFs engineered to express neomycin resistance 
from the Fbx15 locus, a downstream target of the pluripotency associated factor 
OCT4. The transfected cells were cultured in mouse ES cell environment and 
colony resistance to G418 as a selective antibiotic was used to control the 
induction of the Fbx15 locus which is only expressed in embryos and mouse ES 
cells. Cells transduced with a single gene were unable to confer G418 
resistance while cells transduced with all 24 genes formed colonies with mouse 
ES cell characteristics after about 25 days. Then exogenous factors were 
eliminated one by one while monitoring the efficiency and timeline of ES-like 
colony formation until they demonstrated that only four transcription factors, 
OCT4, SOX2, KLF4, and C-MYC, were required to form a G418-resistant 
colony and to bestow ES cell-like properties on fibroblasts. Established iPS cells 
were positive for alkaline phosphatase and SSEA-1 (stage-specific embryonic 
antigen 1). Moreover, iPS cells reactivated the silenced X chromosome in 
female cells and restored telomerase activity. In vitro, iPS cells exhibited the 
ability to form embryoid bodies, which in turn exhibited the ability to differentiate 
into cell types of the three germ layers. Teratoma formation resulting from 
subcutaneous injection of iPS cells into nude mice demonstrated their 
pluripotency in vivo.  
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Figure  1-10: Generation of iPS cells. Yamanaka and colleagues demonstrated 
that retroviral-mediated over expression of a combination of just four 
transcription factors was sufficient to convert somatic cells into pluripotent stem 
cells, called induced pluripotent stem (iPS) cells. 
 
 
Nevertheless, these early attempts generated iPS cells that didn’t show global 
gene-expression patterns similar to those of ES cells, and failed to produce 
viable chimeras upon injection into a developing blastocyst suggesting that the 
reprogramming was incomplete. However, replacing the FBX15-neo selection 
with GFP-IRES-puro cassette introduced into the endogenous OCT4 (OCT4-
neo) or NANOG locus (NANOG-neo) in MEFs allows the generation of iPS cells 
that were similar to ES cells with respect to DNA methylation, gene expression 
profiles and the chromatin state of the reprogrammed cells (Maherali et al., 
2007; Okita et al., 2007). Both OCT4 and NANOG promoters showed 
demethylation in NANOG -selected iPS cells that were almost identical to global 
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histone methylation patterns (H3K4 and H3K27) in ES cells. FBX15 selected 
iPS cells had significantly higher expression levels of the four transgenes and 
lower levels of endogenous OCT4, SOX2, and NANOG gene expression 
compared with NANOG-iPS cells. Importantly, OCT4 -selected iPS cells could 
be maintained through endogenous expression of OCT4, whilst FBX15 selected 
iPS cells required continuous expression of the exogenously provided factors to 
maintain their self-renewal and pluripotency (Takahashi and Yamanaka, 2006). 
These cells were able to form teratomas containing differentiated cell types 
representing all three embryonic germ layers and importantly could contribute to 
the germ line of chimeric offspring following blastocyst injection (Maherali et al., 
2007; Okita et al., 2007) suggesting that the reprogramming was complete. 
Subsequently, mouse iPS cells passed the most stringent in vivo assay of 
pluripotency by showing the ability to give rise to full-term embryos by tetraploid 
complementation, thus becoming functionally highly similar to mouse ES cells 
(Boland et al., 2009; Zhao et al., 2009). On the other hand, Meissner at al 
suggested that the incomplete reprogramming in the original Yamanaka work 
was caused by the early selection for Fbx15 activation and postulated that 
selection for Fbx15 activation at later times would generate fully reprogrammed 
iPS cells based on the finding that the reprogramming process is slow and 
gradual (Meissner et al., 2007). IPS cells have also been derived from 
unmodified somatic cells based upon morphological criteria rather than 
selection for drug resistance. The overall efficiency of reprogramming using 
morphological selection was approximately 5–10 times higher when compared 
to drug-selection strategies. This result endorsed the supposition that 
reprogramming is a gradual process where selection for drug may exclude cells 
before reaching the ultimate pluripotency state. 
1.8.1.2 Induction of pluripotent stem cells from human fibroblasts  
One year later, two groups succeeded in generating iPS cells from adult human 
dermal fibroblasts (HDF) by the introduction of either the same four transcription 
factors (Takahashi et al., 2007) or a slightly different combination (Yu et al., 
2007). Similar to human ES cells, human iPS cells formed tightly-packed flat 
colonies. Disaggregation of these colonies resulted in cells similar to human ES 
cells in morphology characterized by large nuclei and scant cytoplasm. Human 
iPS cells expressed human ES cell-specific surface antigens, including SSEA-3, 
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SSEA-4, and tumour-related antigen (TRA)-1-60, TRA-1-81, and alkaline 
phosphatase. RT-PCR also showed that human iPS cells expressed many 
undifferentiated ES cell-marker genes, such as OCT4, SOX2, NANOG, GDF3, 
fibroblast growth factor 4 (FGF4), embryonic cell specific gene 1 (ESG1), 
developmental pluripotency-associated 2 (DPPA2), DPPA4, and telomerase 
reverse transcriptase (hTERT) at levels similar to those in human ES  and EC 
cell lines as well as  an epigenetic status similar to that observed in human ES 
cells. The OCT4 and NANOG promoters were demethylated and in an active 
state, and exhibited H3K4 methylation and H3K27 demethylation patterns. 
Furthermore, these cells possessed the ability to differentiate into cell types of 
the three germ layers both in vitro and in vivo. However, Yamanaka et al. found 
that each iPS clone contained some retroviral integration, which may increase 
the risk of tumorigenesis. Around 20% of mice derived from iPS cells exhibited 
tumours, which was partially ascribed to reactivation of the C-MYC retrovirus 
(Takahashi and Yamanaka, 2006). Thomson et al. reported that human somatic 
cells can be converted to pluripotent cells using a similar, but distinct 
combination of genes (OCT4, SOX2, NANOG, and LIN28) without 
compromising iPS efficiency. KLF4 and C-MYC therefore may not be required 
for the reprogramming process in human cells. These data demonstrated that 
iPS cells can be generated not only from mouse, but also from human fibroblast 
cultures. After the successful generation of iPS cells from animal and human 
fibroblasts, other cell types have been successfully reprogrammed either in 
animal such as stomach cells (Aoi et al., 2008) and B cells (Hanna et al., 2008), 
or in human such as cord blood (Nishishita et al., 2011), keratinocytes (Aasen 
et al., 2008), adipose tissues (Sun et al., 2009), neural progenitor cells (Kim et 
al., 2009b), platelets (Gekas and Graf, 2010), prostate and bladder cells (Moad 
et al., 2013), and the number of cell types that can be used to generate iPS 
cells is growing steadily. Similar to human ES cells, human iPS cells should be 
very useful for studying the development and function of human tissues, for 
discovering and testing new drugs and for transplantation medicine. 
1.8.1.3 Mechanistic insights to reprogramming  
Several studies have reported that the reprogramming process involves a series 
of transcriptional modifications. Recently, it has been indicated that acquisition 
of epithelial characteristics through mesenchymal to epithelial transition (MET) 
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is an important early step required for the successful reprogramming of a 
mouse fibroblast cell into a pluripotent stem cell. MET takes place before the 
acquisition of ES cell-like properties and is characterised by epithelial-like 
morphological alterations including size reduction, compacting cells with well-
defined intercellular junctions and high cytokeratin expression from day 5 post-
transduction, activation of epithelial-associated genes such as E-cadherin 
(Cdh1), Claudins 3, 4, 7, 11, Occludin, epithelial cell adhesion molecule 
(EpCAM), and crumbs homolog 3 (Crb3 ), as well as repression of 
mesenchymal associated genes, such as SNAIL1/2, SLUG, ZEB1 and ZEB2 (Li 
et al., 2010; Samavarchi-Tehrani et al., 2010). Consistent with these, 
reprogramming can be improved using factors facilitating MET such as TGF-b 
inhibitors, Cdh1, BMPs, microRNA miR200s and miR302/367 (Liao et al., 2011; 
Liang and Zhang, 2013). OCT4, SOX2, KLF4 and C-MYC reprogramming 
factors have a suppressive effect on TGF-b signalling and miRNAs miR-155, 
miR-10b, which are associated with EMT (Peinado et al., 2003; Kong et al., 
2008). Subsequently, OSKM were more effective in generation of iPS cells than 
OSK which might be due to the inefficient block of the TGF-b pathway mediated 
by C-MYC, indicating that MET is essential for the establishment of 
pluripotency.  
However, acquisition of the epithelial status doesn’t guarantee reaching the iPS 
cell fate, since cells undergoing reprogramming will still require continuous 
expression of reprogramming factors to reach bona fide pluripotency found in 
ES cells (Smith et al., 2010). Concurrent with acquiring epithelial cell 
characteristics, reprogrammed cells increase their proliferation rate and escape 
cell cycle arrest. Consistently, knocking down p53-p21 or inhibiting Ink4a/Arf 
has been found to promote the iPS generation by enhancing cell proliferation 
(Smith et al., 2010; Liang and Zhang, 2013).  
Metabolic change is also an important step for inducing pluripotency. Studying 
the metabolome profiles of iPS cells relative to ES cells and to their somatic 
cells of origin showed that iPS cells and ES cells have similar but not an 
identical metabolomic signature (Panopoulos et al., 2012). In addition, the 
metabolome profile of differentiated cells which prefer oxidative phosphorylation 
is converted to pluripotent glycolytic metabolism which fuels induction of 
60 
 
pluripotency (Folmes et al., 2011). Previous studies reported that C-MYC is 
involved in metabolic gene regulation and cell cycle acceleration, indicating that 
C-MYC plays a critical role in the early phase of the reprogramming process 
rather than activation of pluripotency regulators (Sridharan et al., 2009). 
However, successful generation of iPS cells without C-MYC suggests that 
metabolic changes can be achieved by other reprogramming factors (Liang and 
Zhang, 2013).  
The next step in reprogramming involves the activation of the pluripotency 
circuitry. Pioneering studies by two groups reported the first insights into the 
mechanisms of reprogramming fibroblasts into iPS cells using doxycycline-
controlled lentiviral vectors encoding the four reprogramming factors OCT4, 
SOX2, KLF4 and C-MYC to infect MEFs with a knock in of GFP into the 
endogenous OCT4 allele (OCT4-GFP) (Brambrink et al., 2008; Stadtfeld et al., 
2008b). Stably reprogrammed cells were produced after treating with 
doxycycline for at least 8 days. Addition of doxycycline for 10, 11, 12, and 13 
days increased the number of iPS colonies, sequentially. Cell sorting with Thy1 
(expressed in fibroblasts and other differentiated cell types) and SSEA1 
markers (expressed in mouse ES cells) showed that the Thy+/SSEA1− 
phenotype in fibroblasts starts to shift gradually after 3 days of doxycycline 
withdrawal, where Thy1 down-regulation preceded the SSEA-1 upregulation. 
However, the phenotype reversal to Thy1−/SSEA1+ was not significantly 
detected until the doxycycline was removed from the cultures at day 12, 
suggesting that surface markers Thy1 and SSEA1 distinguish early 
intermediates of the reprogramming process and only few Thy1−/SSEA1+ cells 
can pass to the stabilisation phase (Stadtfeld et al., 2008b; Li et al., 2010; Liang 
and Zhang, 2013).  
Previous studies also revealed that direct reprogramming is a slow and gradual 
process encompassing the sequential activation of various pluripotency 
associated markers where alkaline phosphatase appears at day 3 of transgene 
expression followed by expression of the surface marker SSEA1 on day 9. On 
the other hand, endogenous expression of OCT4 or NANOG was first 
detectable on day 16, suggesting that SSEA1+ cells may mark an intermediate 
step of reprogramming whereas the endogenous expression of OCT4 or 
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NANOG was postulated as a marker for fully reprogrammed cells. Retroviral 
silencing also appeared to be a gradual process that started early but finished 
coinciding with the acquisition of late pluripotency gene expression in iPS cells.  
In a more advanced system Wernig et al generated doxycycline-inducible 
secondary iPS cells. Firstly, reprogramming factors were expressed using 
doxycycline-inducible lentiviruses to generate primary iPS cells which were then 
used to generate chimeric mice. Addition of doxycycline to the MEF population 
selected from these chimeric mice resulted in the generation of secondary iPS 
cells with higher efficiency compared to primary iPS cells but was not 100% as 
one might expect (Wernig et al., 2008a). Yamanaka gave explanation for this 
discrepancy in his recent comment about the two models for iPS cell generation 
(Yamanaka, 2009a). First, the elite model, presupposes that only a certain 
population of cells, such as stem/progenitor cells, can be successfully 
reprogrammed into a pluripotent state. Evidence for this model comes from a 
study by Kuroda et al where they reported the existence of “multilineage 
differentiating stress-enduring” (Muse) cells, a type of cell in adult human 
mesenchymal cells such as dermal fibroblasts and bone marrow stromal cells. 
Muse cells were found initially to be stress-tolerant and SSEA3+/CD105+ and 
showed pluripotency characteristics such as self-renewal ability, expression of 
pluripotency markers (OCT4, SOX2, and NANOG) and ability to differentiate 
into the three germ layers in vitro and in vivo, while at the same time they also 
exhibited characteristics of mesenchymal cells (Kuroda et al., 2010). These 
Muse-cells have been found to be more amenable to generating iPS cells when 
transduced with the four factors OCT4, SOX2, KLF4, and C-MYC, while no iPS 
cells could be established from non-Muse cells indicating that human fibroblast 
cells contain a population of adult stem cells that primarily contributes to iPS cell 
generation (Wakao et al., 2011). However, such a model cannot explain the 
existence of the partially reprogrammed cells that acquire epithelial properties 
but without activation of the pluripotency genes.  
The other model, the stochastic model proposed that most differentiated cells 
can be reprogrammed after infected with the reprogramming factors. However, 
genetic and epigenetic obstacles must be overcome to reach successful 
reprogramming. This model may integrally depict the reprogramming process 
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and most data generated appear to support it (Hanna et al., 2009; Yamanaka, 
2009a).  
A study by Tehrani et al revealed three phases of reprogramming termed 
initiation, maturation, and stabilization where the Initiation phase is mainly 
marked by MET. Importantly, the authors found that reactivation of some 
pluripotency markers such as NANOG and SALL4 mark the transition to the 
maturation phase (Samavarchi-Tehrani et al., 2010). NANOG is also found to 
play an important role in initiating the pluripotency state, specifically by driving 
the partially reprogrammed iPS cells to reach pluripotency (Silva et al., 2009) 
and therefore may help in setting up the whole pluripotency circuitry.  
Recently, single-cell gene expression analysis and clonal retrospective tracing 
of cells derived from early time points, intermediate cells, and fully 
reprogrammed iPS cells showed that reprogramming in mouse comprises an 
early stochastic and a late hierarchical stage. Gene expression of Esrrb, Utf1, 
Lin28, and Dppa2 were found to stringently predict successful generation of 
stable iPS cells lines before the pluripotency core circuitry is activated (Buganim 
et al., 2012). Moreover, up-regulation of pluripotency genes such as Fbxo15, 
Fgf4, and unexpectedly OCT4 doesn’t strictly associate with successful 
reprogramming. In the same study, the authors found that the expression of 
SOX2 significantly activated the most upstream pluripotency genes and derived 
a hierarchical activation of key pluripotency genes making it a potential late 
marker. Such a hierarchy proposes that fully reprogramming can be induced 
from multiple entry points and even without any of the original Yamanaka 
factors. Interestingly, generation of iPS cells has been reported by a 
combination of Lin28, Sall4, Esrrb and Dppa2 suggesting specific gene 
expression and hierarchical activation of key pluripotency genes mediate the 
activation of the pluripotency circuitry during the late phase in reprogramming 
(Liang and Zhang, 2013). Upon activation of the pluripotency circuitry, 
reprogramming cells gain the ability for self-renewal independently of the 
exogene expression (Guenther et al., 2010; Newman and Cooper, 2010; Bock 
et al., 2011).  
Dramatic changes in the gene-expression patterns without alterations in DNA 
sequences are referred to as “epigenetic” changes, mainly including DNA 
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methylation, genomic imprinting and histone modification. Epigenetic changes 
allow pluripotent cells to differentiate into tissue specific cells during the normal 
development. Epigenetic changes, such as DNA methylation and histone 
modifications, are also believed to play a critical role in the process of 
reprogramming somatic cells to an undifferentiated state and maintaining stem 
cell pluripotency. Successful reprogramming requires silencing of differentiation 
specific genes and activation of gene expression patterns unique to pluripotent 
cells (Han and Sidhu, 2008). Lysine methylation and acetylation are two of the 
most frequently studied histone post-translational modifications. Changes in 
histone modifications including a deposition of the histone H3 dimethylated at 
lysine 4 (H3K4me2) mark and a gradual depletion of H3K27me3 is observed 
immediately after induction whereas DNA demethylation and X-chromosome 
reactivation can be seen late in the reprogramming process (Buganim et al., 
2013). Collectively, these studies provide deep insights into the molecular 
events that occur during the reprogramming process using integrating viral 
vectors.  
1.8.1.4 Potential application of iPS cells 
Overcoming both immunological rejection and the ethical issues relating to ES 
cells, together with the unique ability to continuously self-renew and differentiate 
into all cell types in the human body gives iPS cells the potential to revolutionize 
the earliest steps of disease modelling and treatment. Therefore, the potential 
use of iPS cells as treatments for various disorders has been investigated in 
vitro and in vivo.  
A proof of principle study for potential clinical applications of iPS cells with 
encouraging results was described by Hanna et al in 2007. Tail-tip fibroblasts 
isolated from a humanized knock-in mouse model of sickle cell anemia were 
transduced with retroviruses encoding for OCT4, SOX2, KLF4, and C-MYC 
transcription factors to generate iPS cells. Then the β-sickle mutation in 
generated iPS cells was corrected by homologous recombination with a human 
βA wild-type globin gene. Haematopoietic progenitors (HPs) derived in vitro 
from gene-corrected iPS transplanted into irradiated mice were able to 
reconstitute the haematopoietic system of sickle mice and correct their disease 
phenotype (Hanna et al., 2007).  
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More recently, neural precursors derived from mouse iPS cells have been 
shown to migrate into various brain regions and differentiate into glia and 
neurons when grafted into the embryonic cerebral ventricles of parkinsonian 
rats. Successfully implanted animals showed functional recovery and significant 
improvement in the disease phenotype (Wernig et al., 2008c). Another 
therapeutic application of iPS has been evaluated using FVIII expressing 
endothelial/endothelial progenitor cells derived from wild-type mouse iPS cells 
to treat haemophilia A mutant animals. Transplantation of these iPS-derived 
cells into the liver of a preclinical mouse model of haemophilia A resulted in 
phenotypic correction of the bleeding disorder. Monitoring plasma levels of FVIII 
revealed long-term functional engraftment and structural integrity of iPS-derived 
donor cells (Xu et al., 2009b).  
Additional technical challenges may be expected when applying these 
therapeutic approaches into human diseases therapies. However, several trials 
to generate disease-specific iPS cells are presently in progress. Initial 
experiments by Dimos et al showed that disease-specific iPS cells can be 
produced utilizing skin fibroblasts cells obtained from an 82-year-old patient 
diagnosed with a familial form of amyotrophic lateral sclerosis (ALS). Generated 
iPS cells could further be successfully directed to differentiate into motor 
neurons, the cell type involved in ALS pathology, providing a potential 
therapeutic model and suggesting that iPS generation is not restricted by the 
age and the source of the cells (Dimos et al., 2008).  
IPS cells were subsequently generated to study disease and drug development. 
IPS cells were successfully generated from patients with 10 different single-
gene disorders including Gaucher disease type III, Shwachman-Bodian-
Diamond syndrome, Huntington disease, Lesch–Nyhan syndrome and 
Parkinson’s disease. The mutation to the wild-type was corrected before 
transplantation by gene targeting. The resulting cells were analysed to confirm 
that gene repair was perfect and specific, thereby decreasing the safety 
concerns of random, viral-mediated gene therapy. Furthermore, all generated 
iPS cell lines expressed markers including OCT4, SOX2, NANOG, REX1, 
GDF3 and hTERT and possessed the ability to differentiate into the three germ 
layers in vitro (Park et al., 2008). Similarly, primary dermal keratinocytes and 
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fibroblasts were obtained from Fanconi Anemia (FA) patients (Raya et al., 
2009). Somatic cells were used either directly or after genetic correction to 
generate iPS- cells. IPS cells generated from genetically corrected FA somatic 
cells showed disease-free phenotype with fully functional FA pathway. 
Furthermore, haematopoietic progenitors of the erythroid and myeloid lineages 
were successfully obtained from FA-iPS cells and maintained the disease-free 
phenotype of FA-iPS cells. However, iPS cells could not be generated from 
patient’s cells before repairing the genetic alteration. Recently Zou et al 
reported the first successful gene targeting by homologous recombination in 
human iPS cells using an engineered gene-targeting vector expressing a zinc 
finger nuclease. This technique increased the efficiency of HR-mediated gene 
targeting by almost 200-fold in human ES and iPS cells without detrimental 
effects on either cell karyotypes or pluripotency. Therefore, this study provided 
a solid foundation to enhance the development of future therapeutic gene 
targeting to efficiently create or correct specific mutations in patient-specific iPS 
cells (Zou et al., 2009).  
Human iPS cells can also be used to model a specific pathology seen in a 
genetically inherited disease. Fibroblast cells isolated from a child with spinal 
muscular atrophy were used to generate iPS cells. IPS derived neurons 
retained the disease genotype and showed selective deficits compared to those 
derived from the patient’s healthy mother (Ebert et al., 2009). Disease-specific 
iPS cells can also help as a small molecule screening platform for drug 
development. IPS cells established from familial dysautonomia patients (FD-
iPS) were differentiated towards neural crest lineages to model functional 
characteristics of pathogenesis in vitro (Lee et al., 2009). This model enabled 
the authors to identify a new drug candidate termed ‘‘kinetin,’’ for the treatment 
of FD, and further supported the potential use of iPS cell technology in disease 
modelling and cell therapy. Professor Schwartz and his colleagues reported 
new, positive data in a paper in Lancet from their clinical trials using retinal 
pigmented epithelial cells (RPEs) made from human ES cells for treatment of 
different forms of macular degeneration (MD). Importantly so far bleeding and 
some adverse side effects were reported and appeared related to the delivery 
procedure itself and to immunosuppression (Schwartz et al., 2014). Recently, a 
Japanese woman in her seventies who had retinal damage owing to a condition 
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known as age-related macular degeneration has been received for the first time 
ever tissue derived from iPS cells. Cells from the patient's skin were 
reprogrammed to produce iPS cells. Then those cells were differentiated into 
retinal pigment epithelium cells and grown into a sheet for implantation. No 
serious side effects have been reported. However, researchers around the 
world are watching to see whether the cells stop the retina from deteriorating 
further and whether any side effects develop (Cyranoski, 2014).  
Overall, iPS cells present a potentially unlimited source of cells that may be 
directed to differentiate into all cell types within the body and used in tissue 
engineering, cell replacement therapies and for regenerative medicine 
applications. A potential major advantage here is that iPS cells have the ability 
to generate other cell types such as neural, endothelial and a smooth muscle 
cell which makes them a valuable cell source for urological tissue engineering 
compared with other cell types. These are integral cell types that make up the 
complete organ. 
1.8.1.5 The limitation of using iPS cells in regenerative medicine 
The unique nature of iPS cells lies in their capability, when cultured, for 
unlimited self-renewal and reproduction of all cell types of the body in the 
course of their differentiation; therefore they represent invaluable tools for 
research into the mechanism of tissue formation. However, there are also 
significant problems associated with the use of these cells in tissue engineering 
(Ibarretxe et al., 2012). Pluripotent stem cells present a safety concern because 
of their potential to form tumours. When these cells are transplanted in the 
undifferentiated state, they form teratomas, tumours derived from all three germ 
layers. Currently, the only way to ensure that teratomas do not form is to 
differentiate the pluripotent stem cells, enrich for the desired cell type, and 
screen for the presence of undifferentiated cells (Zhu et al., 2011). Another 
serious problem is the use of potentially harmful genome integrating viruses to 
deliver reprogramming factor transgenes. Most iPS cells are prepared by viral 
vectors that integrate the reprogramming factors into host genomes, increasing 
the risk of tumor formation (Takahashi and Yamanaka, 2006; Brambrink et al., 
2008). The residual presence of integrated transgenes following the derivation 
of IPS cells is highly undesirable. The four genes used for the induction of 
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pluripotency are recognised oncogenes, thus pose a theoretical risk of 
neoplastic development from cells derived from iPS cells. There are substantial 
grounds to state that the process of nuclear reprogramming by virus-assisted 
factor insertion in the cell genome increases the risk of carcinogenesis (Miura et 
al., 2009). This high risk of carcinogenesis is largely, but not exclusively, related 
to the integration of c-MYC transgenes (Nakagawa et al., 2008). Several 
possible strategies exist for resolving the above mentioned problems including 
the development of delivery protocols for non-integrated genetic constructs 
(adenoviruses, plasmid transfection, doxycycline-inducible excisable piggyBac 
(PB) transposon system), and minimizing the number of genes required for 
reprogramming. Another way to reprogram somatic cells consists of delivery of 
recombinant proteins rather than genes into the cells to be reprogrammed 
(Zhou et al., 2009) or the induction of reprogramming by chemical stimulation 
and screening/selection of effective small molecules, thus reducing the amount 
of factors delivered to cells (Lyssiotis et al., 2009). The opportunity to obtain 
patient-specific iPS cells has brought a big hope on the prospect of future tissue 
engineering regenerative therapies by cell transplant since these new 
pluripotent cells circumvent two of the main problems traditionally associated 
with human ES cells (ethical issues and the possibility of rejection of the 
transplanted cells by the host immune system). One can confidently state that 
both iPS cells and their derivatives are potent instruments applicable in cell 
replacement therapy. Their use for tissue regeneration, however, poses 
considerable health risks, with research into their clinical value still in the 
earliest stages (Medvedev et al., 2010). 
1.8.1.6  “Retentive” memory of reprogrammed cells  
Although iPS cells were shown to be similar to ES cells with respect to gene 
expression of pluripotency markers and the ability to differentiate into cell types 
from the three embryonic germ layers both in vitro and in teratoma assays, 
differences between iPS cells and ES cells in their gene expression profiles 
(Chin et al., 2009), differentiation abilities (Feng et al., 2010), and persistence of 
donor-cell gene expression (Ghosh et al., 2010; Bar-Nur et al., 2011) have been 
recently documented. It has been shown that iPS cells at low passages display 
an epigenetic memory inherited from the original somatic cell that will likely 
favour iPS cell differentiation towards lineages related to that cell (Chin et al., 
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2009; Marchetto et al., 2009; Kim et al., 2010). Genome wide expression 
analysis of human iPS cells and their embryo derived counterparts showed that 
early- and late-passage iPS cells have different gene expression signatures, 
where late-passage appeared to be much more similar to their embryo-derived 
counterparts than early-passage iPS cells. Analysing the expression differences 
between early-passage iPS cells lines and their related human ES cells showed 
that most of the genes highly expressed in iPS cells versus ES cells were 
associated with differentiation. Although extended passaging significantly 
reduced these transcriptional differences, late passage iPS cells were still 
distinguishable from ES cells. These transcriptional differences didn’t appear to 
be due to differences in histone modification patterns (Guenther et al., 2010) 
suggesting insufficient suppression of somatic genes or insufficient induction of 
pluripotent genes (Chin et al., 2009; Marchetto et al., 2009). Other studies also 
revealed unique DNA methylation and gene expression patterns that are 
inherited from a parental cell following reprogramming in both human and 
mouse iPS (Kim et al., 2010; Lister et al., 2011; Ohi et al., 2011).  
Mouse iPS cells in very low-passage were found to maintain a DNA methylation 
memory of their somatic tissue of origin that may influence their differentiation 
propensity toward tissue specific fates related to that origin, and limiting other 
cell destinies (Kim et al., 2010; Polo et al., 2010). These data are consistent 
with previous reports, which indicate that cell origin influences reprogramming 
efficiency (Aoi et al., 2008; Maherali et al., 2008; Miura et al., 2009). 
Importantly, this epigenetic memory may only appear upon differentiation when 
the particular loci that retained epigenetic marks are expressed and not in the 
pluripotent state. Methylation, faulty restoration of bivalent domains and loss of 
key factors that mediate repression of genes expressed only in differentiated 
cells constitute suggested mechanisms of epigenetic memory in iPS cells (Kim 
et al., 2010; Polo et al., 2010). In accordance with these findings, gene 
expression and DNA methylation analysis of human iPS cells established from 
different cell origins showed that iPS cells retain a residual transcriptional 
memory of the original somatic cell which can be partially identified by inefficient 
promoter DNA methylation and silencing of somatic genes. Inhibition of 
C9orf64, one of the main incompletely silenced genes in iPS cells significantly 
decreased the efficiency of iPS generation suggesting that such genes may be 
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required during reprogramming therefore continue to be expressed in nascent 
iPS cells. Notably most of these findings were associated with early passage 
iPS cells (Ohi et al., 2011). However, much additional research will be 
necessary to understand how this memory varies among different cell types and 
tissues. Interestingly, the presence of a tissue-specific epigenetic memory might 
be of benefit rather than a hindrance through generation of iPS cells that retain 
the ability to differentiate into a specific cell type.  
Recently Bar-Nur et al utilised a genetic lineage-tracing approach for monitoring 
the origin of reprogrammed cells and evaluating the differentiation potential of 
iPS cells derived from human beta cells (BiPS). Generated BiPS cells were 
found to retain an epigenetic memory during their expansion in vitro that may 
preferentially drive their differentiation more readily into insulin producing cells. 
BiPS cell lines showed a typical ES-like morphology, expressed most 
pluripotency markers at both RNA and protein levels, silenced the retroviral 
transgenes, maintained a normal diploid karyotype and generated cells from all 
three embryonic germ layers. Importantly, the linear correlation coefficient 
between BiPS cells and ES cells was very similar to the correlation coefficient 
between two different ES cell lines (R = 0.94). These observations collectively 
indicated that BiPS cells were truly reprogrammed pluripotent cells. Chromatin 
immunoprecipitation showed epigenetic imprint preserved in the INSULIN and 
PDX1 gene promoters in BiPS cell lines at similar levels to those of beta cell-
derived (BCD) progeny, while not detected in non-beta pancreatic iPS (PiPS) 
cell lines, iPS cells derived from fibroblasts, or ES cells of similar passage 
numbers. Similar epigenetic memory was observed at the DNA methylation 
level with unique DNA methylation signature in BiPS cells that segregated them 
from BCD, PiPS cells lines, iPS cells, and ES cells. The authors next 
investigated if that observed epigenetic memory may skew the differentiation of 
BiPS cells into insulin producing cells and found that differentiated cells derived 
from BiPS cells expressed higher levels of INSULIN, PDX1, and FOXA2 
compared to differentiated cells derived from PiPS cell lines, iPS cells, and ES 
cells of similar passage numbers, suggesting preferential lineage-specific 
differentiation in BiPS (Bar-Nur et al., 2011). Therefore, it is essential to 
generate human iPS cells from different tissues and compare their safety and 
differentiation capacities. 
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Consistent with these results iPS cells derived from murine ventricular myocytes 
showed a dramatically higher tendency to re-differentiate back to cardiovascular 
progenitors and contribute to functionally beating cardiomyocytes as compared 
to genetically matched ES cells or iPS cells derived from tail-tip fibroblasts (Xu 
et al., 2012). Global gene expression and DNA methylation analysis of these 
iPS cells showed a distinct transcriptional and epigenetic signature that may 
potentially be involved in directing iPS cells to ventricular myocytes fate. Later 
Lee et al extended these studies to demonstrate that the differentiation potential 
of iPS cells may depend on the lineage stage-specific differentiation state of 
donor cells. iPS cell lines established from hepatic lineage cells at an early 
stage (hepatoblast) can differentiate more effectively toward hepatocytic lineage 
as compared to iPS cells established from adult hepatocyte (late stage), mouse 
embryonic fibroblasts, or mouse ES cells (Lee et al., 2012). All the generated 
iPS cell lines showed ES cell-like morphology, expressed pluripotency markers 
and underwent multilineage differentiation in vitro and in vivo demonstrating 
their complete reprogramming. Moreover, a global gene expression analysis of 
hepatoblast derived iPS cells also exhibited a unique gene expression 
signature, which clearly differentiated them from iPS cells established from adult 
hepatocyte as well as mouse ES cells. These differences in gene expression 
were suggested to be responsible for the variability observed in differentiation 
potency. Comparison of the gene expression profiles of the hepatoblast derived 
iPS cells and parental cells allowed identification of 24 genes (7 upregulated 
and 17 downregulated genes) as the hepatoblast derived-iPS cells specific 
donor memory genes. 
Based on this literature, we hypothesised that iPS cells generated from urinary 
tract specific tissue is better able to regenerate differentiated bladder tissue 
than conventional skin fibroblast derived iPS cells. To this end, stromal cell 
isolated from the lower urinary tract were transduced with lentiviral vectors 
encoding the four pluripotency-inducing factors, OCT4, SOX2, KLF4, and C-
MYC in a single polycistronic construct. The cDNA was further ‘Floxed’ by LoxP 
sites to ensure deletion of the viral genome once the cells attained their 
‘ground-state’. Transduced cells were subjected to an optimized protocol 
involving the use of pluripotent-cell as well as feeder cell-conditioned media. A 
total of 31 clones from 5 different patients have been generated. The resultant 
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cells silenced the lentiviral transgenes, and maintained a normal diploid 
karyotype and their credibility were further corroborated by means of ‘paternity’ 
tests showing an identical DNA identity match between parent and the resultant 
UT-iPS cells for a panel of microsatellite markers. All the UT-iPS cells 
expressed embryonic stem-cell characteristics. The cells were expressed 
endogenous pluripotency genes in comparable levels to human ES cells and 
gave rise to differentiated cells representing all the three germ layers in vitro, as 
judged by EB formation assay, and in vivo, as evidenced by teratoma formation 
assay. Taken together, these results demonstrate that UT-iPS cells are truly 
reprogrammed pluripotent cells. We have also found that these UT-iPS cells 
show preferred differentiation towards bladder tissues suggesting that a tissue-
specific molecular and epigenetic imprint may remain contained during iPS cells 
reprogramming.  
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Hypotheses:  
IPS cells generated from urinary tract specific tissue (UT-iPS) are better able to 
regenerate differentiated bladder tissue than conventional skin fibroblast 
derived iPS cells (skin-iPS).  
Aims:  
- Generation of induced pluripotent stem cells from stromal/ urothelial cells 
isolated form the urinary tract tissue (UT-iPS) cells.  
- Evaluate the potential of UT-iPS cells to differentiate into bladder specific cells 
compared with the conventional skin-iPS cells. 
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2 Chapter 2. Materials and methods 
2.1 Cell culturing and maintaining 
3.1.9 Cell line culture: Normal Human Dermal Fibroblast (NHDF) cells 
NHDF cells were kindly donated by Prof. Majlinda Lako (Institute of Genetic 
Medicine, Newcastle University). Cells were cultured in RPMI1640 medium with 
HEPES modification (Sigma) supplemented with 10% heat inactivated foetal 
bovine serum (FBS) (GIBCO, Life Technologies) and 1% L-glutamine (2mM) 
(Sigma). Cells were passaged approximately every week and the medium was 
changed every 48 hours. The main purpose for growing these cells is to be 
used as control cell line for iPS induction. 
3.1.10   Primary tissue culture 
The urothelium is defined as the epithelial cells lining the surface of the renal 
pelvis, ureter, bladder, and proximal urethra; therefore, we used the urothelium 
isolated from human bladder and ureter as a model for studying the urothelial 
cells. All surgical specimens were collected after conforming to ethical 
guidelines and had full patient consent. Samples of bladder and ureter were 
obtained from patients undergoing various urological procedures with no history 
of urothelial dysplasia or malignancy (Department of Urology, Freeman 
Hospital, Newcastle Upon Tyne, UK). Samples were taken to the laboratory as 
promptly as possible. All procedures were performed under sterile conditions. 
2.1.1.1 Isolation and culturing of human urothelial cells 
Two methods were used to isolate and grow human urothelial cells in vitro, 
primary explant culture, and enzymatic digestion method described by 
Southgate et al (Jennifer Southgate, 2002; Southgate et al., 2007). 
I. Primary explant culture 
Ureter samples were opened longitudinally and the urothelium attached to 
underlying tissues was separated mechanically using fine curved scissor and 
forceps (sterilized tools were used to prevent any cross-contamination), and cut 
into small pieces (≈2x2 mm). Tissue pieces were placed into 90 mm Petri dish 
(Figure  2-1) (approx 5 pieces/dish) containing 2-3 ml of keratinocyte serum-free 
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medium (KSFM) supplemented with epidermal growth factor (EGF, 5 ng/ml) and 
bovine pituitary extract (BPE, 50 pg/ml) as provided by the manufacturer 
(GIBCO, Life Technologies) as well as 1% Penicillin-Streptomycin (Sigma), the 
medium was further supplemented with 30 ng/ml of cholera toxin (Sigma) to 
improve cell attachment, this medium was called Complete Keratinocyte Serum-
Free Medium (KSFMc). Using low calcium concentration, bovine pituitary 
extract, and other supplementary growth factors have been found to promote 
the growth of epithelial cells and enable for higher serial passages in culture 
(Chaproniere and McKeehan, 1986). Cultures were kept at 37°C and in a 
humidified atmosphere of 5% CO2. The medium was replaced every 2-3 days. 
Explants outgrowth was maintained until a significant number of cells were 
obtained. Cells were passaged as follows: after removing the explants and 
medium from the dish, 1.5 ml of 0.05% trypsin (Sigma) was added and 
incubated at 37°C for about 5 minutes. Once all the cells were lifted off, the 
trypsin was diluted by adding 5 ml of KSFMc. Cells were centrifuged at 1200 x 
rpm for 4 minutes, re-suspended in fresh medium, and seeded into flasks or 
Petri dishes depending on the density of the cells. 
 
Figure  2-1: A schematic drawing for the initial steps of the primary explant 
culture. 
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II. Enzymatic digestion  
Samples were dissected into approximately 1-2 cm2 pieces. Each piece was 
placed into 10 ml of stripper medium (Table  2-1) for 4 hours at 37°C or 
overnight at 4°C to detach the urothelial cell sheets from the underlying stroma. 
The urothelium sheets were then scraped gently from their stromal counterparts 
using forceps and centrifuged at 1200 x rpm for 4 minutes. The resulting pellet 
was further disaggregated by treating with 2ml of collagenase type IV 100 U/ml 
(Sigma) for 20 minutes at 37°C. Cells were centrifuged and were further purified 
through MACS separation with the help of MACS microbeads linked to an 
antibody against the HEA (Human Epithelial Antigen/CD326/EpCAM/) antigen 
(Miltenyl Biotech Ltd., Surrey, UK). CD326 positive urothelial cells were seeded 
into 60mm tissue culture dish and maintained in KSFMc at 37°C and in a 
humidified atmosphere of 5% CO2 in air. Because the initial yield of urothelial 
cells was in most cases very low, we found that culturing cells initially into 
60mm tissue culture dish rather than 90mm culture dishes increased culture 
success rate since it ensured that the cells are more close to each other. 
Cultures were passaged as follow: the medium was removed and the cells were 
treated with phosphate buffered saline (PBS) containing 0.1% (w/v) EDTA for 5 
minutes at 37°C, followed by incubation in 1 ml of trypsin-versene (containing 
0.25% (w/v) trypsin and 0.02% (w/v) EDTA) to detach the cells. Cells were re-
suspended in KSFMc containing trypsin inhibitor (Sigma) and collected by 
centrifugation at 1200 x rpm for 4 minutes. The supernatant was aspirated and 
the cells were resuspended in KSFMc medium and plated into two 60mm tissue 
culture dish.  
Stripping solution 
Components Quantity Supplier 
Hanks' Balanced Salt Solution (HBSS) without 
Ca2+ and Mg2+ 
500ml Invitrogen 
1% (w/v) EDTA 50ml Sigma 
1 M HEPES buffer pH 7.6 5ml Sigma 
Aprotinin(500,000-KIU) 1ml (20 KIU) Sigma 
Table  2-1: Stripping solution composition. 
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III. CD326 magnetic activated cell sorting (MACS) 
We used the MACS Kit provided by Miltenyi Biotec and CD326 microbeads to 
enrich for epithelial cells. Briefly, cells were incubated in 300 µl MACS buffer 
(1xPBS, 0.25%FCS, and 2mM EDTA), 100 µl FcR Blocking Reagent human (to 
increase the specificity of labelling with MACS Micro Beads), and 100 µl of 
CD236 MicroBeads conjugated to monoclonal antibody (Miltenyi Biotech, 
Bergisch Gladbach, Germany) for 30 minutes at 4 °C. Following incubation, 
cells were washed with cold MACS buffer, and centrifuged at 300 x g for 10 
minutes at 4°C. Finally, cells were re-suspended in 500 µl of MACS buffer. For 
cell sorting, the magnetic separation MS column was placed in the magnetic 
field and prepared by rinsing with 500 µl of MACS buffer. The cell suspension 
was applied onto the column. CD326 positive cells remained on the column in 
the magnetic field whereas unlabeled cells (CD326 negative cells) flowed 
through and were collected in a universal tube. Immediately after removing the 
column from the separator, the labelled cells were flushed out to another 
universal tube with 1 ml MACS buffer and plunger. 
2.1.1.2 Isolation and culturing of human urinary tract stromal cells  
All stromal cells were propagated and maintained in RPMI1640 media with 
HEPES modification (Sigma) supplemented with 10% FBS, 1% L-glutamine 
(2mM), and 1% Penicillin-Streptomycin (Sigma). This medium was called full 
RPMI1640 medium. Firstly, the stroma layer from which the urothelium had 
been detached was minced with sterile scissors to ensure increased surface 
area for digestion (Figure  2-2). Then, resulting tissue pieces were digested by 
incubating with 250 U/mg of collagenase Type I (LS004196, Worthington, Lorne 
Laboratories, Reading, UK) overnight at 37°C with stirring. Collagenase I 
solution was prepared by dissolving 20mg of Collagenase IV powder in 20 ml of 
full medium RPMI1640. The cell suspension was mechanically disrupted by 
aspiration back and forth through a 21 gauge (21G) needle to homogenise and 
increase yield. Cells were then washed with PBS and centrifuged at 1500 x rpm 
for 5 minutes. Finally, cells were seeded in 25cm2 flask containing 5ml of full 
medium RPMI1640. Stromal cells were passaged when approximately 85% 
confluent using either 75cm2 or 175cm2 flasks (Corning, UK) and maintained at 
37°C in a humidified atmosphere of 5% CO2 in air. Subculture was achieved as 
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follows: after removing the medium, cells were washed 1 x with PBS and 
detached from culture surface enzymatically by treatment with 2-3 ml of 0.05% 
trypsin solution and incubating at 37°C for 5 minutes. Then trypsin was 
neutralised by adding 8 ml of full medium RPMI1640. Cells were centrifuged at 
1500 x rpm for 5 minutes and re-suspended in appropriate amount of full 
medium RPMI1640 depending upon flask size. 
 
Figure  2-2: A schematic drawing of the initial steps in isolation and culturing the 
urinary tract stroma. 
 
2.1.1.3 Freezing and thawing human urinary tract cells 
We couldn’t freeze the urothelial cells because the yield of these cells was in 
most cases very low. 80-90% confluent T175 flask of stromal cells was washed 
with PBS and incubated with 5 ml of 0.05% trypsin for 5 minutes at 37°C. The 
cells centrifuged at 1500 x rpm for 5 minutes, and the supernatant was 
discarded and replaced with 1 ml of fresh prepared freezing medium (Table  2-2) 
per original T175 flask of stromal cells. Cell suspension was transferred to 
cryopreservation cryovials (Nunc) and stored in a -80°C freezer. To retrieve 
frozen cells, a cryovial was rapidly transferred into 37°C water until most of the 
contents were thawed. Thawed cells were immediately washed with 9 ml pre-
warmed RPMI1640 full medium and centrifuged at 1500 x rpm for 5 minutes at 
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room temperature. The cells pellet was re-suspended in 10 ml of RPMI1640 full 
medium and plated into T75 culture flasks. After 24 hours, the medium was 
changed and the cells were monitored for adherence and potential 
contamination. 
Freezing medium  
Components  Quantity Supplier 
RPMI1640 8 ml Sigma 
Dimethyl sulfoxide (DMSO) 1 ml Sigma 
Heat treated foetal bovine serum (FBS) 1 ml Invitrogen 
Table  2-2: Freezing Mixture Composition. 
 
3.1.11 Pluripotent stem cell culture 
2.1.1.4 Culturing UT-iPS cells on MEF feeder cells. 
Human UT-iPS cells were routinely cultured in a 0.1% gelatin coated 6-well 
plate (Corning, UK) and were maintained on a layer of mouse embryonic 
fibroblast (MEF) feeder cells in human ES cell medium (Table  2-3). UT-iPS cells 
were checked microscopically to assure cell growth and sterility and maintained 
as mycoplasma negative.  
 
Human Embryonic stem cell medium 
Components Quantity Supplier 
Knockout-Dulbecco’s Modified Eagle’s 
Medium (KO-DMEM) 
120ml – 80% Invitrogen 
Knockout-Serum Replacement (KO-SR) 30ml – 20% Invitrogen 
MEM Non-Essential Amino Acids (100X), 
liquid 
1.5ml – 1% Invitrogen 
Penicillin-Streptomycin Solution 1.5ml – 1% Sigma 
Basic Fibroblast Growth Factor (B-FGF) 120µl- 8ng/ml Invitrogen 
GlutaMAX™-I Supplement, 200 mM 1.5ml– 2mM Invitrogen 
β-mercaptoethanol 2µl- 100µM Sigma 
 
Table  2-3: Human Embryonic Stem Cell Media Composition. 
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2.1.1.4.1  Preparing gelatin coated culture plates 
To improve their adhesion and attachment, MEF cells were plated onto 0.1% 
gelatin-coated plates. To prepare the gelatin solution, 1 gram of gelatin powder 
was dissolved to 100ml of distilled sterile water. This was autoclaved, dispensed 
into 50ml of 1% gelatin aliquots, and stored at -20ºC. To make 0.1% gelatin, 50 
ml of 1% gelatin was dissolved in 450 ml sterile distilled water. A gelatin-coated 
6-well plate was prepared by placing 1 ml of this 0.1% gelatin into each well. 
These gelatinised plates were incubated in a sterile environment for 30 minutes 
at room temperature or for 2 hours at 37°C, and the gelatin solution was only 
removed immediately prior to plating of irradiated MEFs. 
2.1.1.4.2  Thawing and preparing MEF feeder plates 
UT-iPS cells were maintained on irradiated MEF cells, passage 3, purchased 
from VhBio. MEF cells were derived from CF-1 mouse embryos at day 13 and 
mitotically inactivated by treatment with irradiation. The cells can be directly 
plated onto gelatin coated plates. Frozen stocks of MEFs were stored at -80º. At 
a time point 24 hours prior to use, cells were thawed as quickly as possible in a 
37°C water bath, with gentle shaking by hand and transferred to a 20 ml 
universal centrifuge tube (Sterilin, UK) and washed by adding 10 ml of complete 
MEF medium (DMEM medium with HEPES modification supplemented with 
10% FBS and 2mM L-Glutamine) dropwise, slowly with swirling and centrifuged 
at 1500 x rpm for 5 minutes. The cells pellet was re-suspended with an 
appropriate volume of complete MEF medium and directly plated at a 
concentration of 5 x 104 cells / cm2 on pre-gelatinised 6-well plates. The MEF 
coated plates were ready to use 24 hours after plating and always used within 5 
days. 
2.1.1.4.3  Preparation of MEF- conditioned medium (MEF-CM) 
MEF cells were plated at a density of 5 x 104 cells / cm2 on pre-gelatinised 6-
well plates in complete MEF medium. The following day, the MEF medium with 
2ml/well of human ES cell medium was replaced, and incubated at 37°C, and 
5% CO2. The MEF-CM was collected from the wells every 24 hours and 
sterilized by passing it through 0.22 μM disposable filter. MEF-CM was collected 
for up to seven days using this procedure. MEF-CM was used fresh (within 3 
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days), otherwise frozen at -80º. Non-inactivated cell lines were also maintained 
in culture so as to generate feeder-conditioned media. These cells were 
routinely checked to assure cell growth and sterility and were maintained as 
mycoplasma negative. 
2.1.1.4.4  Passaging UT-iPS cells onto MEF feeder cells  
A plate which contained UT-iPS colonies that cover 80-90% of each well was 
ready to be passaged in a ratio of 1 to 3. One day before splitting UT-iPS cells, 
a new MEF plate was prepared. The complete MEF medium was replaced on 
the day of UT-iPS cells culture with 2 ml of human ES cell medium. UT-iPS 
cultures were split using mechanical and enzymatic dissociation passaging 
using a dissecting microscope within a laminar flow cabinet. UT-iPS colonies 
were washed with 1XPBS and treated with 1ml per well of prewarmed 
Collagenase IV solution (1mg/ml, GIBCO, Life Technologies) for 5-8 minutes at 
37ºC until the edge of the colonies could be clearly defined and appeared 
slightly raised from the surrounding MEF cells. At this point the Collagenase 
was replaced with 2 ml of fresh human ES cell medium. To maintain the general 
undifferentiated state of the culture, the differentiated regions were identified 
morphologically and excised manually using a dissecting microscope within a 
laminar flow cabinet with P20/200 sterile plastic Gilson tip. The remaining 
undifferentiated colonies were scored with a 29 gauge (29G) needle or a P20 
Gilson pipette tip into small clumps and transferred with a P200 pipette to new 
6-well MEF plates and mixed gently to spread the clumps evenly over the well. 
The plate was incubated at 37°C in 5% CO2 for 24 hours to allow cells to 
adhere to the bottom. Medium was changed the following day and every second 
day thereafter and colonies were monitored daily with any differentiated area of 
cells removed. Care was taken to avoid disaggregation of UT-iPS colonies to 
single cells during passaging, as this will significantly decrease their survival 
efficiency. On average, UT-iPS colonies were plated at a density of ~250-300 
colonies per well/6-well plate. 5-7 days post-passage, the colonies reached 80-
90% confluent within the wells and were then transferred into fresh MEF plates. 
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2.1.1.5 Culturing UT-iPS cells under feeder-free conditions 
Human UT-iPS cells were cultured in 6-well culture plates coated with BD 
Matrigel™ human ES cell-qualified Matrix (354277, BD Biosciences, Bedford, 
UK) and maintained in a defined serum-free media mTeSR™1(05850, StemCell 
Technologies.) that was changed every 24 hours. To prepare the mTeSR1 
medium, the 100ml mTeSR1 5X supplement was thawed overnight at 2 - 8°C 
and added to 400 ml basal medium for a total volume of 500 ml. The complete 
mTeSR™ medium was dispensed into working aliquots and stored at -20°C for 
up to 6 months. Thawed aliquots were stored at 4°C and used within two 
weeks. Under these conditions, UT-iPS cells were grown in colonies and 
passaged about every 5-7 days at split ratio of 1:6.  
2.1.1.5.1  Preparing Matrigel-coated culture plates 
The BD Matrigel™ matrix was thawed overnight at 4°C on ice. Once thawed, 
the vial was swirled to ensure the Matrigel was evenly dispersed. The content 
was aliquoted into smaller working volumes (160 µl) and stored at -80°C for up 
to 6 months. BD Matrigel was kept on ice at all times while handling, aliquoted 
as quickly as possible using pre-cooled tips and refrozen immediately to prevent 
it from gelling. Multi freeze- thaw was avoided. According to the dilution factor 
provided on the certificate of analysis, each aliquot can be used to coat two 6-
well plates. To coat the plate, the BD Matrigel aliquot was thawed on ice and 
mixed with 13 ml of cold DMEM/F-12 (Sigma). Immediately, the wells were fully 
coated with the diluted BD Matrigel solution using 1ml/ well of a 6 well plate. 
The plates were incubated at room temperature for at least 1 hour before use. 
Otherwise the plates were sealed with Parafilm to prevent evaporation of the 
BD Matrigel solution and stored at 4°C for up to 7 days after coating. Stored 
coated plates were kept at room temperature for 30 minutes before use. Just 
before plating the UT-iPS cells, the BD Matrigel solution was carefully removed 
using a pipette without scratching the coated surface followed by adding 2ml of 
complete mTeSR1 medium. 
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2.1.1.5.2   Passaging UT-iPS cells under feeder-free conditions 
UT-iPS colonies were passaged when about 80% of the culture surface was 
covered with colonies. Before passaging, differentiation areas were visually 
detected and removed by scraping with a pipette tip using an inverted 
microscope in a laminar flow cabinet. To passage, undifferentiated UT-iPS 
colonies were washed with DMEM/F-12 medium (2 mL/well) and loosened from 
the Matrigel by incubation with 1 ml/well of dispase (07923, StemCell 
Technologies) at a concentration of 1 mg/ml at 37°C for 5-7 minutes. Once the 
edges of the colonies start curling up, the dispase solution was removed and 
the cells were gently washed with 2 ml/well of DMEM/F-12 medium to dilute 
away any remaining dispase. Then 2 ml/well of mTeSR1 medium was added 
and the colonies were gently scraped from the substrate with a glass pipette 
and broken into pieces. These pieces were transferred onto new Matrigel-
coated culture wells and grown in mTeSR1 medium. The new plates were then 
placed in an incubator and agitated a few times to disperse the colonies evenly 
over the whole surface. Starting 24 hours after passaging, the cells were 
monitored daily and the medium was changed every other day. 
2.1.1.6 Freezing and thawing of UT-iPS cells  
IPS cells have a low viability when split to single cells and are therefore 
routinely passaged as aggregates or clumps of cells. Unfortunately, when these 
cells are frozen, their viability upon thawing is particularly low making freezing 
and reconstituting of iPS cells a real challenge. Cryopreservation was done at 
the time when they were ready for passaging where wells are 80 % confluent. 
Before freezing, the UT-iPS cell culture was checked to ensure that it was at a 
suitable confluency, healthy situation and free of contamination. UT-iPS clumps 
were stored using both slow (Cryovial Cryopreservation) and fast (Vitrification) 
freezing methods. Vitrification is a rapid process and usually provides better 
post-thaw recovery rate of iPS cells compared to that in slow freezing 
procedure. However, the latter one is generally more conveniently performed 
and hence desired. 
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2.1.1.6.1   Slow freezing of the UT-iPS cells  
I. Cryopreserving using DMSO:  
Cell aggregates were collected as per routine UT-iPS cells passaging and kept 
as big as possible. Cells were pelleted at 200g for 4 minutes at room 
temperature. During the spin, the freezing medium was prepared, which 
contains: 50% human ES cell medium and 50% cryopreservation medium 
(Table  2-4). The supernatant was aspirated and the cells pellet was 
reconstituted in 200µl of freezing medium and mixed quickly and gently. It has 
been previously shown that the addition of Rho-associated Kinase (ROCK) 
inhibitor Y-27632 to the freezing medium minimises cell apoptosis and 
significantly enhances survival by as much as 27 fold (Watanabe et al., 2007). 
Cells harvested from one 6-well plates were frozen in 1 cryovial, to this 10μM of 
ROCK inhibitor (Stemolecule ™ Y27632, Stemgent) was added and the 
cryovials were placed in a -80˚C freezer for short term storage and were later 
transferred to liquid nitrogen (-196°C) for long-term storage.  
Cryopreservation medium(x10) 
Components Quantity Supplier 
Heat Treated Foetal Bovine Serum (FBS) 600µl- 60% Invitrogen 
DMSO 200µl- 20% Sigma 
HESC Media 200µl- 20% - 
Y-27632 Rho-associated Kinase (ROCK) 
inhibitor 
10µM Stemgent 
Table  2-4: Cryopreservation medium composition. 
 
II. Cryopreserving using STEM-CELLBANKER: 
Cells were harvested as per routine UT-iPS cells passaging. Cell clumps were 
centrifuged at 200g for 4 minutes at room temperature, the supernatant was 
removed and cells were gently suspended with 1 ml STEM-CELLBANKER 
cryopreservation medium (11890, AMSBIO LLC) with no other supplements and 
transferred to one cryovial. Cryovials were directly placed in a -80˚C for storage. 
For every well of a 6-well plate being frozen 1 mL of STEM-CELLBANKER was 
used. 
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2.1.1.6.2   Cryovial cryopreservation thawing 
To thaw the UT-iPS cells, we removed the frozen UT-iPS Cryovial from the 
liquid nitrogen storage tank and quickly thawed the cells by swirling gently in a 
37°C water bath. The vial was wiped with 70% Ethanol and the cells were 
washed with 10 ml of human ES cell medium. Cells were centrifuged at 200 x g 
for 4 minutes at room temperature and the cells pellet was resuspended in 2 ml 
of fresh human ES cells medium containing 10 µm ROCK inhibitor and plated in 
one well of a freshly prepared 6-well culture plate. The medium was changed 
the following day, and subsequently every 2 days. Small colonies initially 
appeared after one week. In our hands, unfortunately, only 1-5 colonies can 
often be recovered when used 10% DMSO to freeze the UT-iPS cells. However, 
we found that about 50% of the UT-iPS cells cryopreserved with STEM-
CELLBANKER were recovered. 
2.1.1.6.3   Fast freezing of UT-iPS cells 
Protocol courtesy of Dr. Sun Yung and Professor Majlinda Lako (Institute of 
Genetic Medicine, Newcastle University, International Centre for Life.). 
I. Open straw vitrification freezing: 
This procedure allows high cooling and warming speeds which helps to avoid 
chilling injury and minimise toxic and osmotic harm to the cells. 
Collagenase/dispase treated UT-iPS colonies were collected as pieces that are 
larger than those used for passaging and placed into well number 1 (Figure  2-3) 
of a 4-well vitrification plate (TKT-190-130V, Thermo Scientific Nunc ) 
containing 500 µl of ES-HEPES solution (Table  2-5) for 1 minute at 37°C. 8 to 
10 colony pieces were transferred to well number 2 which contains 500 µl of 
10% vitrification solution (Table  2-6) and incubated for 1 minute at 37°C. During 
this minute, a 20 µl drop of 20% vitrification solution (Table  2-8) was placed on 
the inside of the lid of the plate, one per straw to be frozen. The colony pieces 
were transferred to well number 3 containing 500 µl of 20% vitrification solution 
(Figure  2-3) and incubated for 25 seconds at 37°C. The colony pieces were 
transferred to the 20 µl drop of 20% vitrification solution. The colony fragments 
were aspirated in a 3 µl volume from the 20 µl drop and deposited as a 
85 
 
separate small, peaked droplet on the lid (Vajta et al., 1998). The narrow end of 
the vitrification straw was immediately inserted into the side of the 3 µl drop at a 
30° angle to the plane of the dish, and the pieces were sucked up into the straw 
by capillary action. The straw was plunged into liquid nitrogen at a 45° angle 
and stored in a labelled tube within a nitrogen storage canister. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2-3: Open straw vitrification plate – freezing. 
 
 
 
ES-HEPES solution 
Components Quantity Supplier 
Knock Out-Dulbecco’s Modified Eagle’s 
Medium (KO-DMEM) 
15.6ml Invitrogen 
Heat Treated Foetal Bovine Serum (FBS) 4ml Invitrogen 
HEPES (1M) 0.4ml Sigma 
Table  2-5: ES-HEPES solution composition. Stored at 4°C for up to one week. 
 
 
 
 
1 
2 3 
20 µl droplet 3 µl droplet 
Well Solution/Media 
1 ES-HEPES 
2 10% Vitrification 
3 20% Vitrification 
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10% Vitrification solution 
Components Quantity Supplier 
ES-HEPES Solution 2ml - 
Ethylene Glycol 0.25ml Sigma 
DMSO 0.25ml Sigma 
Table  2-6:10% Vitrification solution composition. Stored at 4°C. Unused solution 
discarded after each day. 
 
1M sucrose stock 
Components Quantity Supplier 
Sucrose 3.42g Sigma 
ES-HEPES Solution 14ml - 
Heat Treated Foetal Bovine Serum (FBS) 2ml Invitrogen 
Table  2-7: 1M sucrose stock composition. Stored at 4°C. Unused solution 
discarded after each day. 
 
20% Vitrification Solution 
Components Quantity Supplier 
ES-HEPES Solution 0.75ml - 
1M Sucrose Stock 0.75ml - 
Ethylene Glycol 0.5ml Sigma 
DMSO 0.5ml Sigma 
Table  2-8: 20% Vitrification solution composition. Stored at 4°C. Unused 
solution discarded after each day. 
 
II. Open straw vitrification thawing 
A 4 well vitrification thawing plate was prepared as follow:  
500µl of 0.2M sucrose solution (Table  2-10) was pipetted into well number 1 
(Figure  2-4), 500µl of 0.1M sucrose solution (Table  2-9) was pipetted into well 
number 2, and 500µl of ES-HEPES solution (Table  2-5) was pipetted into wells 
number 3 and 4. The tube that containing the vitrification straw in vitrification 
solution was collected from nitrogen storage in a receptacle containing liquid 
nitrogen. The straw was removed using forceps and immediately the narrow 
end was submerged into the first well containing 0.2M sucrose solution 
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(Figure  2-4) at 30° angle to the plane of the plate. As soon as the liquid column 
melts, a 10 µl pipette was placed at the top end of the straw and the liquid was 
gently pipetted out. After 1 minute at 37°C, the colony pieces were transferred 
to the next well containing 0.1 M sucrose solution and incubated for 5 minutes 
at 37°C. The colony pieces were transferred to the next well containing ES-
HEPES medium and incubated for 5 minutes at 37°C, and then the pieces were 
moved to ES-HEPES solution in well number 4 and incubated for a final 5 
minutes at 37°C. The fragments were harvested and placed into a single well of 
a 4-well plate which contained MEF cells in 500 µl of human ES cell medium.  
 
 
 
 
 
 
 
 
 
Figure  2-4: Open straw vitrification plate - thawing. 
 
0.1M sucrose solution  
Components Quantity Supplier 
ES-HEPES Solution 4.5ml - 
1M Sucrose Stock 0.5ml - 
 
Table  2-9: 0.1M sucrose solution composition. Stored at 4°C. Unused solution 
discarded after each day. 
 
0.2M sucrose solution 
Components Quantity Supplier 
ES-HEPES Solution 4ml - 
1M Sucrose Stock 1ml - 
Table  2-10: 0.2M Sucrose solution composition. Stored at 4°C. Unused solution 
discarded after each day. 
 
Well Solution/Media 
1 0.2M Sucrose 
2 0.1M Sucrose 
3 ES-HEPES 
4 ES-HEPES 
 
1 2 
3 4 
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2.2 Optimizing the transduction efficiency 
The optimal transduction efficiency was regarded as the MOI that would be 
sufficient to transduce the majority of the target cells with the least toxicity. 
Urinary tract stromal cells were seeded at 50,000 cells/well of a 6-well plate and 
transduced with MOIs of 2, 5, 10, 20, and 30 using mWasabi GFP empty 
lentiviral vector (Allele Biotech, USA) in the presence of polybrene 10µg/ml (TR-
1003-G, Millipore, Massachusetts, USA) for 48 hours after which GFP 
expression was analysed and compared against a polybrene-only control (or 
MOI = 0). All FACS analysis was performed on FACSCalibur system using FL1-
H channel for GFP detection and Cyflogic for analysis and interpretation of 
results. 
2.3 Cell viability analysis by flow cytometry 
Cells were exposed to polybrene at concentrations ranging from 0 to 20µg/ml 
for 48 hours. Cells were collected and resuspended in 500µl of MACS buffer. 
Immediately before injection into the flow cytometry, 20µl of 1mg/ml propidium 
iodide (PI, Sigma) was added to each sample. Samples with low PI staining 
were considered viable, while PI-high cells were considered unviable. 
2.4 Alkaline phosphatase staining 
Alkaline phosphatase (ALP) activity was analysed in the UT-iPS cells after five 
days in culture and at low to medium density. The cells were fixed with 4% 
Paraformaldehyde in PBS for 1-2 minutes maximum as fixing for longer period 
will result in the inactivation of alkaline phosphatase. Fixed colonies were 
washed with 1 X wash Buffer (20mM Tris-HCL, pH 7.4, 0.15 NaCl, 0.05% 
Tween-20). The colonies were then treated with Fast Red Violet, AS-BI 
phosphate solution and distilled water in a 2:1:1 ratio and incubated in the dark 
at room temperature for 15 minutes after which the staining solution was 
removed and the colonies were washed again with 1 X wash buffer. The cells 
were covered with 1 X PBS to prevent drying and observed under observed 
under light microscope for AP expression. 
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2.5 Live immunofluorescence staining  
Live cell imaging of emerging colonies was performed by staining with 1:100 
dilutions of anti-TRA-1-60, Clone TRA-1-60-FITC conjugate (Millipore) and anti-
SSEA-4, Clone MC-813-70-PE conjugate (SCR001, Millipore). Cells were 
incubated with 1ml/well of human ES cell medium containing these antibodies. 
After 2 hours of incubation at 37ºC, Hoechst dye was added to wells at a final 
concentration of 0.5μg/ml. After 10 minutes of incubation at 37ºC, cells were 
washed twice with 1ml/well of human ES cell medium and 500µl of medium 
were added before viewing under fluorescent Nikon TE2000-4 inverted 
microscope using NIS elements – BR 3.0 software. 
2.6 Immunofluorescence 
Cells were fixed in 4% Paraformaldehyde/PBS for 15 minutes at room 
temperature. After washing with PBS, cells were permeabilized with 0.1% Triton 
X-100/PBS for 10 minutes at room temperature and blocked in PBS with 4% 
goat serum for 30 minutes followed by incubation with primary antibody 
overnight at 4ºC, and with secondary antibodies for 1 hour at room temperature. 
Primary antibodies included anti-OCT4 (1:100, Millipore); anti-NANOG (1:100, 
Cell Signaling Technology); anti-SSEA-4, anti-TRA-1-60 and anti-TRA-1-81 
(1:100; Millipore); anti-CD31 (1:100, BD Pharmingen), anti-βIII-Tubulin (1:100; 
Covance), anti-αFP (1:100, Sigma), and anti-UPIb (1:100, Santa Cruz). 
Secondary antibodies used were Alexa546-conjugated goat anti-mouse, 
Alexa488-conjugated goat anti-mouse, and Alexa568-conjugated rabbit anti-
goat (all at 1:400, Invitrogen). The nuclei were counterstained with 4’,6-
diamidino-2-phenylindole (DAPI) and cells were mounted (Vectashield; Vector 
Laboratories Inc, Burlingame, CA, USA). Images were obtained using a 
confocal laser scanning microscopy system (Nikon Corp, Tokyo, Japan).  
2.7 Karyotyping of human UT-iPS cells 
UT-iPS cells were karyotyped at passage 25. Karyotyping was performed based 
on the following protocol:   
1) collect cells and arrest at metaphase:  
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Once UT-iPS colonies reached 85% confluence, they were treated with the 
mitotic spindle poison colcemid (kindly donated by Mr. Arman Esfandiari and 
Prof. John Lunec) for 2 hours at 37˚C. Following colcemid treatment, the 
medium was collected and stored in 37ºC. UT-iPS colonies were harvested as 
per routine UT-iPS cells passaging, re-suspended in the previously collected 
medium and allowed to stand for another 10 minutes which further ensured the 
separation of any remaining MEF cells from the UT-iPS colonies. The iPS 
colonies were then washed in 1XPBS and broken down to single 
cell suspensions by treating with 1% trypsin for 5 minutes at 37˚C after which 
the trypsin was inactivated with 10% FBS-PBS. These were then centrifuged at 
1500 rpm for 5 minutes and the supernatant was carefully removed by 
aspiration leaving approx. 200µl of supernatant to re-suspend the mitotic cells in 
by gently flicking the side of the tube. 
2) Addition of hypotonic solution 
To swell the cells and separate the chromosomes, 1ml of ice-cold hypotonic 
solution (1:1 0.4% KCl + 0.4% sodium citrate) was added to the side of the tube 
to make up the final volume to 2ml. Cells were incubated at 37˚C for 7 minutes 
following which the cells were centrifuged at 1500 rpm for 6 minutes and re-
suspended in the remaining 200µl supernatant. 
3) Fix the cells 
Drops of fixative (3:1 methanol and acetic acid) were added slowly to the 
suspension to make up a final volume to 2 mL while gently tapping the tube. 
After 30 minutes of incubation at room temperature, cells were again 
centrifuged, the supernatant was removed and the pellet was resuspended in 
the remaining fluid. The previous step was repeated but with 20 minutes 
incubation at room temperature. At this point, the fixed cells were either 
dropped onto slides or stored at -20˚C. 
4) Prepare the slides 
The glass slides were rinsed with ice cold water and were then rinsed with the 
fixative. The cells fixed earlier were washed once in the fixative. Using a plastic 
transpipet, 2-3 drops of the cell suspension were dropped at 45˚ angle onto the 
slides. The slides were left to dry at room temperature for at least 24 hours.  
5) G-banding of chromosomes and generation of Karyogram, protocol 
courtesy Dr. Claire Schwab 
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Pots were arranged in the following order (reagents kindly provided by Dr. 
Claire Schwab): 
a) 1ml trypsin in 25 ml saline/25 ml Leishman’s buffer , pH 6.8 
b) 50 ml saline 
c) 50 ml saline 
d) Staining solution: Giemsa and Leishman’s staining solutions, 0.4 
ml Giemsa staining solution added to 8ml Leishman’s stain and 40 
ml Leishman’s buffer 
e) 100+ ml pot of cold deionized water 
The slides were placed in freshly prepared trypsin solution (a) for 15 seconds. 
At end of this time period, slides were immediately immersed in the saline 
solution (b). These were then rinsed twice in the third saline pot (c) and 
immersed in the Staining solution (d) for 4-5 minutes. The stained slides were 
then rinsed in deionized water (e), mounted with coverslip using DPX and 
analysed using the Kario software or Cytovision®. Karyogram analysis was 
performed by Dr.Sarah Fordham). 
2.8 DNA fingerprinting: 
DNA fingerprinting was carried out to confirm the genetic source of the 
generated UT-iPS cell to their parent stromal cells and to rule out any possibility 
of contamination with skin iPS cell line that was cultured concurrently in our lab. 
Cells were harvested as per routine passaging. The cells pellet of UT-iPS cells, 
parental urinary tract stromal cells and skin-iPS cells were sent off to Northern 
Molecular Genetics Service, (Newcastle Upon Tyne, UK) where the total 
genomic DNA was extracted and amplified through the Promega PowerPlex® 
16 system for the detection of 16 different human microsatellite markers. This 
system is designed specifically for co-amplification and three-color detection of 
sixteen human loci (fifteen STR loci and Amelogenin): Penta E, D18S51, 
D21S11, TH01, D3S1358, FGA, TPOX, D8S1179, vWA, Amelogenin, Penta D, 
CSF1PO, D16S539, D7S820, D13S317 and D5S818. One primer for each of 
the Penta E, D18S51, D21S11, TH01 and D3S1358 loci is labeled with 
fluorescein (FL); one primer for each of the FGA, TPOX, D8S1179, vWA and 
Amelogenin loci is labeled with carboxy-tetramethylrhodamine (TMR); and one 
primer for each of the Penta D, CSF1PO, D16S539, D7S820, D13S317 and 
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D5S818 loci is labeled with 6-carboxy-4´,5´-dichloro-2´,7´-dimethoxy-fluorescein 
(JOE). The results were analysed on an ABI 377 sequence detector using 
Genotype software (Applied Biosystems, Foster City, CA). 
2.9 Embryoid body (EB) formation from UT-iPS cells 
Using a sterile pipette tip or needle, UT-iPS cells were collected using the same 
protocol for passaging. Gently, the colony pieces were placed into low-adhesion 
culture plate (Corning, UK) containing standard EB differentiation media 
(Table  2-11) and incubated at 37°C with 5% CO2 with medium changed every 3 
days. To change the medium, the EBs were transferred to a 15ml conical tube 
and allowed to settle to the bottom of the tube for 10 minutes. The supernatant 
was removed leaving about 20% and replaced with fresh EB media into a new 
low-adhesion culture plate. 
EB differentiation medium 
Components Quantity Supplier 
Knockout-Dulbecco’s Modified Eagle’s Medium  120ml – 80% Invitrogen 
Heat Treated Foetal Bovine Serum (FBS) 30ml – 20% Invitrogen 
MEM Non-Essential Amino Acids (100X), liquid 1.5ml – 1% Invitrogen 
Penicillin-Streptomycin Solution 1.5ml – 1% Sigma 
GlutaMAX™-I Supplement, 200 mM 1.5ml– 2mM Invitrogen 
Table  2-11: EB basic differentiation medium composition 
2.10 Teratoma formation assay 
Teratoma formation assay was performed using immunodeficient NSG mice as 
recipient. 24 hours before injection. 
1. Preparing UT-iPS cell for injection 
Cells were harvested according to the normal protocol for UT-iPS cells 
passaging and placed in a 15-ml conical tube which was placed upright for 4-5 
minutes to separate the disrupted colonies from MEF cells through gravity 
rather than centrifuging the cells. Then the supernatant was carefully removed 
and the UT-iPS cells were broken down to single cells by trypsinization. Cells 
were then collected, counted, and resuspended in sufficient human ES cell 
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medium at a concentration of 5 million cells per ml. Each injection was prepared 
by mixing 100µl of cells for each cell line with 100µl of Matrigel. 
2. Injecting cells 
Injection procedure was performed by Dr. Lyle Armstrong. Cells were injected 
subcutaneously into the right flanks of each mouse. One cell line was used per 
mice and in total each cell line was replicated through three mice. Ear notching 
was used to identify each mouse. 
3. Harvesting and fixation of teratomas 
Mice were euthanized by Mrs. Shirley Dodd by cervical dislocation after 6–12 
weeks. Xenografts were extracted and fixed for 24 hours in 20X volume of 
Bouin’s fluid. Bouin’s fixation provides good penetration and 
morphological/structural preservation of tissues. The following day, tissues were 
washed three times in water and placed in 30-40ml of 70% ethanol for 2 hours. 
The procedure was repeated with 80%, 90% and 95% ethanol. Tissues were 
stored in 95% ethanol until ready for processing. 
2.11 Induce differentiation of bladder specific cells from human UT-iPS 
cells in vitro.  
To induce differentiation, both UT-iPS cells and skin-iPS cells were treated with 
conditioned media (CM) for 14 days. Two main types of CM were used in this 
study: urothelial cells derived CM (U-CM) collected from cultured human 
urothelial cells and stroma cells derived CM (S-CM) collected form human 
urinary tract stromal cells. CM was collected After 24 hours, centrifugation was 
performed at 1500 x rpm for 5 minutes to remove cells, filtrated with a 0.2-µm 
syringe membrane filter and diluted with one-third the volume of DMEM with 
serum at a final concentration of 2% (U-CM), or with an equal volume of RPMI 
10% FCS (S-CM).  
2.12 Lentiviral transduction 
Stromal cells were seeded in a 6-well plate at 5 x 104 cells per well one day 
before transduction. Cells were transduced using a single polycistronic lentiviral 
vector (ABP-SC-LVI4in1, Allele Biotechnology, San Diego, USA) at MOI=10 in 
the presence of 10μg/ml polybrene. On day 2, the transduction medium was 
replaced with standard stromal medium. On day 6, cells were harvested and 
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plated onto previously prepared MEF 6-well plate in human ES cell medium and 
maintained till day 10. From this point, the transduced cells were cultured in 
MEF-CM supplemented with human iPS culture medium collected from 
cultivated skin-iPS cells. ES cell-like colonies were manually picked based on 
morphology and transferred to a new plate on MEF cells.  
2.13 Lentivirus production 
PLenti- EF1α-citrine lentivirus was constructed by Dr.Fiona Frame (YCR Cancer 
Research Unit, Department of Biology, University of York). The lentiviral 
particles stock was generated by cotransfecting the pLenti- EF1a-citrine 
construct and the optimized packaging plasmid mix (GIBCO, Life Technologies) 
into the 293T cell line. One day prior to transfection (Day 1), 5 x 106 293T cells 
were plated onto a 10cm tissue culture plate and incubated overnight in 10ml of 
full RPMI1460 without antibiotic. The next day (Day 2), the culture medium was 
replaced with 5 ml of OPTI-MEM I medium. For each transfection sample, DNA-
Lipofectamine™ 2000 complexes was prepared as follows: 9 µg of the 
ViraPower lentivirus packaging mix and 3 µg of pLenti expression plasmid DNA 
were added to 1.5 ml of OPTI-MEM I medium without serum and mixed gently 
in 5 ml tube. In a separate sterile tube, 36 µl of Lipofectamine 2000 with 1.5ml 
of OPTI-MEM I medium without serum was added, mixed gently by finger 
tapping and incubated for 5 minutes at room temperature. After the incubation, 
the diluted DNA was mixed gently with the Lipofectamine containing solution, 
and incubated for 20 minutes at room temperature to allow the DNA 
Lipofectamine 2000 complexes to form. The DNA-Lipofectamine 2000 
complexes were added dropwise to each plate of cells and swirled gently. After 
24 hours of incubation at 37°C in a humidified 5% CO2 incubator (day3), the 
transfection mixture was replaced with 10 ml of full RPMI1460 without antibiotic 
and incubated for another 24 hours at 37°C in a humidified 5% CO2 incubator. 
Virus-containing medium was collected 48 hours post-transfection (Day 4) and 
filtered using a 0.45 µm pore-size polyethersulfone syringe filter to remove 
remaining cells. To yield a higher titration, the viral supernatant was 
concentrated 10-fold by centrifugation at 120,000g for 2 hours at 4°C in an 
Optima XL-100K ultracentrifuge (Beckman Coulter). The supernatant was 
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discarded and the viral pellet was resuspended in DMEM-F12 medium and 
stored as aliquots at -80°C. 
2.14 Transduction and establishment of transgenic UT-iPS cell lines 
3.1.12 Lentiviral transduction of UT-iPS cells  
Undifferentiated UT-iPS cells were detached from the Matrigel by incubation 
with dispase for 5 -7 minutes at 37°C. The detached aggregates were then 
plated into a 6-well matrigel-coated culture plate with an overall confluency of 
<40%. 24 hours after plating, the medium was replaced with the virus 
supernatant diluted in mTeSR1 medium in the presence of 6 µg/ml polybrene. 
The following day, the virus suspension was replaced with fresh mTeSR1 
medium. 5 days post transduction, blasticidin was added at final concentration 
of 1 µg/ml. Selection with blasticidin lasted 12 days with medium and blasticidin 
changes every 2 days. 
3.1.13 FACS analysis and cell sorting of transduced UT-iPS cells  
FACS analysis and sorting of β-actin-mOrange and EF1a- mWasabi/Citrine 
expressing cells was performed on a BD FACSAria III system, according to their 
fluorescent emission. Undifferentiated UT-iPS cells were used to set the 
background level of fluorescence. UT-iPS cultures were pre-treated with 10µM 
Y-27632 ROCK inhibitor for one hour prior to analysis and sorting by FACS and 
subsequently sorted as follow: UT-iPS clumps were dissociated to single-cell 
suspensions by 7-10 minutes of incubation with Accumax solution (SCR006, 
Chemicon) at 37°C. Cells were subsequently resuspended in mTeSR1 medium 
containing 5mM EDTA at a concentration of 5x106 cells/ml. Cells were sorted at 
approximately 20 PSI using a 100-micron nozzle at an average acquisition rate 
of 3,000 cells per second into mTeSR1 medium. Following centrifugation at 
200xg for 4 minutes, the sorted cells were resuspended in mTeSR1 medium 
containing 10μM of Y27632 ROCK and plated onto 6-well Matrigel coated plate 
at a concentration of ~ 1-2 x 106 cells/well. 1% Penicillin/Streptomycin was 
added to the medium for one week after sorting to avoid bacterial 
contamination.  
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2.15 RNA extraction and analysis 
3.1.14 RNA isolation 
All products used for RNA extraction were from certified RNAse free sources. 
During the procedure, all samples, reagents, and plasticware were handled with 
gloved hands to avoid any contamination from RNases found on human skin. 
The choice of RNA extraction procedure and the kit to use were determined 
depending on the cell number. RNA was extracted from cells ≥ 5x105 using EZ-
RNA (Biological Industries, Beit haemek, Israel). RNA from cells ≤ 5x105 was 
extracted using RNeasy® Micro-kit (Qiagen, West Sussex, UK).  Steps were 
performed in a fume hood and appropriate face protection was used when 
required. 
2.15.1.1 RNA isolation with EZ-RNA kit 
Cells were lysed in 0.5ml of denaturing solution, vortexed until complete lysis 
and incubated for 5 minutes at room temperature. 0.5ml of extraction solution 
was added to the homogenate, shaken vigorously for 15 seconds, and 
incubated for 10 minutes at room temperature. Sample was centrifuged at 
12,000 x g for 15 minutes at 4°C. The upper aqueous phase was carefully 
transferred to a fresh RNase-free microcentrifuge tube without disturbing the 
white precipitate layer, which contains DNA and protein and 0.5ml of analytical 
grade isopropanol (Sigma) was added to precipitate the RNA. To increase yield, 
the sample was stored at this point at -20°C overnight. After incubation, 
samples were centrifuged at 12,000 x g for 8 minutes at 4°C and the 
isopropanol was carefully removed leaving a small amount behind in order to 
avoid disturbing the pellet. The pellet was washed with 1ml of 75% ethanol, and 
centrifuged at 7,500 x g for 5 minutes. The ethanol was removed completely 
and the pellet air dried for 5-7 minutes at room temperature to remove any 
residual ethanol. RNA was dissolved in DEPC-treated water by incubating at 
55ºC for 15 minutes. RNA was either used immediately or stored at −80°C to 
minimise degradation and maintain RNA integrity. 
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2.15.1.2 RNA isolation with Qiagen Micro RNeasy extraction kit 
The Kit included all the required buffers apart from the ethanol. The protocol 
followed was as described in the manufacturer’s handbook (RNeasy® Micro 
Handbook, Qiagen). Cell pellet was lysed in 350µl of lysis buffer (guanidine-
thiocyanate containing RLT buffer supplemented with 1% of β-
mercaptoethanol), briefly vortexed until complete lysis. Following this, 350µl of 
RNase-free 70% ethanol was added to the lysed cell, mixed well, and directly 
pipetted to an RNeasy MinElute spin column placed in a 2 ml collection tube 
and centrifuged at 10,000 x rpm for 15 seconds. Ethanol promotes selective 
binding of RNA to the spin columns silica membrane. The flow through was 
discarded and the samples were washed with 350µl of RW1 wash buffer. The 
spin columns were centrifuged and the flow through was discarded. Samples 
were then treated with DNase I solution (70µl of RDD buffer and 10µl of DNase 
I stock) for 15 minutes at room temperature to degrade DNA contaminants and 
ensure purity of resultant RNA. The sample was washed again by adding 350µl 
of buffer RW1 onto the RNeasy MinElute Spin Column and centrifuged at 
10,000 x rpm for 15 seconds. The column was transferred to a new 2 ml 
collection tube and another wash with 500µl buffer RPE was performed. Then, 
500µl of RNase-free 80% ethanol was pipetted to the RNeasy column before 
spinning the tube for 2 minutes at 10,000 x rpm. Following the centrifugation, 
the RNeasy MinElute Spin Column was carefully removed from the collection 
tube and placed into a new 2 ml collection tube. The membrane of the column 
was dried by centrifuging the column with the lid opened at full speed for 5 min. 
RNA was eluted by pipetting 14µl of RNase-free water directly onto the centre 
of the silica-gel membrane and spinning for 1 minute at full speed. RNA was 
either used immediately or stored at −80°C to minimise degradation and 
maintain RNA integrity. 
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3.1.15  Quantification of RNA 
RNA concentrations of samples were quantified using NanoDrop® ND-1000 
spectrophotometer (NanoDrop Technologies, Delaware, USA). The data was 
logged in and recorded through the supplied NanoDrop software which controls 
the machine and runs from a desktop computer. To clean the lower and upper 
surface of the sample retention platform of the Spectrophotometer, 1µl of DEPC 
treated water was pipetted onto both surfaces, the lever arm closed and then 
the surfaces wiped with a clean fresh laboratory wipe. The machine was set up 
and calibrated according to the manufacturer’s instructions. DEPC treated water 
was used as a blank reference. The optical surfaces were firstly cleaned with a 
fresh clean laboratory wipe. 1.2µl of RNA was pipetted onto the end of the 
optical surface and the lever arm was closed to bring the second surface into 
contact with the liquid sample making the sample link the optical ends together 
before taking the measurement with the NanoDrop software. Before applying 
the next sample the optical surfaces were cleaned again. The ratio of sample 
absorbance at 230nm, 260nm and 280nm was used to measure the purity of 
RNA. The resultant RNA should be free of DNA, proteins, or other contaminants 
for which a ratio of ~2.0 for the 260/280 ratio and 1.8-2.2 for the 260/230 ratio 
should be expected. Resultant RNA was either used immediately or stored at 
−80°C to minimise degradation and maintain RNA integrity 
2.16 Reverse Transcriptase and cDNA synthesis  
To prepare the isolated RNA for the production of cDNA, 1 - 2 µg of total RNA 
from each sample was diluted in DEPC treated water to a final volume of 12.7µl 
and incubated for five minutes at 65°C to remove the secondary structure. 
Reaction mixture containing: 4µl 5X Moloney Murine Leukaemia Virus Reverse 
Transcriptase (M-MLV RT) buffer (Promega), 2µl 4mM dNTPs (Promega), 1µl 
of 50µM Oligo dT16 primers (Applied Biosystems) and 0.3µl M-MLV RT enzyme 
(Promega) was added to RNA and incubated for 1 hour at 37°C. Reverse 
transcription was terminated by incubating at 95°C for 5 min. Resultant cDNA 
was either used immediately or stored at −20°C. 
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2.17 Real-time PCR  
Real-time polymerase chain reaction (PCR) was performed using an ABI 
PRISM® 7900 HT sequence detection system according to the manufacturer’s 
instructions (Applied Biosystems, UK). SYBR green (Platinum®Sybr®Green 
qPCR supermix-UDG with ROX, Invitrogen) reporter was used wherein SYBR 
green dye binds to the minor groove of double-stranded DNA and the 
fluorescence emitted is directly proportional to the amount of amplicons 
produced. Reactions were performed in an optical 384-well plate containing 9μl 
of reaction mixture (Table  2-12) + 1µl of cDNA in each well. The reaction plate 
was sealed with a transparent adhesive cover and centrifuged briefly at 1000 x 
rcf for 1 minute to spin down the contents and eliminate any air bubbles from 
the solutions. The plate was placed in the 7900HT real time PCR system where 
it went through the following PCR temperature cycles, 50°C for 2 minutes, 95ºC 
for 10 minutes, and 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. 
The reaction was finished with dissociation step which consisted of 15 seconds 
at 95ºC, 15 seconds at 60ºC and 15 seconds at 95ºC. A single peak in the 
resultant dissociation plot represented a single specific product. Each sample 
was performed in triplicate, and negative control reactions without cDNA were 
included in each experiment. Glyceraldehyde-3-phosphate dehydrogenise 
(GAPDH) was used as a housekeeping gene to normalise expression. Serial 
dilutions of cDNA that were known to express transcripts of interest were used 
to quantify the relative amounts of cDNA produced in the PCR reactions. Data 
were analysed using ABI 7900 HT SDS 2.3 software (Applied Biosystems). 
Absolute quantities were measured for each gene, then subsequently 
normalised to GAPDH to account for differences in loading the samples.  
Real-time PCR reaction mixture 
Components Quantity Supplier 
SYBR green 5µl Invitrogen 
Forward primers 0.4µl Sigma 
Reverse primers  0.4µl Sigma 
DEPC treated water 3.2µl - 
Table  2-12: Real-time PCR reaction mixture. 
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The following primers (Table  2-13) were used for evaluating genes expression:   
Genes Forward primer (5′−3′) Reverse primer (5′−3′) 
GAPDH CGACCACTTTGTCAAGCT
CA 
GGGTCTTACTCCTTGGAGGC 
CD24 TGAAGAACATGTGAGAGG
TTTG 
GAAAACTGAATCTCCATTCCA
C 
vWF ACTGAAGCGTGATGAGAC
GC 
TTCATCAAAGGGTGGGCAGC 
CD45 GAAATTGTTCCTCGTCTG
AT 
CTTTGCCCTGTCACAAATAC 
α-SMA CCGACCGAATGCAGAAG
GA 
ACAGAGTATTTGCGTCCGAA 
CD90 CACACARACCGCTCCCG
AACC 
GCTGATGCCCTCACACTT 
ENDO- 
OCT4 
GCAAGCCCTCATTTCACC
AGGCC 
AGGATCAACCCAGCCCGGCT 
ENDO- 
SOX2 
TCACATGTCCCAGCACTA
CC 
CCCATTTCCCTCGTTTTTCT 
NANOG CCAAATTCTCCTGCCAGT
GAC 
CACGTGGTTTCCAAACAAGAA
A 
GDF3 CTTATGCTACGTAAAGGA
GCTGGG 
GTGCCAACCCAGGTCCCGGA
AGTT 
REX1 CGTACGCAAATTAAAGTC
CAGA 
CAGCATCCTAAACAGCTCGCA
GAAT 
DNMT3B TGCTGCTCACAGGGCCC TCCTTTCGAGCTCAGTGCACC
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GATACTTC ACAAAAC 
AR CTGGACACGACAACAACC
AG 
CAGATCAGGGGCGAAGTAGA 
PSA CAATGACGTGTGTGCGCA
A 
CGTGATACCTTGAAGCACACC
A 
UPIb GGGACAGACAAGGTGCC
TGTTAT 
TATTGGCTGGCTTGCTTCTCT
CCA 
UPII CAGTGCCTCACCTTCCAA
CA 
TGGTAAAATGGGAGGAAAGTC
AA 
UPIIIa TCACTGGCACCCACGAG
GTCT 
CGTTGAGCCCAGTGGGGTGTT 
UPIIIb CCCTGGCCCTGGACCCT
ATCG 
CCACAGGCTGGAGAAGCGCA 
Calponin TTTGAGGCCAACGACCTG
TT 
CCTTTCGTCTTCGCCATGCT 
Desmin CCATCGCGGCTAAGAACA
TT 
TCGGAAGTTGAGGGCAGAGTA 
Claudin1 ATGGAAAGGGTGTTGGC
ATTGGTG 
AATGCCTTGCTCAAACACAGA
CGG 
Claudin5 CTGTTTCCATAGGCAGAG
CG 
AAGCAGATTCTTAGCCTTCC 
CK7 TGTGGTGCTGAAGAAGG
ATGTGGA 
TGTCAACTCCGTCTCATTGAG
GGT 
Transgene TGCTGCCAAGAGGGTCA
AG 
AGCCATACGGGAAGCAATAG 
Table  2-13: List of primer sets and sequences. 
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2.18 Statistical analyses 
All experiments were independently repeated at least 3 times and the average 
values were considered. All graphs plotted show the respective standard error 
of the mean. A paired t-test analysis was used to evaluate the statistical 
significance between two independent variables.  
* P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001. 
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Results 
3 Chapter 3. Establishing and characterising cell cultures of 
primary human urothelial and stromal cells 
3.1 Introduction 
Histological examination confirmed the absence of urothelial dysplasia or 
malignancy. Both urothelial and stromal single cell suspensions were prepared 
from the primary tissue samples. Primary culture protocols were optimised to 
obtain healthy and homogeneous primary cultures of both urothelial and stromal 
cells, which is critical for effective transduction and successful reprogramming. 
Isolated urothelial cells were purified via CD326 (EpCAM) Magnetic-activated 
cell sorting (MACS) sort while homogeneous stromal cells were obtained 
through multiple passages. Cells were characterized according to morphology, 
growth characteristics, and mRNA expression of a panel of cell lineage 
markers.  
3.2 Aims 
1. To establish viable primary cultures of human urothelial and stromal 
cells. 
2. To produce highly pure cultures of primary urothelial and stromal cells. 
3. To evaluate the mRNA expression levels of pluripotency markers in pure 
primary cultures. 
3.3 Results 
3.3.1 Isolation and culture of human urothelial cells 
Primary cultures were established for both urothelial and stromal cells using 
either the outgrowths from explanted tissues, ‘explant culture method’, (Fischer 
et al., 1980; Reznikoff et al., 1983; Jing et al., 2011) or by dissociating the tissue 
with EDTA, trypsin and collagenase following protocol described by Southgate, 
‘the enzymatic digestion method’ (Southgate J, 2002; Southgate et al., 2007). 
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3.3.1.1 Isolation and culture of human urothelial cells using explant 
culture method  
The primary explant method was tested on 15 patient samples. Cultures were 
initiated on a 90mm diameter culture dish in KSFMc medium. 11 out of 15 
samples exhibited outgrowth, giving an overall success rate of about 73% for 
growing and culturing primary urothelial cells using this method. Passage 1 was 
reached by most of the samples. However, urothelial cells showed low 
propensity to survive when subcultured, with only 26% of cultures reaching 
passage 2, after which all cultures eventually died (Figure  3-1). This might be 
due to the toxic effects of trypsin which was used to detach the cells from the 
plate. About 65-75% of the explants attached to the growth surface of dishes 
within 24 to 36 hours after plating and eventually gave rise to urothelial cells. 
Frequent observation of the culture was avoided particularly on the first day as 
this may cause explant detachment from the surface of the culture dish.  
 
Figure  3-1: A summary of primary urothelial explant cultures. About 73% of 
samples grew successfully in culture. Only 4 of 15 samples could be maintained 
to passage 2. Y-axis represents the patient samples ID. X-axis represents the 
passage number. 
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3.3.1.1.1 Morphology of epithelial cells 
Following 48h, polygonal cells began to migrate from the explants and 
increased gradually in number over the following days (Figure  3-2). Cells at the 
leading edge of growth often exhibited rounded surface with ruffles, while in 
confluent regions, cells exhibited more cuboidal appearance. Fresh samples 
(collected and processed within 24-48 hours) grew more readily than old ones 
(collected and processed after 48 hours). Although the conditioned culture 
medium was used to inhibit the growth of stromal cells and to stimulate the 
growth of urothelial cells, few stromal cells were seen in some cases. All 
cultures identified with fibroblastoid growing cells were discarded. Generally, 
growing cells migrated from the tissue and formed a crown of confluent cells 
around it. At higher magnification, polygonal cells grew with a cobble-stone 
pattern. These cells were uniform in size and shape and exhibited epithelial 
morphology. The morphology and the growth characteristics of the derived 
urothelial cells using ureter or bladder as tissue source were comparable 
(Figure  3-3).  
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 Figure  3-2: Procurement of human urothelial cells. (a) The explants were plated 
onto 90mm culture dish and maintained in KSFMc medium. (b, c) Phase 
contrast photomicrograph showing normal urothelial cells migrated away from 
the ureteral explant at days 2 and 5, respectively. (d) Cells adhere closely 
together and yield a cobblestone epithelial morphology in a more confluent 
layer. (e) Membranes of cells at the outer regions of the growth are often ruffled. 
(f) Example of non-urothelial cells contamination. Scale bars: 50 µm (b, c); 10 
µm (d, e, f). 
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 Figure  3-3: Explant culture of human urothelial cells. (a) Explant of normal 
ureter growing on 90mm culture dish at day 10. Outgrowths continuously 
expanded from the tissue resembling a ring around of confluent cells around the 
explants. (b) Higher magnification shows the cobble-stone morphology. (c) 
Urothelial cells derived from ureter tissue. (d) Urothelial cells derived from 
bladder tissue. Scale bars: 100 µm (a, b); 10 µm (c, d). 
 
As an alternative to repeated subculture, the potential of re-plating the explant 
tissue was investigated (Figure  3-4). In two experiments, three explants were 
re-plated three times and each time a new confluent culture of cells was 
reinitiated that continued to express epithelial morphology. The survival of these 
cells may be related to the gradual release in culture of growth factors known to 
be present in the extracellular matrix, or produced by mature cells of the 
urothelium. However, this technique of initiating new cultures by re-plating 
explants was not quantitative, whilst the purity of these cells and the effect of 
serial re-plating were not investigated. The number of viable cells isolated per 
sample was higher when more than one tissue piece was plated in the same 
well (6- 8 tissue pieces per well). Culturing one tissue piece per well had a 
suppressive effect on the growth efficiency and most of the explants failed to 
produce outgrowing cells (Figure  3-5) suggesting that the interactions between 
these tissues may play a role in stimulating the growth of urothelial cells, or the 
outgrowth from one tissue may enhance the growth from other tissues. 
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Figure  3-4: (a) Schematic diagram outlining the technique used to re-plate 
tissue explants. Repeated urothelium outgrowth from tissue explants, (b) Day 5. 
(c) Day 10. Continuous cell outgrowth was observed after replating the explants 
onto 90mm diameter culture dish under the same conditions. (d) Cell outgrowth 
from a recycled explant has a similar growth pattern to the initial culture. (e) 
Outgrowing cells subcultured from explants (1st passage) day7. Scale bars: 100 
µm. 
a 
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Figure  3-5: Outgrowing cells from explants tissues, Day 8. (a) On 90mm culture 
dish. (b) On 6-wells plate. Scale bars: 100 µm. 
 
 
3.3.1.1.2 Purity of urothelial cells from explant primary culture 
Although validating the epithelial cells by appearance is a well-accepted 
method, some epithelia might exhibit greater variations in shape. Hence, to 
confirm their origin and to check their purity, mRNA expression of cell lineage 
markers in primary outgrowing cells from tissue explants (CD24 as marker for 
epithelial cells (Gracz et al., 2013), CD45 as marker for haematopoietic cells 
(Altin and Sloan, 1997), CD146 as marker for endothelial cells (Elshal et al., 
2005), and α-SMA as marker for stromal cells (Lazard et al., 1993)) was tested 
using real-time PCR assay (Figure  3-6). Although morphologically outgrowth 
cells were epithelioid, only one sample expressed CD24 (epithelial cell marker), 
but also co-expressed α-SMA and CD146, suggesting that growing cells 
contained both epithelial and nonepithelial cells. No expression of CD45 was 
detected in any of the samples so excluding any haematopoietic contamination.  
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 Figure  3-6: Explant outgrowth showing haematopoietic and stromal 
contamination. Real time-PCR for mRNA expression of CD24 (epithelial cell 
marker), CD146 (endothelial cell marker), and α-SMA (stromal cell marker) in 
explant outgrowth. Y-axis depicts expression of the cell marker normalized to 
GAPDH expression. X-axis depicts the patient samples ID. Error bars represent 
standard error of the mean (SEM).    
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3.3.1.2 Isolation and culture of urothelial cells using enzymatic digestion 
method  
Because real time-PCR showed that the outgrowing cells from explant tissue 
were not pure epithelial cells, an alternative technique to isolate human 
urothelial cells was investigated. A total of 36 samples were prepared according 
to the method of Southgate et al. Isolated cells were further purified through 
MACS separation using CD326 microbeads. The CD326 antigen (also known 
as human epithelial antigen (HEA), epithelial-specific antigen (ESA), and 
EpCAM) is a 40 kDa transmembrane glycoprotein that is extensively expressed 
by normal and tumour epithelial cells. 7 out of 36 samples failed to grow giving 
a success rate of about 80% for growing and culturing primary urothelial cells 
using this technique. Higher subcultures were attained with difficulty with only 
three samples reaching passage 5 (Figure  3-7). After selection, both CD326 
positive and negative cells were cultured. Following 24 hours in culture, 
satisfactory growth by CD326 positive cells was observed whilst only a small 
number of CD326 negative cells grew (Figure  3-8). 
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 Figure  3-7: A summary of primary urothelial cultures using enzymatic digestion 
method. About 20% of samples did not grow in culture. Y-axis represents the 
patient samples ID. X-axis represents the passage number. 
 
 
 
Figure  3-8: Phase contrast photomicrographs of CD326 positive and negative 
cells after 24 hours in culture. Scale bars: 100 µm. 
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3.3.1.2.1 Morphology of epithelial cells 
Cells started to cluster and form colonies after 1 week in culture and took about 
2-3 weeks to reach 70-80% confluency. At this point, cultures were subcultured 
as cell differentiation might occur progressively after that point. The urothelial 
cells derived from both normal bladder and ureter tissues showed similar 
epithelial appearance. Cells grew as colonies of compact cells with tight 
borders. Typically, cultures contained near isodiametric and cuboidal cells that 
arranged themselves in a cobblestone pattern (Figure  3-9). No fibroblast 
contamination was visually observed in these cultures.  
 
Figure  3-9: Phase contrast photomicrographs of normal human urothelial cells 
(CD326+) passage 1 growing on 60mm dish in KSFMc medium. (a) day 1, (b) 
day 3, (c) day 6, (d) day 12, and (e) day 19. Higher magnification showed 
compacted cells growing in colonies with a cobblestone pattern. Scale bars: 50 
µm. 
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Beyond week 3, no notable increase in colony size could be observed; instead 
cells showed an increased tendency towards differentiation and senescence 
represented by an increase in cell size, shape irregularities and cytoplasmic 
vacuolation. It was also observed that in cultures beyond Passage 3, urothelial 
cells started to diffuse over the whole dish rather than form well-circumscribed 
patches, lost their cobblestone appearance and were made up of cells with high 
level of morphological heterogeneity (Figure  3-10).  Southgate et al (Southgate 
et al., 2007) demonstrated separation of the urothelium lining from the outer 
layer following incubation in the stripper medium either for 4 hours at 37ºC or 
overnight at 4ºC. In my experiments I observed that the viability was higher in 
the shorter incubation time (N=10). 
 
Figure  3-10: Phase contrast photomicrographs of urothelial cells at day 7.       
(a) Passage 2. (b) Passage 4, cell population shows high degree of 
morphologic heterogeneity and shape irregularities. Scale bars: 50 µm. 
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3.3.1.2.2 Purity of urothelial cells cultured following the enzymatic 
digestion protocol 
To confirm the enrichment of cultured urothelial cells following the enzymatic 
digestion protocol, mRNA expression of cell lineage markers (α-SMA, CD90, 
CD24, CD45; CD146; and Von Willebrand factor (vWF)) was assessed by real 
time-PCR in both CD326 positive and negative fractions separated by MACS 
technique. Expression of all genes was investigated in cells from passages P0, 
P1, and P2. As shown in (Figure  3-11), CD326 positive cells overexpressed 
epithelial cell marker (CD24) suggesting their epithelial origin. Importantly, none 
of the samples exhibited expression of stromal cell markers (α-SMA, CD90), 
endothelial cell markers (CD146, vWF) or haematopoietic cell marker, (CD45) 
therefore excluding any obvious contamination. In CD326 negative cells, real 
time-PCR showed expression of CD24 which might be due to the existence of 
some epithelial cells as MACS enriches for epithelial cells. However, these cells 
also co-expressed CD45, and vWF. This data indicated that isolating urothelial 
cells via enzymatic digestion followed by MACS selection for CD326+ cells 
resulted in highly pure urothelial cells. 
 
Figure  3-11: Primary urothelial cells showing absence of stromal 
haematopoietic and endothelial contamination. Real time-PCR for mRNA 
expression of α-SMA and CD90 (stromal cell markers), CD24 (epithelial cell 
marker), CD45 (haematopoietic marker), and vWF and CD146 (endothelial cell 
markers) in CD326 positive and negative cells after MACS selection. Error bars 
show standard error of the mean (SEM) for N=4. 
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3.3.1.2.3 Cell identification 
The optimised protocol we used to isolate the urothelial cells from the 
underlying tissue ensures that only epithelial cells become established in 
culture. However, to establish the identity of cultured cells more objectively, the 
expression of differentiation-specific markers including α6 integrin, β4 integrin, 
CK13, CK14, claudin7 (CLD7), and UPIb was investigated. CK13 is present in 
all but the superficial cell layer of the urothelium. Uroplakin is a selective marker 
for urothelial cell differentiation. In particular, UPIb is expressed by the 
superficial and the intermediate cells. In addition, normal human urothelial cells 
express the α6 β4 integrin in vitro. Real time-PCR showed that urothelial cells 
expressed these markers at variable levels (Figure  3-12). Expression of CK14 
was higher than that of CK13 which may be an indicator that cells in culture 
tend towards a more squamous phenotype (Southgate et al., 1994; R. Ian 
Freshney, 2002). Expression of UPIb marker was further validated at the protein 
level; immunofluorescence showed that isolated cultured cells exhibited typical 
UPIb expression. Altogether, these results verified that upon isolation and 
culture, a homogeneous population with typical epithelial morphology of primary 
urothelial cells could be obtained and further subcultured. 
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 Figure  3-12: Expression of selected differentiation markers by human 
urothelium. (a) Real time-PCR for mRNA expression of differentiation-specific 
markers in normal human urothelial cells. Y-axis depicts expression of 
differentiation-specific markers normalized to GAPDH expression. X-axis 
depicts expression of individual differentiation-specific markers. Error bars show 
SEM for N=3. (b) Normal urothelial cells immunostained for UPIb (red), cell 
nuclei were counterstained with DAPI (blue). Scale bar: 10 µm. 
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3.3.2 Isolation and culture of human urinary tract (UT) stromal cells 
After culturing the urothelial cells using either explant or enzymatic digestion 
method, their associated stromal cells were cultured using the protocol 
previously described in the methods (Chapter 2). A total of 45 stroma samples 
were cultured with almost 95% success rate. Stromal cultures appeared more 
able to survive higher serial subcultures than their epithelial counterparts. The 
first passage was performed on stromal cells growing in 25 cm2 flask from 
which they were transferred into 75 cm2 and 175 cm2 flasks for further 
propagation. Stromal cells could be serially subcultured for at least ten 
passages after which they were frozen and stored at -80°C.  
3.3.2.1 Morphology of UT-stromal cells 
Initial culture of stromal cells from tissues following isolation of the urothelium 
using the explant method didn’t exhibit typical morphology of stroma 
(Figure  3-13). Clumps of cells with a sunburst-like outgrowth and some cells 
with epithelioid appearance were observed. This may be expected as 
separating the urothelium mechanically from the stroma was very difficult and 
subsequent contamination could be possible. In time, the clumped cells tended 
to scatter and epithelioid growth gradually diminished. In advanced subcultures, 
only cells with stromal morphology were seen. On the other hand, stroma 
cultures derived from tissues after isolating the urothelium using enzymatic 
digestion exhibited typical stromal morphology even from the initial cultures. 
Cells showed distinct morphology from their epithelial counterparts in terms of 
cell size, shape and culture-type. Unlike urothelial cells, primary UT-stromal 
cells grew as monolayers rather than colonies (Figure  3-14). In preconfluent 
culture, cells exhibited a spindle-shaped, elongated, and fibroblast-like 
morphology with whorl-like patterns associated with greater confluence. No 
visible changes in morphology between the initial cultures and subcultures were 
observed (Figure  3-15).  
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 Figure  3-13: Phase contrast photomicrographs of human UT-stroma culture 
after isolating the urothelium using explant culture. (a, b, c, and d) represent 
stroma culture at day 2, 7, 14, and 21 days, respectively. Scale bars: 50 µm. 
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 Figure  3-14: Phase contrast photomicrographs of UT-stroma culture from 
tissues after isolating the urothelium using enzymatic digestion showing typical 
morphology of stromal cells. (a) Day 2. (b) Day 7. (c) Day 10. Stromal cells were 
fibroblastic in appearance, in the more confluent culture the stromal cells 
exhibited “streaming,” forming loops and whorls. Scale bars: 100 µm. 
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 Figure  3-15: Phase contrast photomicrographs showing typical morphology of 
the stromal cells at different subcultures. Scale bars: 100 µm. 
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Another observed difference in UT-stroma cultures following urothelium 
isolation using explant method or enzymatic digestion method was that stromal 
cultures following explant method required ~33-37 days to reach 80-90% 
confluency, whilst stromal cultures following enzymatic method only required 8-
12 days (Figure  3-16). However, this difference was not observed in 
subcultures, suggesting that stromal cell proliferation might be repressed in the 
presence of the more slowly dividing epithelial cells. 
 
 
Figure  3-16: Days required for reaching 80-90% confluence culture of UT-
stromal cells after isolating the urothelium using two different methods (explants 
and enzymatic digestion method). Y-axis depicts days between two passages. 
X-axis depicts passage number. Error bars show standard error of the mean 
(SEM) for N=5. 
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3.3.2.2 Purity of stromal cells  
Morphologically, stromal cells isolated via enzymatic digestion method exhibited 
typical fibroblast structure. The purity of cultured UT-stromal cells was checked 
by investigating the mRNA expression of a panel of cell lineage markers (α-
SMA; CD90; CD24; CD45; and vWF). Primary stromal cultures at initial 
passages (P0, P1) showed evidence of contamination with epithelial cells 
(through positive expression of CD24), haematopoietic cells (through positive 
expression of CD45), and endothelial cells (through positive expression of 
vWF). As these cells were progressively passaged (P2, P3), cells expressed 
stromal cell markers α-SMA and CD90, with no significant expression of 
epithelial cell marker CD24, haematopoietic cell marker CD45, and endothelial 
cell marker vWF (Figure  3-17). Collectively, these data indicated that passaging 
was enriching for stromal cells and cells at P2 were apparently pure stromal 
cells. 
  
 
Figure  3-17: Primary UT-stromal cells at passage 0, 1, 2, and 3 showing 
significant reduction of epithelial, haematopoietic, and endothelial 
contamination. Real time-PCR for mRNA expression of α-SMA and CD90 
(stromal cell markers), CD24 (epithelial cell marker), CD45 (haematopoietic 
marker), and vWF (endothelial cell markers) in UT-stromal cells from serial 
subcultures (P0; P1; P2; and P3). Error bars show standard error of the mean 
(SEM) for N=3. 
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3.3.3 Evaluation of pluripotency markers at different passages 
The endogenous expression of certain reprogramming factors in different cell 
types has permitted their exclusion from the factor cocktail (Maherali and 
Hochedlinger, 2008). Generally, generating iPS cells from somatic cells that 
already express endogenous reprogramming factors tends to be easier and 
may require less exogenes. Therefore, the expression of pluripotency markers 
in pure urothelial and stromal cultures was evaluated. 
3.3.3.1 Evaluation of pluripotency markers in normal human urinary tract 
cells 
Real time-PCR showed that mRNA expression of OCT4, SOX2, and NANOG 
was detectable in cells at P0. This expression was significantly reduced with 
increasing passage number (Figure  3-18).  
As shown previously, stroma cells at P0 and P1 were not pure, therefore the 
pluripotent transcript expression at this stage were not assessed. Transcript 
expression of OCT4; SOX2; and NANOG was detectable at P2, and P3; 
however the expression levels decreased with increasing passage number. 
Previous study showed that the pluripotency-associated OCT4A is not 
expressed by normal or malignant human urothelium, but indicated the 
presence of alternative isoforms (OCT4B, and OCT4B1) or potentially 
translated pseudogenes (Wezel et al., 2013). Therefore we studied the 
expression of the alternatively spliced variant OCT4B1. 
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Figure  3-18: Expression of pluripotency markers in normal human urinary tract 
cells at different passages. (a) mRNA expression of (OCT4, SOX2, and 
NANOG) in pure urothelial cells at (P0; P1; P2) of the same sample. (b) mRNA 
expression of (OCT4, SOX2, and NANOG) in pure UT-stroma cells at (P2; P3) 
of the same sample. Y-axis depicts expression of pluripotency markers 
normalized to GAPDH expression. X-axis depicts the expression of individual 
pluripotency markers. Error bars show standard error of the mean (SEM) for 
N=3. 
 
a 
b 
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3.4 Discussion 
Primary culture is the early in vitro culture of cells isolated from donor tissue. 
Such cultures are widely used for basic research as they are assumed to 
display key characteristics similar to those seen in vivo. Usually, maintaining 
primary cell culture requires specific media with several supplementary 
components due to their limited life time and their tendency to change their 
differentiated characteristics with time in culture. Specifically, establishing and 
maintaining primary culture of normal human epithelial cells in vitro has been 
deemed to be difficult and challenging (Reznikoff et al., 1983; Michael Aschner, 
2011). Herein, primary cultures of urothelial and stromal cells from human 
ureter and bladder biopsies were established using two different techniques. 
Although the time-honoured method to validate epithelial cells in culture is by 
morphology, some cell types can show greater plasticity in shape, for example 
endothelial cells derived from mesenchyme can display epithelioid shape in a 
confluent culture (R. Ian Freshney, 2002). Urothelial and UT-stroma cells were 
subjected to real time-PCR analysis using a panel of cell specific or 
differentiation-specific markers. Markers were selected as most representative 
of the class of cell type concerned. Morphology and growth characteristics were 
also utilized to monitor and follow culture progress of both cell types in vitro 
after separation.  
Initiating cells using explant culture is an old technique and it has been used to 
culture epithelial cells from various tissues in vitro (Stonington and 
Hemmingsen, 1971; Fischer et al., 1980). Although the explant culture method 
showed that it might be a simple technique, outgrowth cells show low viability 
and limited application, since mixed cultures of urothelial and stromal cells are 
produced. Minor contamination of stromal cells can eventually overtake the 
urothelial cells, even under improved conditions for urothelial growth, since 
stromal cells have higher proliferation rate compared with that of urothelial cells. 
In recent years, culture systems have been developed to achieve high purity of 
homogeneous primary urothelial cultures. In particular, Southgate and colleges 
dissociated the urothelium from the basement membrane using EDTA. This 
method permits high cell yields that show high plating efficiencies (Southgate et 
al., 1994; Southgate J, 2002). In our hands, isolating urothelial cells using this 
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technique followed by MACS selection for CD326 was found to produce almost 
pure urothelial cells. Although urothelial cells showed extended culture lifetime 
many fold as compared to explant culture, their overall growth potential is still 
limited (Southgate et al., 1994; Southgate J, 2002; Southgate et al., 2007). 
Notably, due to limitation in the number of cells that can be extracted and 
expanded from a small biopsy of clinical material from the urinary tract, we 
didn’t examine the doubling time which can give a more intuitive sense of the 
long-term impact of growth. On the other hand, UT-stroma cells displayed 
typical fibroblastic characteristics including robustness and proliferative capacity 
and could be successfully thawed and subcultured after freezing. We accept the 
limitation of not showing the protein expression to confirm the origin of the 
stomal cells. However, showing that cells have mRNA expression of stomal 
markers and no expression of epithelial, haematopoietic, and endothelial 
markers strongly suggested the stromal origin and the purity of cultured cells. 
Moreover, the protocols were directly learnt from a placement in Prof Jenny 
Southgate’s lab, who has extensively characterised the nature of these cells 
from human tissue (Southgate J, 2002; Southgate et al., 2007), including 
protein expressions.  
After producing highly pure cultures of primary urothelial and stromal cells, as 
quantified by real time-PCR, the expression of the main pluripotency markers in 
these cultures at different passages were assessed. Previous reports showed 
that reprogramming somatic cells which already express high endogenous 
levels of reprogramming factors is easier and may require fewer ectopic factors 
(Kim et al., 2008; Kim et al., 2009b). Thus in general, the higher the expression 
of reprogramming factors in the cells the more easily they are to reprogram. In 
addition, cultured cells might change qualitatively over time (Utikal et al., 2009).  
By real time-PCR, higher expression levels of OCT4, SOX2, and NANOG at P0 
and P2 of urothelial and stromal cells, respectively was observed. Therefore, 
urothelial cells at P0 and stromal cells at P2 were selected for transduction. 
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4 Chapter 4. Generation of iPS cells from normal human 
urinary tract cells 
4.1 Introduction 
This chapter will describe in detail the experimental protocol designed to 
produce iPS cells from primary UT-stroma and urothelial cells by means of 
lentiviral overexpression of OCT4, SOX2, KLF4, and C-MYC (OSKM). 
Lentiviruses provide particularly attractive vectors for iPS generation as they 
can stably integrate into the genome without incurring cellular toxicity and 
maintain sustained expression of the transgene during prolonged proliferation 
and subsequent differentiation. Additional advantages of lentiviruses are their 
ability to transduce both proliferating and non-proliferating cells at high 
efficiency. Reprogramming into iPS cells was mediated by a single polycistronic 
construct encoding the transcription factors that are involved in maintaining the 
pluripotent state. The reprogramming factors in this vector are driven by the 
elongation factor 1 alpha (EF1a) promoter and fused in-frame into a single open 
reading frame (ORF) via self-cleaving 2A sequences flanked by loxP sites 
(Figure  4-1). These advances in vector design have significantly improved 
vector safety and reprogramming efficiency, ensuring that all transduced cells 
receive equal amounts of each of the four transcription factors, and enables 
excision of the exogene through a Cre-recombinase technology (Ma et al., 
2003; Shao et al., 2009). 
 
Figure  4-1: Schematic representation of the lentiviral construct. 
 
4.2 Aims  
• To induce iPS-phenotype in normal human primary UT-stromal cells.  
• To induce iPS-phenotype in normal human primary urothelial cells. 
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4.3 Results 
4.3.1 Transduction of human UT-stromal cells 
Having confirmed the homogeneity of the stromal cells by real time-PCR using 
a panel of cell lineage markers, the lentiviral transduction was subsequently 
optimised.  
4.3.1.1 Determination of optimal Polybrene concentration for transduction 
One method to improve the very low transduction efficiency is to use an additive 
substance in the transduction cocktail such as polybrene (hexadimethrine 
bromide). Polybrene is a cationic polymer that is usually used with viruses to 
improve the transduction efficiency (Toyoshima and Vogt, 1969; Lin et al., 
2011a). Polybrene acts by neutralizing the negative electrostatic repulsion 
between the viral particles and the surface of their target cells leading to 
enhanced absorption of the virus by the cells (Davis et al., 2002; Lin et al., 
2011a). Polybrene is tolerated well at low concentrations. However, at 
concentrations greater than 10 µg/mL, significant inhibition of cell proliferation 
has been reported in some cell types, such as keratinocytes (Seitz et al., 1998) 
and human mesenchymal stem cells (Lin et al., 2011a). To investigate the effect 
that different concentrations of polybrene have on stroma cell viability, cells 
were exposed to polybrene at concentrations ranging from 0 to 20 µg/ml for 48 
hours and apoptosis was analysed by flow cytometry and propidium iodide (PI) 
staining. PI staining was analysed and compared against control (vehicle 
control). Under standard culture conditions, the percentage of PI-positive cells 
(approximately 6%) were variously increased after a polybrene treatment 
(Figure  4-2). Increasing the concentration of polybrene dramatically increased 
its unfavourable impact on cell viability especially at the concentration of 
20µg/ml and that was in accordance with the morphological observations 
(Figure  4-3). Low cytotoxic effects with polybrene at 10ug/ml is to be expected 
and accepted, therefore this concentration was selected for further experiments.  
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 Figure  4-2: Polybrene induced apoptosis of UT-stroma cells. The graph 
represents % apoptosis in UT-stroma cells after polybrene exposure (0, 1µg/ml, 
5µg/ml, 10µg/ml, 15µg/ml, and 20µg/ml) for 48 hours. Y-axis depicts percent PI 
positive cells. X-axis depicts different concentrations of polybrene. Error bars 
show SEM for N=3. * P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001. 
 
    
 
Figure  4-3: Phase- contrast micrographs of cultured stroma cells either not 
exposed or exposed to 10 and 20ug/ml of polybrene for 48 hours. Control cells 
(0ug/ml) showing healthy spindle-shape cells with long, delicate processes. 
Incubation with 10ug/ml of polybrene results in low cytoxicity. Incubation with 
20ug/ml of polybrene results in high cytotoxicity. Scale bars: 100 µm. 
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4.3.1.2 Determination of optimal MOI for transduction 
To determine the most efficient multiplicity of infection (MOI) with the least 
toxicity for transduction of stromal cells a range of MOIs were investigated using 
mWasab GFP control transduction particles. 5 × 104 stromal cells seeded on 6 
well plate in 2 ml of complete RPMI1640 medium were transduced with MOIs of 
2, 5, 10, 20, and 30 in the presence of polybrene 10µg/ml for 48 hours. GFP 
expression was analysed and compared against control (MOI = 0). The 
percentage of GFP positive cells increased in a linear fashion from ~5% to 
~45% as MOI was increased from 2 to 30, respectively (Figure  4-4). At lower 
MOIs, an only minimal difference in cell viability was observed, as determined 
by PI dye exclusion (Figure  4-4). With MOIs of more than 10, a more dramatic 
effect was apparent with an approximate 50% decrease in surviving cells.  Also, 
it is essential that the amount of virus used is kept to a minimum so as to 
prevent multiple integral sites and to ensure silencing of the transgene. 
Therefore, MOI=10 and polybrene = 10µg/ml were determined as optimal 
conditions in subsequent experiments.  
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Figure  4-4: Determination of optimal MOI for transduction. (a) Transduction 
efficiency of UT-stroma cells by control lentivirus particles mWasabi (EF1a). 
Flow cytometry analysis of transduced cells, bar graph representation of the 
efficiency of transduction at increasing MOIs, as indicated on the x axis.  
(b) Cells viability after 48h of transduction with different MOI. At higher MOI cell 
death was observed more frequently. Error bars show SEM for N=3 
a 
b 
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4.3.1.3 Transduced cells underwent a mesenchymal to epithelial 
transition 
It has been shown that reprogramming of fibroblast cells to iPS cells inevitably 
involves an early event termed mesenchymal to epithelial transition (MET); 
during which cells undergo changes in morphology and gene expression. The 
characterisation of MET had become a recognised and central phenomena in 
the generation of iPSCs from mesenchymal cells (Li et al., 2010; Samavarchi-
Tehrani et al., 2010). We undertook a preliminary assessment of this process 
using transcript expression of markers that are strongly indicative of this 
process. we accept that further characterisations with protein levels of these 
markers would be stronger evidence, however, given that definitive proof of iPS 
cells in generating teratomas and embryoid bodies is presented, the further 
descriptions of MET was not considered to be critical. Overall, the picture of 
MET was apparent given the transcript changes and final functional proof of iPS 
cells. Phase-contrast photographs taken at day 10 post transduction showed 
few cells that became aggregated and had acquired a rounded shape 
(Figure  4-5). Real-time PCR analysis of transduced cells at day 10 post 
transduction validated the upregulation of epithelial gene expression (E-
cadherin, and Ep-CAM), and showed a concomitant downregulation of 
mesenchymal gene gene (slug, snail, twist1, and vimentin), indicating that the 
exogenous factors initiated the MET program in stromal cells.  
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 Figure  4-5: MET changes in primary UT-stroma post transduction. (a) Phase- 
contrast micrographs of transduced stromal cells 10 days post transduction; 
cells displayed an altered epithelial morphology. (b) Higher magnification, x100 
(c):  Real time PCR analysis showed upregulation in epithelial markers (E-
cadherin and Ep-CAM accompanied by downregulation of mesenchyme 
markers (Slug, Snail, Twist1, and Vimentin) in stromal cells 10 day post 
transduction suggesting the occurrence of an MET. Error bars show SEM for 
N=3. Scale bars: 100 µm. * P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001. 
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4.3.1.4 Generation of iPS cells from human UT- stroma cells 
Our protocol for human UT-stroma cells transduction is summarized in 
(Figure  4-6). One day prior to transduction, 5 × 104 cells were seeded onto a 6-
well plate and incubated overnight in complete RPMI 1640. The following day, 
cells were washed once in 1XPBS and freshly prepared lentiviral transduction 
mixture containing OSKM virus MOI=10 and 10µg/ml of polybrene was added to 
the cells. ‘media only’ and ‘media and polybrene’ controls were used. After 48 
hours, the transduction media was replaced with fresh complete RPMI 1640 
medium and the cells were cultured for another 4 days.  
The cells grew normally and appeared healthy against the control. On day 6, 
cells were transferred to 6-well plate seeded with inactivated mouse embryonic 
fibroblasts (MEFs) in human ES cell medium. On day 10, the transduced cells 
were cultured in human ES cell medium conditioned from inactivated MEFs 
(MEF-CM) and supplemented with human iPS culture medium and maintained 
in such a manner for 4-6 weeks. MEF-conditioned ES cell medium was 
prepared by treating MEF cells at a density of 50,000 cells/well with human ES 
cell medium. Media was collected every 24h for 5 to 7 days after plating and 
was filtered through 0.2 μm filter before use. Similarly, human iPS culture 
medium was collected from skin-iPS culture 3-5 days after plating, centrifuged 
for 5 min at 1500 x rpm to remove cells, and the supernatant media was 
collected and filtered through 0.2 μm filter.  
Because the conditioned medium was collected after treating the relevant cells 
for 24h at 37˚C, some of the media chemicals components might be broken 
down, therefore, freshly prepared human ES cell medium was added to the 
MEF-conditioned ES cell medium and human Skin-iPS culture medium in a 
1:1:1 ratio. MEF-and ES cell conditioned medium have been shown to increase 
the reprogramming efficiency at least 10 times by enhancing the transition of 
pre-iPS cell colonies to a fully reprogrammed state. Combination of different 
factors provided by MEFs and pluripotent stem cells has been found to help the 
transduced cells undergoing reprogramming to survive and gain pluripotent 
state (Katarzyna Tilgner, 2010). The reprogramming progress was monitored on 
a daily basis by light microscopy to identify any presumptive colonies. 
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 Figure  4-6: Time line for UT-iPS cell generation. 
 
Four weeks after transduction with the lentivirus, several small, tight cell 
colonies with dark appearance were detected that grew slowly and were distinct 
from both ES cells and parental stromal cells in morphology. By week 6 after 
transduction, rapidly growing colonies displaying morphology similar to that of 
human ES cells were observed (tight and flat colonies with clear-cut edges 
comprising of small cells with a high nucleus-to-cytoplasm ratio) (Figure  4-7).  
In this manner a total of thirty one ES cell-like colonies (17 bladder and 14 
ureter derived) were successfully expanded and stably maintained throughout 
the cell passages (>50 passages, >10 months). Patient details from which 
successful iPS cell lines were established are summarised in (Table  4-1). Since 
each colony represents one separate human iPS cell line, these colonies were 
individually picked out and each was placed into a separate wall for expansion 
and identity analyses.  
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 Figure  4-7: (a) Phase- contrast micrographs of UT-stroma cells 48h post 
transduction. The control represent untransduced cells, OSKM+ represent cells 
transduced with lentivirus at MOI = 10 and Polybrene = 10ug/ml. (b) Example of 
small and tight cell colonies observed 4 weeks after transduction. (c) Example 
of established UT-iPS colonies on MEFs feeder layer showing standard 
hallmarks of human ES cell colonies, including sharp borders and tightly packed 
cells within the colonies. Scale bars: 100 µm 
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Patent identifier Age Gender History of patient iPS clones 
12380 65 Female Ureter from radical 
nephrectomy for renal cell 
carcinoma 
4 
12459 66 Male Ureter from 
Cystoprostatectomy for 
benign functional disorder 
7 
12491 48 Male Bladder from 
Cystoprostatectomy for 
benign functional  
neurological disorder 
10 
12502 54 Male Ureter from radical 
nephrectomy 
3 
12506 56 Male Bladder from 
Cystoprostatectomy for 
benign functional  
neurological disorder 
7 
Table  4-1: Patient details from which UT-iPS cell lines were established. 
 
4.3.1.5 Characterization of generated UT-iPS cells 
4.3.1.5.1 Morphological analysis of UT-iPS cells 
Colony and cellular morphological characteristics were assessed by phase-
contrast microscopy. Some of the early forming colonies appeared with slightly 
fuzzy margins with a high frequency to undergo differentiation (Figure  4-8). This 
might be expected since the nascent reprogrammed cells are highly prone to 
differentiation, especially within the first few passages (Hochedlinger and Plath, 
2009). However, as they expanded, colonies became uniformly round or oval 
shaped with well-defined margins and flatter appearance (Figure  4-8).  
The cells within these colonies showed large round nuclei with prominent 
nucleoli and displayed a large nuclear to cytoplasmic ratio and phase-bright 
borders. Within the same colony a variety of cell shapes and sizes were 
observed but most of the cells were typically trapezoidal. As a colony increased 
in size, the cells packed more tightly causing the cells to appear smaller. 
Therefore, cells in smaller colonies looked larger than those in big colonies. In 
addition, cells in the centre of the colony appeared smaller than those at the 
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edge. While maintaining the human iPS cells in culture, a fraction of the cells 
underwent spontaneous differentiation.  
Typically, 10% spontaneous differentiation was seen in human ES cell cultures. 
Differentiation is represented by loss of border integrity and the appearance of 
obvious different cell types. The two frequent types of differentiation observed 
included central differentiation at the top of the colonies and peripheral 
differentiation where undifferentiated UT-iPS cells were surrounded by a ring of 
differentiated cells as shown in (Figure  4-9).  
During each passage, differentiated cells were carefully scraped and removed 
from the culture to avoid deterioration of cell quality. To maintain sterility of the 
iPS cell cultures, this process was performed using an inverted light microscope 
in a tissue culture hood. Notably, long intervals between passages or incubating 
with culture media for more than 48h resulted in increased differentiation of the 
cells. The size and confluence of iPS colonies were visually observed and used 
as a guide for assessing when to passage. In general, UT-iPS cell cultures were 
regularly passaged approximately every 5 to 7 days. 
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 Figure  4-8: Phase- contrast micrographs of established UT-iPS colonies on a 
feeder layers. (a) Passage 1. (b) Passage 7, Inserts show higher magnification. 
Scale bars: 100 µm. 
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 Figure  4-9: Visual inspection of human UT-iPS cell culture. (a) Example of 
undifferentiated UT-iPS colony. Types of differentiation observed during 
propagation of UT-iPS cell colonies vary, but they include: (b, c) Central 
differentiation and (d) Peripheral differentiation where an undifferentiated UT-
iPS colony is surrounded by a ring of differentiated cells. Scale bars: 100 µm. 
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4.3.1.5.2 Genetic analysis of UT-iPS cells (Surface marker and gene 
expression) 
Clones were expanded by standard human ES cell culture procedures on MEF 
feeder cells and gave rise to cell lines with human ES cell–like morphology. 
Three clones were selected for further analyses and the remaining clones were 
frozen and stored in liquid nitrogen.  
I. Surface marker analysis in UT-iPS cells 
Consistent with their human ES cell-like morphology, immunostaining using 
antibodies for the surface antigen stage–specific embryonic antigen SSEA-4, 
tumour rejection antigen TRA-1-81 and TRA-1-60 and also transcription factors 
OCT4, and NANOG showed positive staining for these iPS markers 
(Figure  4-10). Furthermore, alkaline phosphatase activity typical of an ES cell-
phenotype was demonstrated in the induced cells (Figure  4-10).  
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Figure  4-10: (a) Immunofluorescence of generated UT-iPS cells for the 
expression of specific human ES cell surface markers, SSEA-4, TRA-1-81, 
TRA-1-60, and nuclear transcription factors NANOG and OCT4. Nuclei were 
stained with DAPI (blue). (b) Alkaline phosphatase staining of UT-iPS cell 
colonies. MEF feeder cells served as the negative control. Scale bars: 100 µm. 
 
a 
b 
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II. Testing transgene expression in UT-iPS cells 
Transgene silencing is associated with the generation of iPS cells, where there 
is a critical switch to endogenous expression of key ES cell regulatory factors 
such as OCT4, SOX2 and NANOG. Expression level of the exogenous factors 
was analysed in the induced cells by real time-PCR using primers specific for 
lentiviral transcripts and demonstrated that transgenic expression of these 
defined genes had ceased in UT-iPS clones (Figure  4-11).  
 
 
 
Figure  4-11: Real time-PCR using primers specific for the transgenes, and not 
detecting endogenous gene expression levels confirm lentiviral transgene 
silencing in UT-iPS cells (Passage 5). Control represents parental stromal cells 
6 days after transduction. H9 human embryonic stem cell line was used as a 
negative control. Clone1, clone4, and clone6 are three different clones of UT-
iPS cells. Error bars show SEM for N=3. 
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III. Transcript analyses 
Furthermore, endogenous expression of the pluripotency markers OCT4, 
SOX2, and NANOG, was consistent with that of H9 human ES cells ( cDNA was 
kindly donated by Prof. Majlinda Lako (Institute of Genetic Medicine, Newcastle 
University) ) and markedly increased compared with that in the parental stromal 
cell population (Figure  4-12), whilst fibroblast lineage specific genes α-SMA, 
calponin, and desmin were down-regulated (Figure  4-13).  
 
 
 
Figure  4-12: Real time-PCR analysis for expression of endogenous OCT4 and 
SOX2 and NANOG in three different clones of UT-iPS cells (Passage 5). 
Control represents parental stromal cells before transduction. All values were 
calculated with respect to the value for H9 human ES cell which was set to 1.  
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Figure  4-13: Real time-PCR analysis for fibroblast lineage specific genes α-
SMA, calponin, and desmin in UT-iPS cells (Passage 5). Control represents 
parental stromal cells before transduction. Error bars show SEM for N=3. 
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IV. Expression of other pluripotent transcripts in UT-iPS cells 
A recent publication reported that the expression of DNMT3B, GDF3, and REX1 
markers can distinguish the bona fide iPS cells from partially reprogrammed 
cells (Chan et al., 2009a). The generated UT-iPS clonal cells expressed these 
markers at comparable levels to human ES cells, confirming their full 
reprogramming capacity (Figure  4-14). The UT-iPS cell lines derived from 
bladder and ureter were shown to be identical in terms of ES cell-like 
morphology, proliferation and gene-expression signatures. 
 
 
Figure  4-14: Real time-PCR analysis of stem cell marker genes in three 
different clones of UT-iPS cells for expression of DNMT3B, GDF3, and REX1. 
Control represents stromal cells before transduction. All values were calculated 
with respect to the value for H9 human ES cell which was set to 1. 
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4.3.1.5.3 Identity testing of UT-iPS cells 
Authentication of UT-iPS cells derivation from parental stromal cells was 
confirmed using DNA fingerprinting. The patterns of 16 short tandem repeat 
(STR) markers were completely identical between UT-iPS clones and the 
parental stromal cells. In addition, these patterns differed from skin-iPS line that 
was cultured concurrently in the laboratory ruling out any contamination of our 
iPS cell lines by pre-existing skin-iPS cells (Table  4-2). 
 
Name Parental cells UT-iPS Skin-iPS 
Amelogenin XY XY XY 
D3S1358 12   17 12   17 17   18 
THO1 6   9.3 6   9.3 6   9 
D21S11 29   30 29   30 29   30 
D18S51 13   15 13   15 12   13 
PentaE 5   15 5   15 7   12 
D5S818 10   12 10   12 11  12 
D13S317 11   13 11   13 9   9 
D7S829 8   9 8   9 10   11 
D16S539 10   13 10   13 11   11 
CSF1PO 12   12 12   12 10   12 
PentaD 9   10 9   10 10   10 
vWA 14   14 14   14 16   17 
D8S1179 12   12 12   12 13   15 
TPOX 8   10 8   10 8   9 
FGA 21   24 21   24 21   27 
Table  4-2: DNA fingerprinting showing that UT-iPS cells have DNA genetic 
profiles matched to their parental stromal cells and differ from that of pre-
existing skin-iPS cells. 
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4.3.1.5.4 Karyotyping of UT-iPS cells 
Karyotyping was performed to demonstrate that the generated UT-iPS cells 
maintain a stable karyotype after serial passages. UT-iPS cells showed a 
normal diploid 46, XY chromosome arrangement with the absence of any 
aneuploidy (loss or duplication of chromosome) and heteroploidy (having 
abnormal numbers of chromosomes) (Figure  4-15).  
 
Figure  4-15: Karyotype analysis shows normal karyotype of established UT-iPS 
cells at passage 25. 
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4.3.1.6 In vitro differentiation capacity of UT-iPS cells 
As mentioned before, the pluripotent stem cells are characterized by their ability 
to differentiate into representative derivatives of all three embryonic germs. 
Although the iPS cells were very similar to human ES cells with respect to 
morphology, proliferation, antigen markers and gene expression markers, it 
remained unclear whether these generated cells are true pluripotent cells with 
full differentiation capacity. To investigate this, the differentiation potential of 
these putative iPS clones was evaluated in vitro using floating cultivation to form 
embryoid bodies (EBs). Typically, within a suspension culture, pluripotent stem 
cells aggregate and form three-dimensional structures or spheroids called EBs 
because they mimic many features of normal embryonic development. UT-iPS 
cells formed ball-shaped EB-like structures after 8 days in suspension culture 
with differentiation medium (Figure  4-16). These EBs were transferred to 
gelatin-coated cell culture plates and cultured for a further 8-10 days.  
 
 
Figure  4-16: UT-iPS cells formed EBs in suspension culture. Phase- contrast 
micrographs of EBs created by human UT-iPS cells at day 3, and 8. Scale bars: 
500 µm. 
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The ability to differentiate to cells derived from three germ-cell layers was 
examined by immunofluorescence. Outgrowth cells were detected to be positive 
for CD31 (mesoderm marker), alpha-fetoprotein (endoderm marker), and βIII 
tubulin (ectoderm marker) (Figure  4-17).  
Differentiation to three germ-cell layers was further confirmed by real time-PCR. 
Differentiated cells showed marker gene expression for all three embryonic 
germ layers: alpha-fetoprotein (endoderm marker), PAX6 (ectoderm marker), 
and α-SMA and vimentin (mesoderm marker) (Figure  4-18).  
Moreover, following iPS cells differentiation into the three germ layers, the 
pluripotent transcripts should be down regulated, otherwise potential integrated 
proviruses might be present (Stadtfeld et al., 2008b). UT-iPS embryoid-body 
derived cells showed down regulation of the endogenous expression of OCT4, 
SOX2, and NANOG (Figure  4-19).  
Although integrated transcription factors become transcriptionally silenced over 
time, spontaneous reactivation of these exogenous factors during cell culture 
and upon differentiation into various lineages have been reported (Nakagawa et 
al., 2008; Shao and Wu, 2010). Therefore the expression of the exogenous 
factors in UT-iPS embryoid-body derived cells was analysed by real time PCR 
and this demonstrated that transgenic expression of these defined genes is still 
silenced (Figure  4-20). Together, these results indicate that these ES cell-like 
colonies not only expressed pluripotency markers, but also could differentiate 
into ectoderm, mesoderm, and endoderm-derived germ layers in vitro. 
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 Figure  4-17: Characterisation of Pro-iPS embryoid body differentiation through 
immunofluorescence staining. Immunofluorescence analysis of EBs derived 
from UT-iPS cells shows expression of the lineage markers beta-tubulin 
(ectodermal marker; Red), CD31 (mesodermal marker; Green ) and alpha-
fetoprotein (AFP) (endodermal marker; Green ). Nuclei were stained with DAPI 
(blue) (scale bar = 100µm). 
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 Figure  4-18: UT-iPS derived embryoid bodies differentiate into cells of 
ectodermal, mesodermal, and endodermal lineage. Real time-PCR analysis for 
mRNA expression of PAX6, and vimentin (ectodermal marker), α-SMA 
(mesodermal marker), and AFP (endodermal) in EBs derived from UT-iPS cells 
compared to undifferentiated UT-iPS cells. Error bars show SEM for N=3. 
 
Figure  4-19: Real time-PCR analysis for endogenous expression of OCT4, 
SOX2, and NANOG in EBs derived from UT-iPS cells shows down-regulation of 
these markers. Error bars show SEM for N=3. 
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 Figure  4-20: Real time-PCR using primers specific for the transgenes confirm 
that lentiviral transgene is still silenced in EBs derived from UT-iPS cells (week 
4). Control represents parental stromal cells 6 days after transduction. Error 
bars show SEM for N=3. 
4.3.1.7 In vivo differentiation capacity of UT-iPS cells 
The most instructive in vivo test of pluripotency is the ability to contribute to all 
cell types, including germ cells, in chimeric offspring generated by mixing ES 
cells with mouse blastocysts (Evans and Kaufman, 1981; Martin, 1981). 
However, due to obvious ethical concerns, human ES cells cannot be subjected 
to the same definitive test. Therefore, the gold standard to assess the 
developmental potency of human ES cells is the formation of teratomas in 
immunodeficient murine hosts.  
Approximately 5 x 105 UT-iPS cells for three clones were injected 
subcutaneously to immunodeficient NSG mice. Similarly, 5 x 105 human ES 
cells (H9) were used as a positive control. Teratomas that developed from 
grafted UT-iPS cells were surgically removed, fixed in Bouin’s, and paraffin 
embedded. The tissues in the teratoma were analyzed histologically and 
confirmed that UT-iPS cells formed tissues derived from all three embryonic 
germ layers confirming their pluripotency. Areas of germ layer specific 
differentiation were evident with sections containing structures consistent with 
endoderm, mesoderm and ectoderm lineages (Figure  4-21).         
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 Figure  4-21: Histological sections of identified cells within teratoma formed by 
UT-iPS cells representing all three embryonic germ layers: ectoderm (neuronal 
rosette-like structures), endoderm (intestinal epithelial-like cells) and mesoderm 
(muscle-like tissue). The histopathological analyses was kindly performed by 
Prof. Simon Hayward, Vanderbilt University, USA. 
 
4.3.2 Transduction of human urothelial cells 
Urothelial cells were cultured as described in the previous chapter. Once 
confluent, the media was replaced with freshly prepared transduction media 
containing the OSKM 4 in 1 construct in the presence of polybrene 10 μg/ml 
final concentration. Prior transduction, mRNA expression of cell lineage markers 
(α-SMA; CD90; CD24; CD45; and vWF) was assessed in urothelial cells by real 
time-PCR to confirm their purity (Figure  4-22).  
All samples expressed the epithelial cell marker, CD24 while no expression of 
stromal, haematopoietic and endothelial cell markers was detected. Urothelial 
cells were transduced using the same protocol as for stroma cells and at day 14 
post-transduction, small and dense colonies were observed (Figure  4-22). 
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 Figure  4-22: Transduction of human urothelial cells. Urothelial cells were 
transduced with OSKM lentivirus vectors, and plated onto MEFs feeder cells in 
human ES cell medium. (a) Real time-PCR for mRNA expression of α-SMA and 
CD90 (stromal cell markers), CD24 (epithelial cell marker), CD45 
(haematopoietic cell marker), and vWF (endothelial cell marker) for two samples 
of urothelial CD326+ cells at P0. (b, c, d). Phase-contrast photomicrographs of 
urothelial colonies in ES cell environment at different magnifications. These 
cells didn’t exhibit ES/iPS cells morphological features including small round 
cells with large nuclei, notable nucleoli, and spaces between cells. (e) Control 
phase-contrast photomicrograph of UT-iPS cells. Scale bars: 100 µm (b, c), 50 
µm (d, e).  
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4.3.3 Live- cell staining of transduced urothelial cells  
A live-cell staining of urothelial colonies using anti SSEA-4 and TRA-1-60 
antibody was performed in conjunction with Hoechst 33342 nuclear staining, as 
previously described. SSEA-4 expression is particularly interesting as it seems 
to be expressed more rapidly than other commonly used markers (Enver et al., 
2005; Stewart et al., 2006) while the TRA-1-60 antigen exhibits an intermediate 
behaviour (Draper et al., 2002). Moreover, these markers are located on the 
exterior surfaces of the cell membrane; therefore they can be detected by live 
cell imaging and allow us to culture these colonies following the staining 
process and further observe their progress over time without damaging the 
cells. Interestingly, analysis of the photomicrographs revealed that some of 
these colonies exhibit SSEA-4 and TRA-1-60 positive phenotype (Figure  4-23). 
Although it was expected that these colonies would grow, no such proliferation 
was observed. Even after dividing into smaller clumps and transferring to fresh 
MEFs, it was not possible to detect any noteworthy proliferation in the resulting 
clumps. These nascent reprogrammed cells might fail to reach the fully 
reprogrammed state and possibly reverted back or simply died. Since these 
colonies were easily distinguishable by behaviour from human ES cell–like iPS 
colonies, it was decided that these would be categorized as either partially re-
programmed or abortive colonies.  
On the other hand, control cells (un-transduced cells) started to form colonies 
on the MEFs feeder layer at day 5-7 after plating (Figure  4-24). However, 
staining for SSEA-4 and TRA-1-60 was undetectable in any of these colonies 
(Figure  4-25). Once substantial-sized colonies were noticed, these were split 
into smaller fragments and transferred to fresh MEFs. However, they didn’t 
grow as fast as the parental colonies and remained negative for SSEA-4 and 
TRA-1-60. Most of these colonies eventually died or stopped proliferating.  
Alternatively, epithelial cells were directly seeded after MACS sorting onto 
MEFs in human ES cell medium and once substantial-sized colonies were 
noticed these were transduced with the OSKM 4 in 1 construct and 10 μg/ml of 
polybrene. Growing prostate epithelial cancer cells in such an environment has 
been shown to upregulate the transcription factors (OCT4, SOX2, NANOG) in 
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these cells which in turn might increase the reprogramming efficiency 
(Anastasia Hepburn, NICR, unpublished data). In addition, this may avoid the 
cells the stress resulting from replating process. After 48 hours of transduction, 
the media was replaced with fresh human ES cell medium and the cells were 
cultured in this media for another 4 weeks. No iPS colonies were noted.       
 
 
Figure  4-23: Live cell imaging analysis of transduced urothelial cells (12165). (a) 
Day 14. (b) Day 30 post transduction. (c) Primary urothelial cells (negative 
control). (d) Human skin iPS cell colony (positive control). Colony was analysed 
by phase contrast (top left) and fluorescence microscopy for expression of 
pluripotency markers SSEA-4 (red), and TRA-1-60 (green); nuclei were stained 
with Hoechst 33342 (blue). Scale bars: 100 µm (a, b), 50 µm (c, d). 
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 Figure  4-24: Phase-contrast photomicrographs of colonies formed by 
untransduced urothelial cells cultured in ES cell environment. (a) Day 8. (b) Day 
15. Colonies on low power magnification showed tight borders and smooth 
surface. Scale bars: 100 µm. 
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Figure  4-25: Live cell imaging analysis of untransduced urothelial cells. (a) Day 
10. (b) Day 20 post transduction. (c) Human skin iPS cell colony (positive 
control). Colony was analyzed by phase contrast and fluorescence microscopy 
for expression of pluripotency markers SSEA-4 (red), and TRA-1-60 (green); 
phase contrast (top left), nuclei were stained with Hoechst 33342 (blue). Scale 
bars: 50 µm. 
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4.4 Discussion  
Since iPS cells may retain an epigenetic memory of their original cell types 
(Chin et al., 2009; Marchetto et al., 2009; Kim et al., 2010), it is important to 
establish human iPS cells from different tissue origins and compare their 
differentiation potentials. In this chapter successful reprogramming of adult 
human stromal cells isolated from both bladder and ureter into iPS cells (UT-
iPS) is successfully described following the method developed in the Yamanaka 
laboratory, with modifications described by Tilgner and colleges (Katarzyna 
Tilgner, 2010). In addition to exhibiting ES cell morphology, the newly derived 
UT-iPS cells highly expressed the pluripotency markers OCT4, SOX2, NANOG, 
SSEA-4, TRA-1-60 and TRA-1-81 and alkaline phosphatase, showed efficient 
transgene silencing and maintained a normal diploid karyotype. It should be 
noted that karyotyping relies on G-band quality and resolution and poor quality 
chromosomes increase the risk of missing small subtle abnormality may not 
detect mosaicism. Therefore more sensitive technique such as CGH Microarray 
testing (array CGH), MLPA (multiple ligation-dependent probe amplification) or 
FISH (fluorescence in-situ hybridisation) that  can detect copy number change 
(deletion or duplication) in the genome at a higher resolution than G-band 
analysis should be performed in the future.   
Furthermore, human UT-iPS cells showed functional pluripotency by the 
generation of endodermal, ectodermal and mesodermal lineages in vitro and in 
vivo. UT-iPS colonies were morphologically selected by microscopic 
observation, which is consistent with previous reports that drug selection with 
pluripotent markers is not essential for iPS cells derivation (Meissner et al., 
2007; Nakagawa et al., 2008; Ohnuki et al., 2009). This result is also consistent 
with the findings that reprogramming to pluripotency is a slow and gradual 
process where cells that have not yet reached the pluripotency state may be 
eliminated by drug selection. In addition, using a selection system will need 
genetic modification which may constitute a potential drawback for therapeutic 
application of similar approaches (Lyssiotis, 2009).  
Yamanaka in his original work used multiple individual retroviral vectors to 
deliver each transcription factor to generate iPS cells (Takahashi and 
Yamanaka, 2006; Takahashi et al., 2007) which can lead to high number of 
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genomic integrations. In addition, each of the reprogramming factors was 
individually integrated into different sites within the genome leading to an 
increased risk of gene mutagenesis and genomic instability. In this project, to 
avoid these problems, cells were transduced using a single, self-inactivating 
(SIN), polycistronic lentiviral vector encoding for the four transcription factors 
separated by 2A sequences with a loxP site in truncated 3` LTR and controlled 
by the EF1α promoter. This system improves the reprogramming efficiency and 
silencing of transduced exogenous and ensures that all transduced cells will 
receive equal amounts of each of the four transcription factors (Shao et al., 
2009). Most importantly the integrated provirus can be deleted from the iPS cell 
genome through transient expression of Cre-recombinase in transduced cell 
and therefore allows the derivation of transgene-free human iPS cells (Oh et al., 
2012; Awe et al., 2013). Although C-MYC is a cancer-causing gene which is 
known to cause death and differentiation in human ES cells (Sumi et al., 2007); 
it markedly increased the reprogramming efficiency and OSKM factors have 
been shown to be more efficient to reprogram human fibroblasts compared to 
OSK, and OSLN (Robinton and Daley, 2012). Hence, OSKM set was used for 
the establishment of UT-iPS cells.  
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5 Chapter 5. Induced differentiation of bladder specific cells 
from UT-iPS cells in vitro 
5.1 Introduction  
Pluripotent stem cells are functionally characterized by their ability to self-renew 
and differentiate into all cell types derived from all 3 germ layers. In this project, 
the generated UT-iPS cells are proven to be pluripotent and must be able to 
differentiate to any cell type including urothelial and stromal cells. However, 
recent evidence revealed that during the reprogramming process, iPS cells 
retain an epigenetic memory of the starting cell type that increase their 
propensity to redifferentiate back into the parental cell types (Kim et al., 2010; 
Bar-Nur et al., 2011; Ohi et al., 2011; Lee et al., 2012; Xu et al., 2012), the 
exact mechanisms behind this donor memory are not fully understood. This 
raises the question whether UT-iPS cells will exhibit higher propensity to 
differentiate in vitro into bladder lineages as compared to classical skin-derived 
iPS cells. To address this question, both UT-iPS and skin-iPS cells were 
differentiated using the protocol described by Tian et al with minor modifications 
(Tian et al., 2010b). 
5.2 Aim:  
To investigate the basic ability of the UT-iPS cells to differentiate into urothelial 
and stromal like cells by using CM derived from bladder cells and comparison 
with conventional skin derived iPS cells for potential use in urological tissue 
engineering and regeneration. 
5.3 Results:  
Primary urothelial and stromal cells from urinary bladders or ureters were 
isolated and cultured in accordance with the methods described in the previous 
chapter. Two different protocols were used to induce the differentiation of UT-
iPS and skin-iPS cells into urothelial and stromal cells (Figure  5-1).  
UT-iPS cell were collected as clumps and cultured on low adhesion dishes in a 
urothelial cell-derived CM (U-CM) collected from cultured human urothelial cells 
and alternatively on a stromal cell-derived CM (S-CM) collected from human 
urinary tract stromal cells where they were observed to round up into embryoid 
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body-like masses and were referred to as bcm-EB (bladder conditioned medium 
embryoid body). After 10 to 14 days of suspension culture, bcm-EBs were 
transferred onto gelatin coated plates and further cultured in the same CM for 
another 3 weeks. The other protocol used was previously described by Tian et 
al (Tian et al., 2010b), but with minor modifications. Briefly, iPS cells were 
initially plated in a 6-well plate for 5-7 days in human ES cell medium. Then 70-
80% confluent iPS cell cultures were washed with 1XPBS and incubated in 
various differentiated media for a further 2 weeks. For urothelial cell 
differentiation, U-CM was collected from cultured human bladder urothelium and 
diluted to one-third volume with fresh DMEM. For stormal cells differentiation, S-
CM was collected from cultured human bladder stromal cells and diluted with an 
equal volume of RPMI1640 10% FCS. The medium was changed at 24 h prior 
to collection and the filtered CM was also stored at -80oC to retain the biological 
activity of the secreted factors. Differentiated cells were analysed for a panel of 
urothelium and stromal smooth muscle specific genes using real time-PCR. The 
expression of specific markers in the differentiated cells derived from UT-iPS 
cells and skin-iPS cells were compared after the same planned period of culture 
and using the same CM. UT-iPS that were not induced were processed in 
parallel as a negative control.  
 
Figure  5-1: General outline of the two protocols used for iPS differentiation. 
Scale bars: 100 µm 
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5.3.1 Characteristics of newly differentiated urothelia/stroma-like cells 
Morphological examination of the differentiation cells derived from UT-iPS cells 
showed characteristically small, epithelioid cells. To investigate the ability of 
generated UT-iPS to differentiate into bladder tissues, the mRNA expression of 
urothelium differentiation specific genes (UPIb, UPII, UPIIIa, UPIIIb, CLD1, 
CLD5, and CK7) and stromal smooth muscle cells specific markers (a-SMA, 
calponin, and desmin) in differentiated cells derived from UT-iPS cell line was 
analysed and compared to that derived from the skin-iPS cell line. 
5.3.2 Differentiated UT-iPS cells expressed urothelial and stromal-
specific genes 
Real time-PCR was performed on UT-iPS and skin-iPS cells before and after 
induction. Amplification of urothelium differentiation specific genes ( UPIb, UPII, 
UPIIIa, and UPIIIb, CLD1, CLD5, CK7) and stromal smooth muscle cells 
specific markers (a-SMA, calponin, and desmin) showed specific products in 
induced cells from both UT-iPS cells and skin-iPS cells using both U-CM and S-
CM although some variation was observed between expression of uroplakins. 
However, mRNA expression of uroplakins was significantly higher in induced 
UT-iPS cells using both S-CM and U-CM, when compared to that in non-
induced UT-iPS cells and induced skin-iPS cells (Figure  5-2). Similarly, induced 
UT-iPS cells particularly after treating with U-CM showed higher levels of other 
markers for epithelial cells, CLD1, CLD5, and CK7 (approximately 15 to 20 
fold), as compared to non-induced UT-iPS cells and induced skin-iPS cells. In 
addition, all urothelium differentiation specific genes were more strongly 
expressed when UT-iPS cells were treated with U-CM compared to those 
treated with S-CM.  
Stromal smooth muscle cell-specific transcripts (a-SMA, calponin, and desmin) 
also showed a significant increase in induced UT-iPS cells compared to non-
induced UT-iPS cells and induced skin-iPS cells. Amongst the stromal smooth 
muscle markers, there was a massive increase in a-SMA transcription (150-200 
fold) but about 5-10 fold induction in calponin and desmin transcription 
compared to the non-induced UT-iPS cells and induced skin-iPS cells. 
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 Figure  5-2: Expression of urothelial and smooth muscle lineage specific 
transcripts in differentiated cells derived from UT-iPS cells and Skin-iPS cells at 
day 14. The mRNA levels are shown as a fold change relative to control 
(undifferentiated cells) (N=3). (a) Differentiation induction with conditioned 
medium from urinary tract urothelium. (b) Differentiation induction with 
conditioned medium from urinary tract stroma.  
* P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001. 
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5.3.3 Urothelial marker expression in differentiated UT-iPS cells 
The above findings using real time-PCR have demonstrated that differentiated 
UT-iPS cells express a panel of urothelial specific genes. To further examine 
whether these cells had differentiated into urothelial cells, the expression of 
UPIb was measured at the protein level by immunofluorescence. Cells immuno-
positive for UPIb were seen in differentiated cells derived from UT-iPS cells 
after 2 weeks in U-CM as shown in (Figure  5-3) 
 
Figure  5-3:Immunofluorescence of differentiated cells derived from UT-iPS cells 
treated with conditioned medium at day 14, showing (a) Bright field; (b) Positive 
staining for UPIb (red) juxtaposed with an area of UPIb negative staining, with 
DAPI nuclear counterstain (blue); and (c) High magnification of UPIb 
immunostaining. (scale bar = 100µm).                                 
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5.4 Discussion 
Stem cell fate is mainly controlled by the extracellular environment represented 
by the cells and secreted proteins (Moore and Lemischka, 2006; Liu et al., 
2009a). Therefore, the local environment is likely to be a critical factor in 
defining stem cell features (Van Vranken et al., 2005). Our results demonstrated 
that CM from bladder tissue may provide a niche that is favourable for urothelial 
differentiation of iPS cells in vitro. The mammalian bladder is composed of a 
three layer arrangement of serosa, smooth muscle and urothelium. The 
urothelium consists of three cell layers, basal, intermediate, and umbrella 
superficial cell zones and contains a group of integral membrane proteins called 
uroplakins, UPIa/b, UPII and UPIIIa/b, which represent highly sensitive and 
specific markers for mature urothelium. Moreover, cytokeratins (CKs) and 
claudins are expressed by different types of epithelial cells. Specifically, 
Urothelial cells in culture express various types of CKs and claudins which also 
provide useful markers to identify the urothelial cells (Varley and Southgate, 
2008; Liu et al., 2009a). The results showed that urothelium and stromal smooth 
muscle gene expression was detected in differentiated UT-iPS cells after 
treating with either U-CM or S-CM. Differentiation into urothelial like cells was 
further confirmed by showing that UT-iPS cells can give rise to cells expressing 
UPIB (which is one of the most commonly used urothelial cell markers) on the 
protein level. Its expression is very specific and many experts in the field would 
consider the expression of this marker at a protein level to be definitive of 
urothelium. Ideally additional markers could be assessed for urothelial and 
smooth muscle cell phenotypic characterisation. In addition further studies to 
determine whether UT-iPS cells can differentiate into functional urothelial cells 
and smooth muscle cells for potential use in tissue engineering would be 
desired (Southgate et al., 1994; Wezel et al., 2014). This experiment is also 
limited by the fact that UT-iPS and skin iPS cell lines are not derived from the 
same patient. Hence it will be interesting to investigate the differentiation 
potential between two different iPS cell lines derived from the same patient. 
Previous study reported that CM derived from bladder cells was able to induce 
the differentiation of human bone marrow mesenchymal stem cells into smooth 
muscle cells and urothelium-like cells (Tian et al., 2010b). UT-iPS cells were 
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also shown to be more proficient than skin-derived iPS cells in generating 
urothelial and stromal like cells which was demonstrated by expression of 
urothelial-specific markers including uroplakins, claudins, and cytokeratin and 
stromal smooth muscle markers including α-SMA, calponin, and desmin. These 
disparities highlight the epigenetic differences between individual iPS lines and 
represent the importance of organ-specific iPS cells for tissue-specific studies 
and justify sourcing iPS cells from the urinary tract tissue rather than the more 
accessible skin tissue for potential applications in clinical regenerative medicine 
and modelling urinary tract disease. Furthermore, these results suggest that the 
growth factors might be sufficient to induce differentiation of iPS cell along the 
urothelial and stromal lineage and that physical contact between iPS cells and 
the inductor cells is not always a requisite. 
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6 Chapter 6. Induce differentiation of bladder specific cells 
from UT-iPS cells in vivo 
6.1 Introduction 
In the previous chapter it was demonstrated that the generated UT-iPS cells 
have skewed ability to differentiate into bladder cells in vitro. The next step was 
to investigate the ability of these cells to differentiate into bladder specific 
tissues in vivo. Previous experiments reported that embryonic bladder 
mesenchyma (EBLM) is an appropriate inductor that regulates differentiation of 
mouse ES cells and bone marrow derived mesenchymal stem cells toward 
mature bladder tissue (Oottamasathien et al., 2006; Oottamasathien et al., 
2007). Therefore, the behaviour of the UT-iPS cells was assessed when co-
cultured with appropriate inductive mesenchyme in vivo. Inducing the 
differentiating of UT-iPS cells into mature bladder tissue in vivo might be a 
major step towards the clinical use of iPS cells in regenerative medicine and 
tissue engineering of urological organs and also may lead to a better 
understanding and studying of human bladder embryogenesis and diseases. To 
this end, it was decided to establish a feeder free culture using a matrigel matrix 
with optimised human ES cell media. Thereafter, to enable tracking their 
differentiation in vitro and in vivo, UT-iPS cells were labelled with a fluorescent 
marker. Such a model might enable us to capture early events involved in 
bladder development and also facilitate the ability to identify bladder progenitor 
cells.  
6.2 Aims 
- Adapting and maintaining UT-iPS cells to feeder-free culture.  - Generate stable transfectant iPS clones using lentiviral vectors encoding for 
fluorescent marker genes. - Investigate the potential of UT-iPS cells to undergo complex differentiation to 
form mature bladder tissue under the inductive signaling environment 
provided by EBLM. 
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6.3 Results: 
6.3.1 Feeder-free adaptation, culture and passaging of human UT-iPS 
cells 
To avoid loss of lentivirus into the feeder layer and to exclude the effect of 
Blasticidin on MEFs, attempts were made to establish UT-iPS cells feeder-free 
culture. UT-iPS cells were seeded and maintained in culture dishes coated with 
BD Matrigel human ES cell qualified matrix in optimised human ES cell media- 
mTeSR1. BD Matrigel human ES cell qualified matrix is a soluble basement 
membrane extract optimized for stem cell research mainly consisting of laminin, 
collagen IV, entactin, and heparan sulfate proteoglycan (Kleinman et al., 1982). 
MTeSR1 is complete, serum-free standardized media for feeder-free 
maintenance of human ES and iPS cells in culture (Yu et al., 2007; Sun et al., 
2009). No adaptation step is required when switching iPS cells from feeder to 
mTeSR1. Simply, at the time of passaging, undifferentiated UT-iPS aggregates 
were scraped from the surface of the plate under a low power microscope, 
washed with DMEM/F-12 and seeded in appropriate volume of mTeSR1 on BD 
Matrigel-coated plates. High magnification images demonstrated that UT-iPS 
cells grew as compact and multicellular colonies with a distinct border and 
displayed prominent nucleoli with a high nuclear-to-cytoplasm ratio (Figure  6-1). 
Cells at the margins of the colony appeared larger than the cells in the colony 
centre. Healthy colonies were multilayered in the centre, resulting in clusters of 
phase-bright cells.  
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 Figure  6-1: Morphology of human UT-iPS cells cultured on a Matrigel coated 
plate in mTeSR1 medium. (a) An undifferentiated human UT-iPS colony at day 
1. (b) and day 5. (c) Higher magnification, feeder-free colonies appear to have a 
flatter morphology, whereby individual cells are more easily observed within the 
colonies. (d) Cells at the margins of the colony appear larger than the cells in 
the colony centre. Insert shows UT-iPS cells with high nuclear to cytoplasmic 
ratio and prominent nucleoli. Scale bars = 100µm. 
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As human iPS cells are maintained in culture, a subset of the cells 
spontaneously differentiate. Differentiation is characterized by loss of border 
integrity, and the appearance of obvious different cell types as shown in 
(Figure  6-2). These differentiated cells were scraped off the dish surface and 
removed before each passage. In our hands, the percentage of the 
differentiated cells didn’t exceed 2%.  
To ensure continued quality with optimum attachment and continued 
undifferentiated proliferation, iPS cells should be passaged at the proper time. 
Extending the time between passaging in feeder free system results in 
overgrowing and increased differentiation of the iPS cells and cannot be 
rescued. Passaging too early, however, resulted in reduced attachment and 
poor survival. During the first few passages after transferring to feeder free 
culture, UT-iPS cells grew slowly and they therefore passaged to matrigel plates 
at a 1:1 ratio. Later, cells were split using 1:6 ratio.  
Cells were passaged when the colonies became large with a dense and phase-
bright centre compared to their edges when viewed using phase contrast 
microscopy and when the colonies start to touch and fuse with one another 
(Figure  6-3). This generally happened around 5–7 days after seeding. UT-iPS 
cells were passaged using dispase at a concentration of 1 mg/ml at 37°C for 7 
minutes until the edges of the colony appear slightly folded back (Figure  6-3). 
All cultures were observed in the days immediately following passage to ensure 
that they already passaged at the appropriate time. In the first two days after 
seeding colonies may not be very densely packed with cells. However, the 
density of the colonies increased quickly after this time point. UT-iPS cells were 
phenotypically homogeneous and could be maintained and expanded in 
undifferentiated state for more than 30 passages. 
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Figure  6-2: (a) An undifferentiated human UT-iPS colony day 5. (b) UT-iPS 
colony showing an area of differentiation in the centre. (c) Area of differentiation 
between 2 undifferentiated human UT-iPS colonies. Scale bars = 100µm. 
 
 
Figure  6-3: Passaging of UT-iPS cells on feeder - free culture. (a) UT-iPS cells 
ready to be passaged. (b) UT-iPS colonies growing on Matrigel have a very flat 
appearance with the edges of the colonies tightly adhering to the Matrigel 
coated dish surface. (C) Exposure to dispase for ~7 minutes results in the 
curling of the colony edges but the colonies should remain attached to the plate. 
(d) Higher magnification. Scale bars = 100µm. 
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6.3.2 Generation of stable transfectant UT-iPS cell lines 
The second aim of this part of project was to generate stable transfectant UT-
iPS clones to enable tracking them through and after their differentiation. To 
achieve this, UT-iPS cells were transduced with β-actin-mOrange self-
inactivating lentiviral vectors and blasticidin selected (Figure  6-4) (gifted by 
Norman J. Maitland, YCR Cancer Research Unit, York, UK). The m-Orange 
marker and the selectable marker are driven by β-actin and SV40 promoters, 
respectively. Drug selection is a simple and widely used approach to separate 
the stable transfectant cells from other cells that have not integrated the vector 
DNA into their chromosomes. Drug selection performs two important roles, both 
to remove untransduced cells, but also to force integration of the vector. The 
lowest dose of blasticidin that would completely kill 100% of un-transduced UT-
iPS cells by 12 days after drug addition was taken as a starting point for 
selection trials. 
 
 
Figure  6-4: Diagram of mOrange (β-actin)-Bsd lentiviral particles lentivirus 
construct. Modified from (Frame et al., 2010). 
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In brief, undifferentiated iPS cells were plated at a confluency of <40% per well 
into a 6-well culture plate, taking care to maintain cells as aggregates.  After 
24h, media was replaced with the desired amount of virus particles diluted in 
mTeSR1 medium supplemented with 6µg/ml of polybrene. Medium was 
changed after 24h. 5 days post transduction, blasticidin was added at a final 
concentration of 1 µg/ml, as determined previously through kill curves. Selection 
lasted 12 days. Medium and selective antibiotic were replenished every 2 days. 
After blasticidin selection the mOrange expression was analysed by 
fluorescence microscopy and by flow cytometry. A control experiment was first 
carried out to validate the virus stock, in which an easy to handle cell line 
(HEK293) was transduced with 10, and 100 µl of virus using the same protocol. 
Three days after transduction, few fluorescent positive cells were observed 
confirming that the virus was working well (Figure  6-5).  
 
 
Figure  6-5: HEK293 cells transduced with β-actin-mOrange lentivirus, day 3. 
Phase contrast (left), Fluorescence (middle), and merged (right) micrographs 
are shown. Scale bar = 100µm. 
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6.3.2.1 Promoter activity in undifferentiated UT-iPS cells 
As the concentration of the virus was not known, the MOI couldn’t be 
determined, therefore, the initial transduction of UT-iPS was carried out using 
different amounts of virus (100, 500, and 1000µl). Undifferentiated UT-iPS cells 
were prepared for transduction as described previously; transduced cells were 
subsequently subjected to blasticidin selection (1 µg/ml for 12 days). Five days 
after transduction, mOrange was constitutively expressed in very few cells 
(Figure  6-6). An attempt was made to clone the positive cells. However, 
colonies of lentivirus-infected UT-iPS cells showed silencing of the β-actin 
promoter in blasticidin-selected cells (Figure  6-7).  
 
     
Figure  6-6: UT-iPS cells transduced with β-actin-mOrange lentivirus. Five days 
after transduction, very few mOrange-positive cells were detected. Phase 
contrast (top row) fluorescence (middle row), and merged (bottom row) 
micrographs are shown. Scale bar = 10µm. 
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 Figure  6-7: Colonies of mOrange(β-actin) lentivirus- transduced UT-iPS cells 
showing silencing of the β-actin promoter in blasticidin-selected cells. 
Fluorescence (top row) and merged (bottom row) micrographs are shown. 
Scale bar = 50µm. 
 
 
Lentivirus (β-actin)-transduced UT-iPS cells were analysed after blasticidin 
selection, to quantify the proportion of cells expressing the mOrange fluorescent 
proteins and to isolate the positive cells. Flow cytometry analysis demonstrated 
that mOrange was negative in about 99% of the cells (Figure  6-8). mOrange 
positive cells were isolated and cultured for 10 days. Colonies formed from 
these sorted cells showed heterogeneity in mOrange expression and remained 
blasticidin-resistant. After three weeks in culture, the flow cytometry was 
repeated and it was observed that less than 1% of the sorted cells expressed 
the mOrange marker (Figure  6-9). In addition, differentiated cells derived from 
transduced UT-iPS cells did not constitutively express the mOrange marker 
(Figure  6-10).  
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 Figure  6-8: Flow cytometry of mOrange (β-actin) lentivirus- transduced UT-iPS 
cells. (a) P1 gated the cells after ruling out the cellular debris. (b) Doublets 
discrimination. (c) Control untransduced cells. (d) Lentivirus- transduced UT-iPS 
cells, ~ 99% of the cells were mOrange negative. UT-iPS cells control cells, 
mOrange negative (purple events); mOrange positive cells (yellow events); 
Doublets (red events). 
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 Figure  6-9: Flow cytometry of mOrange (β-actin) lentivirus-transduced UT-iPS 
cells 3 weeks after selection. (a) P1 gated the cells after ruling out the cellular 
debris. (b) Doublets discrimination. (c) Control untransduced cells. (d) 
Lentivirus-transduced UT-iPS cells, less that 1% of the cells are mOrange 
positive (green events). UT-iPS cells control cells, mOrange negative (purple 
events). Doublets (red events). 
 
  
Figure  6-10: Phase contrast (left) and fluorescence (right) micrographs of 
mOrange(β-actin)lentivirus-transduced UT-iPS cells showed silencing of the β-
actin promoter upon differentiation. Scale bar = 100µm. 
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As a result of this, fluorescent markers driven by human elongation factor 1-
alpha (EFIα) constitutive promoter were alternatively used in further studies. 
UT-iPS cells were transduced with EF1α-mWasabi or EF1α-Citrine self-
inactivating lentiviral vectors following the same protocol described above. 3 
days post transduction; iPS cells were identified demonstrating mWasabi or 
citrine expression by fluorescence microscopy (Figure  6-11). 
 
Figure  6-11: UT-iPS cells transduced with EF1α-mWasabi (left column) or 
EF1α-Citrine lentivirus (right column). Phase contrast (top row) fluorescence 
(middle row), and merged (bottom row) micrographs at day 3 are shown. Scale 
bar = 100µm. 
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To generate relatively homogeneous cell populations, positive cells were 
isolated by FACS and cultured on matrigel coated plates in mTeSR1 medium. 
Human iPS cells prefer close cell-to cell contacts, and will rarely survive as 
single cells. It was found that the density of initial plating after sorting was 
critical for sorted cells recovery; therefore, to maximize their recovery, wasabi+ 
or citrine+ sorted cells were seeded at a very high density (1–2x106 cells/well of 
a 6-well plate). In addition, as widely performed, a pre-incubation with the Rho 
kinase (ROCK) inhibitor before harvesting the cells for FACS was found to 
enhance the cell survival following sorting. mWasabi and Citrine positive sorted 
cells exhibited characteristic human ES cells morphology and maintained the 
fluorescent expression upon extended iPS cell culture (Figure  6-12). FACS 
analysis of transduced cell lines indicated that the purity of sorted mWasabi- 
and Citrine-expressing cells were 98% (Figure  6-13) and 90.4%, respectively 
(Figure  6-14) even after 10 passages when cultured in normal proliferation 
conditions. 
         
Figure  6-12: Clonal populations of UT-iPS cells transduced with EF1α-mWasabi 
lentivirus at day 3 (top row), day 7 (middle row), and day 14 (bottom row). 
Phase contrast (left column), fluorescence (middle column), and merged (right 
column) micrographs are shown. Scale bar = 100µm. 
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Figure  6-13: Flow cytometry of UT-iPS transduced with EF1α-mWasabi 
lentivirus. (a) P1 gated the cells after ruling out the cellular debris. (b) Doublets 
discrimination. (c) Control untransduced cells. (d) Lentivirus-transduced UT-iPS 
cells, 98% of the cells are positive. mWasabi positive (purple events). Doublets 
(red events). 
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 Figure  6-14: Flow cytometry of UT-iPS transduced with EF1α-Citrine lentivirus. 
(a) P1 gated the cells after ruling out the cellular debris. (b) Doublets 
discrimination. (c) Control untransduced cells. (d) Lentivirus-transduced UT-iPS 
cells, 90.4% of the cells are positive. Citrine positive (purple events). Doublets 
(red events). 
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6.3.2.2 Promoter activity in differentiated UT-iPS cells 
Although promoter silencing was not detectable in undifferentiated cells, it might 
occur during iPS cell differentiation. Thus, it was considered whether mWasabi 
fluorescence would be maintained during differentiation of the transduced UT-
iPS cell line. Differentiation was induced by culturing EF1α/mWasabi-
transduced UT-iPS cells as embryoid body for 2 weeks followed by replating 
and culture on gelatin coated plate for 2 weeks. As shown in (Figure  6-15), the 
cells maintained their mWasabi- expression during differentiation suggesting 
that EF1a is a stable promoter during differentiation. 
 
         
Figure  6-15: lentivirus-transduced UT-iPS cells maintained their mWasabi- 
expression upon differentiation. mWasabi expression in embryoid bodies of UT-
iPS cells at day 14 (top row). mWasabi expression in embryoid bodies 
outgrowth (bottom row). Phase contrast (left column) fluorescence (middle 
column), and merged (right column) micrographs are shown. Scale bar = 
100µm. 
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6.3.3 Tissue Recombination Grafts of UT-iPS cells with mouse EBLM 
To investigate the ability of UT-iPS cells to undergo complex differentiation and 
form mature urothelium with bladder tissue formation under the inductive 
signalling environment provided by EBLM, initial experiments with other 
colleagues from the department of urologic surgery, Vanderbilt university were 
carried out using UT-iPS cells recombined with EBLM and injected under the 
kidney capsule of male athymic nude mice (CD-1 nu/nu Charles River) aged 7–
8 weeks. Grafts were harvested at 42 days post in vivo incubation and tissues 
were processed, paraffin embedded, and sectioned for staining. All the 
recombinants grew under the kidney capsule and no gross invasion outside of 
the renal capsule or into the renal parenchyma was observed. However, these 
experiments were not optimised and multiple differentiated structures 
representing a teratoma were observed with no evidence of bladder tissue 
formation (Figure  6-16). Oottamasathien et al reported similar problem while 
trying to differentiate mouse ES cells into bladder tissues. The authors found 
that using 1000 ES cells + one EBLM shell per graft was not sufficient to avoid 
teratoma formation and yield pure bladder tissue while simply using four shells 
of EBLM in each graft, along with increasing the number of ES cells to 1500 
cells resulted in only pure bladder structures in each graft with no evidence of 
teratoma formation. Therefore, it is evident that further optimisation of both the 
number of EBLM shells in each graft, and the number of UT-iPS cells is 
required. 
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Figure  6-16: (a) Gross appearance of xenografts on host mouse kidney; Two 
grafts were placed beneath the renal capsule of each kidney. (b) H&E staining 
showing complex structures representing a teratoma. 
 
6.4 Discussion  
Human iPS cells are unique in their dual ability to continuously self-renew and 
differentiate into any cell in the adult body (Kreft et al.) without immune rejection 
or the ethical issues involved in destroying human embryos. These 
characteristics give iPS cells the potential to be suitable in many different 
aspects of basic and clinical research, including use as an ex vivo source for 
cellular transplantation; and producing cells for use in studying new drug 
candidates and assessing their toxicity; and as an in vitro system for modelling 
human development and disease. However, some of the most promising 
applications of iPS cells in research are restricted by the difficulty in generating 
genetically modified iPS cell lines. This chapter describes feeder-free 
adaptation, culture and passaging of human UT-iPS cells and the generation of 
stable transgenic UT-iPS cell lines, specifically for use in fluorescent lineage 
tracking.  
Although studies have previously reported successful integration of exogenous 
DNA into ES cells, isolation of stable transfectant cell lines is still inefficient 
because of the poor integration of the construct into the genome and high 
tendency of the exogenous gene to be silenced (Eiges et al., 2001; Liew et al., 
2007). UT-iPS cells were cultured onto BD Matrigel hESC qualified Matrix in 
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mTeSR1 medium. Previous reports showed that ES cells and iPS cells cultured 
and maintained in this environment have homogeneous phenotype, maintain a 
normal karyotype, high levels of appropriate ES cell markers expression, 
including OCT4, TRA-1-60, TRA-1-81, SSEA-4 and the ability to form all three 
germ layers both in vitro and in vivo (Yu et al., 2007; Sun et al., 2009). iPS cells 
were initially transduced with lentivirus vector that contains a gene encoding 
mOrange, under the control of the β-actin and the blasticidin resistance gene 
under control of SV40. Since iPS cells grow as colonies and prefer close cell-to 
cell contacts, starting the antibiotic selection too early, may isolate the stably 
transfected cells and reduce their survival rates. Therefore, the addition of 
selective antibiotics was postponed until day 5 post transduction. In this way, 
resistant cells are afforded time to form small colony of daughter resistant cells 
before selection initiates. However, it was found that UT-iPS cells transduced 
with mOrange driven by β-actin promoter showed silencing of this promoter in 
both undifferentiated and differentiated cells while cells transduced with either 
mWasabi or citrine under the control of the constitutive promoter EFIα showed a 
purity of more than 90% even after long term culture.  
Fluorescent tracking of cells using lentivirus vectors has recently been used 
successfully in other tissues (Naldini et al., 1996; Frame et al., 2010). Actually, 
many constitutive promoters have successfully been reported to conserve 
stable transgene expression in stem cells and are therefore good candidates in 
generation of fluorescent reporter cell lines. Previous studies reported promoter 
silencing with lentivirus constructs (Xia et al., 2007) and suggested that EF1a 
promoter acts as a strong and stable promoter for transgene fluorescent 
expression in human ES cells (Kim et al., 2007). Our results demonstrate that 
lentiviral transduction can successfully be used to produce stable transfectants 
in iPS cells with good viability. Moreover, consistent with previous studies, it 
was found that EF1a is a stable promoter during differentiation of iPS cells and 
therefore is suitable for long term transgene expression. Notably, lentivirus 
vectors have the potential to activate oncogenes or inactivate tumour 
suppressor genes in the modified cells since they randomly integrate into the 
genome which raises concerns regarding clinical applications.  
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7 Chapter 7. General discussion and conclusion 
The urinary tract is subject to damage from a variety of different diseases and 
conditions such as congenital and neuropathic disorders, and malignancies. 
Mature, differentiated native cells collected from the patient remain one of the 
few tools available for replacement and repair of the urinary tract. Nevertheless, 
the shortage of native tissue in congenital disorders and malignancies, and the 
limited regenerative potential of fully differentiated mature cells, even if 
available, is still a crucial drawback (Lakshmanan et al., 2005; Atala, 2008). 
Therefore, cellular systems simulating urinary tract characteristics are in urgent 
need for development of disease specific models for investigations of new 
therapeutic targets as well as for surgical treatment through regenerative 
medicine and transplantation therapies.  
7.1 Stem cells for bladder tissue regeneration 
Numerous trials have attempted to differentiate both embryonic and adult stem 
cells into bladder specific tissue in vitro and in vivo (Liu et al., 2009a; Tian et al., 
2010a; Tian et al., 2010b; Ning et al., 2011). Early studies using both mouse ES 
cells and human BMSCs have raised the possibility to generate bladder-like 
lineages by xenografting ES cells with EBLM in vivo (Oottamasathien et al., 
2006; Oottamasathien et al., 2007; Anumanthan et al., 2008). However, ethical 
issues associated with the destruction of an embryo and the difficulty in isolating 
and growing adult stem cells limited their use in human therapy. It is also 
important to distinguish between mouse and human studies. Despite being a 
useful and powerful model organism, mouse models cannot always completely 
mimic human disorders and promising results with preclinical trials in animal 
models are not always replicated in human clinical trials. About 1% of mouse 
genes have no detectable homologues in the human genome. In addition, 
obvious differences between species have been found in morphology, gestation 
period, and the spatial and temporal regulation of gene expression during 
embryonic development (Zhu and Huangfu, 2013). 
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7.2 Potential advantages of iPS cells 
Human iPS cells present a unique and potential source of cells for tissue repair 
or regeneration since they have the ability to propagate themselves through 
self-renewal, differentiate into multiple lineages and importantly overcome the 
ethical barriers that have limited human ES cell research, since oocytes and 
embryos are not required. In addition, autologous iPS cells can be derived 
directly from patients, such patient-specific iPS cell lines would be compatible 
with the immune system thus provide a potential cell source for cellular therapy 
and give the opportunity to develop diseases models for the study and 
treatment of human diseases (Yamanaka, 2009b; Trounson et al., 2012). This 
pluripotent nature of iPS cells makes them very attractive as a potentially 
inexhaustible source of various cell types that could be used in regenerative 
medicine, drug discovery, disease modeling, and pharmaceutical applications 
(Hochedlinger and Plath, 2009; Onder and Daley, 2012).  
In this project for the first time, successful reprogramming of cells isolated from 
adult human urinary tract tissue to an ES cell-like pluripotent state is reported. 
These cells were validated as de facto iPS cells by confirming their ability for 
sustained self-renewal, silencing of transgenes, expression of ES cell-specific 
genes such as NANOG, reactivating of endogenous OCT4 and SOX2 to levels 
comparable to those found in human ES cells, and pluripotent differentiation 
into cell types from the three embryonic germ layers both in vitro and in vivo. 
Furthermore, within the appropriate inductive environment, UT-iPS cell 
differentiation could be directed into bladder-specific lineages allowing for 
enormous scope in the future for studies of tissue engineering, disease 
mechanisms and drug treatments. UT-iPS cells have remarkable potential for 
regenerative medicine applications and studying the biochemical and 
physiological features of the human urinary tract system.  
7.3 Generating iPS cells from UT-stromal cells 
Since the reprogramming efficiency might be affected by the heterogeneity of 
the targeted cellular population and differentiation state (Stadtfeld and 
Hochedlinger, 2010) we started with producing highly pure cultures of primary 
cells, as quantified by real time-PCR.  
191 
 
We next aimed to establish iPS cells from UT-stroma cells using the four 
classical Yamanaka factors (OCT4, SOX2, KLF4, and C-MYC) and following 
the protocol described before. ES cell-like colonies were first observed around 
week 5-6 post transduction. Subsequently, these generated cells 
passed through a series of checkpoints to ascertain that genuine fully 
reprogrammed UT-iPS cells have been obtained. Morphologically, UT-iPS cells 
looked indistinguishable from human ES cells and demonstrate unlimited self-
renewal. On a molecular level, UT-iPS cells showed high expression levels of 
key pluripotency markers at both transcript and protein levels, and ES cell-
specific surface antigens (SSEA-4, TRA-1-81, TRA-1-60) with a concomitant 
downregulation of lineage-specific genes associated with the cell of origin. 
Silencing of exogenous genes was demonstrated in UT-iPS clones indicating 
that they become factor-independent. On a functional level, UT-iPS cells 
showed the ability to differentiate into lineages from all three embryonic germ 
layers in vitro and in vivo.  
7.3.1 Identification of UT-iPS cell colonies 
Non-reprogrammed cells can be easily distinguished from reprogrammed ones. 
However, differentiating between partially reprogrammed cells and fully repro-
grammed cells is more challenging. Previous studies reported that partially 
reprogrammed cells have clearly distinct gene expression from both parental 
and iPS cells. Although they can be morphologically similar to ES cells and can 
reactivate many pluripotency genes, they fail to express many genes that are 
directly related to pluripotency, including OCT4 and NANOG, and showed  
incomplete silencing of somatic genes, and DNA hypermethylation at the 
promoters of  pluripotency-related genes (Mikkelsen et al., 2008; Plath and 
Lowry, 2011). Chan et al. reported that SSEA-4, GDF3, hTERT and NANOG 
cannot sufficiently distinguish the partially reprogrammed from bona fide iPS 
cell lines whereas silencing the transgenes and expression of TRA-1-60, 
DNMT3B and REX1 are validated as sufficient markers (Chan et al., 2009a). 
Generated UT-iPS cells were positive for many pluripotency factors including 
SSEA4, TRA-1-81, TRA-1-60, OCT4, NANOG, GDF3, DNMT3B, and REX1 at 
comparable levels to human ES cells. In addition, most of the clones showed 
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efficient transgene silencing demonstrating that these cell lines are completely 
reprogrammed into bona fida induced pluripotent stem cells. 
7.3.2 Mechanisms underlying iPS cell generation 
7.3.2.1 Acquiring epithelial properties 
Gene expression profile analyses proposed that the reprogramming process 
could be divided into 3 phases, termed initiation, maturation and stabilization; 
the initial phase is delineated by a mesenchymal-to-epithelial transition (MET), 
while the maturation and stabilisation phases are marked by the activation of a 
subset of pluripotency related genes (Li et al., 2010; Samavarchi-Tehrani et al., 
2010). Initiating and maintaining the reprogramming of fibroblasts inevitably 
requires a process called MET, in which cells undergo morphological changes 
toward epithelial-like cells and epithelial-associated genes are activated while 
mesenchymal genes (such as Snail1, Snail2, Zeb1, and Zeb2) are robustly 
suppressed (Mikkelsen et al., 2008; Li et al., 2010; Samavarchi-Tehrani et al., 
2010; Smith et al., 2010). Around day 7, we observed that some transduced 
UT-stromal cells undergo epithelial-like morphological changes. Real time PCR 
analysis showed overexpression of MET genes in accordance with suppression 
of the important inducers of EMT, such as transcription factors Snail, Slug and 
Twist1, consistent with the occurrence of a MET.  
Cells should go through MET before moving on to the next step, termed 
maturation which is characterized by activation of the pluripotency marker 
genes including NANOG, Sall4, and OCT4. However, the regulatory network 
controlling pluripotency is not completely activated until the late stabilization 
phase (Samavarchi-Tehrani et al., 2010). By tracking clonally derived cells, 
researchers were able to analyse the late stages of reprogramming including 
late maturation and stabilization phases for understanding the global changes 
that occur in cells during reprogramming and gaining mechanistic insights of 
reprogramming. Golipour et al. found that transgenes silencing is essential for 
the transition from the maturation to the stabilization phase and becoming 
pluripotent (Golipour et al., 2012). 
Another study used genome-wide analyses to examine intermediate cell 
populations poised to become iPS cells (Polo et al., 2012) reported major gene 
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activity in two distinct waves during iPS cell formation: the first wave occurred in 
all cells between days 0 and 3, mostly mediated by MYC and was identified by 
the upregulation of genes involved in proliferation, metabolism, and 
cytoskeleton organization and downregulation of genes related to development, 
while the second wave was observed after day 9 and was more restricted to 
reprogrammable cells. The second wave was characterized by the activation of 
genes responsible for embryonic development and stem cell maintenance, 
specifically OCT4 and SOX2. KLF4 was involved in both phases by 
downregulating the differentiation related genes in the first phase and by 
promoting the expression of pluripotency genes during the second one.  
Gene expression analysis of 48 genes included those related to pluripotency, 
proliferation, epigenetic modification, and ES cell-maintaining pathways in 
single cells derived from early time points, intermediate cells, and fully 
reprogrammed iPS cells, revealed that the four factors induce the somatic cells 
to acquire early stochastic gene expression changes. These stochastic 
epigenetic expression changes are followed by a late ‘deterministic’ or more 
‘hierarchical’ phase that leads to activation of the pluripotency circuitry with 
SOX2 being the triggering factor in a gene expression hierarchy (Figure  7-1). 
During the early stage of reprogramming, cells will undergo MET, increase 
proliferation, undergo alterations in DNA methylation and histone modifications 
in specific genes, and activate DNA repair and RNA processing. The 
reprogrammable cells will then pass to an intermediate phase with an unknown 
rate-limiting step that delays their progress toward a fully reprogrammed state 
and therefore supposed to be responsible for the low efficiency of the 
reprogramming process. In some rare cases, the stochastic gene expression 
can trigger the activation of ‘‘predictive markers’’ like undifferentiated embryonic 
cell transcription factor 1 (Utf1), oestrogen-related receptor beta (Esrrb), 
developmental pluripotency associated 2 (Dppa2) and Lin28, which then identify 
the cells that have a higher probability to move on to the second phase, starting 
with the activation of SOX2 which in turn will trigger a series of deterministic 
events that eventually leads to stabilise the cells into the pluripotent state. This 
late hierarchic phase includes silencing of transgene expression, activation of 
the core pluripotency circuit, remodelling of the cytoskeleton to an ES cell-like 
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state, and resetting the epigenome of a somatic cell to a pluripotent state. 
(Buganim et al., 2013).  
 
Figure  7-1: Phases of the reprogramming process. Modified from (Buganim et 
al., 2013). 
 
7.3.2.2  Stochastic versus elite model  
The overall efficiency in generating UT-iPS cells was low (~0.03%), but is 
comparable to the reported efficiency of iPS cells generated from human dermal 
fibroblasts (Takahashi et al., 2007). The so-called ‘‘elite’’ or ‘‘deterministic’’ 
model can explain the low efficiency of iPS cell derivation by proposing that only 
the few somatic stem or progenitor cells that present naturally in a somatic cell 
culture are amenable to reprogramming (Yamanaka, 2009a). However, the elite 
model cannot explain the successful reprogramming of somatic cells derived 
from different starting tissues at similar efficiency rates, including fully 
differentiated B and T lymphocytes (Hanna et al. 2008; Eminli et al. 2009) as 
well as pancreatic b cells (Stadtfeld et al. 2008a). In addition, long-term analysis 
of reprogramming monoclonal populations of early B cells and monocytes 
showed that nearly all donor cells are amenable to attain the fully 
reprogrammed pluripotent state albeit, at different times due to different 
latencies (Hanna et al., 2009). In contrast, the ‘‘stochastic’’ model proposes that 
all somatic cells regardless of their tissue origin, are equally susceptible to 
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reprogramming upon continuous overexpression of stemness-related genes, 
but have to transit through sequential stochastic epigenetic events toward the 
pluripotent state. Only a few cells may pass all of these roadblocks, resulting in 
the overall low efficiency (Yamanaka, 2009a; Stadtfeld and Hochedlinger, 
2010). Indeed, current evidence revealed that induction of the pluripotent state 
is a multistep procedure, in which somatic cells have to go through sequential 
gene expression steps to acquire pluripotency. Failure to move between any of 
these steps would result in blocked or incomplete reprogramming (Hanna et al., 
2009; Papp and Plath, 2013). Utilizing specific surface marker combinations, it 
has been found that successfully reprogramming cells first downregulate the 
fibroblast-associated marker Thy1 followed by activation of the embryonic 
marker SSEA1 and, eventually, reaching the fully pluripotency state (Brambrink 
et al., 2008; Stadtfeld et al., 2008b; Polo et al., 2012). The silencing of Thy1 
was detected in the majority of the starting cell population. However, only a 
small portion of Thy1-negative cells showed subsequent gain of SSEA1 and 
only a small subset of the SSEA1-positive cells completed the reprogramming 
process and became iPS cells (Wernig et al., 2008a; Stadtfeld and 
Hochedlinger, 2010). These finding might explain somehow why efficiency of 
iPS cell generation is typically so low. It was also found that cells which remain 
positive for Thy1 upon OSKM expression become refractory to reprogramming. 
Notably, during the first two weeks, SSEA1 positive cells are phenotypically still 
elastic and may revert to earlier reprogramming state, later on in 
reprogramming, they exhibit much more commitment to a stable pluripotent cell 
fate (Polo et al., 2012; Papp and Plath, 2013). Accordingly, following clonal 
populations of early B cells and monocytes revealed that almost all starting cells 
ultimately have the potential to form iPS cells even though the reprogramming 
process may take more than 6 months (Hanna et al., 2009). However, the 
differentiation phase itself has been suggested to influence the efficiency of 
reprogramming. Indeed, establishing iPS cells from adult progenitor and stem 
cells have been found to be more efficient and take less time as compared to 
mature, differentiated cells (Eminli et al., 2009; Galende et al., 2010). Hence, 
recent studies suggested a modified stochastic model that integrates an elite 
component to help explain the low efficiency of reprogramming (Smith et al., 
2010; Stadtfeld and Hochedlinger, 2010).  
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7.3.3 Transduction efficiency 
Transduction efficiency of lentivirus for reprogramming factors is critical for iPS 
generation. The ratio of active virus to target cell is referred to as the multiplicity 
of infection (MOI). As there are substantial differences in cell types that affect 
their susceptibility to transduction, MOI should be optimized for each cell line 
before transduction. Transduced cells with a very high MOI can lead to multiple 
vector copy integration and persistence of the exogenes, on the other hand 
transduction with very low MOI would result in ineffective transduction and thus 
failed iPS induction; therefore we modified the MOI during the initial 
transduction step to achieve efficient transduction with fewer copies per cell. We 
found that an MOI of 30 resulted in transduction efficiency of approximately 
45%. However, with this MOI the lentivirus was very toxic to stromal cells with 
about 30 % of the cells dying, while the percentage death dropped down to 13% 
with an MOI of 10. Taking in mind to use the minimal amount of virus particles 
to minimise the number of integrating sites and to ensure silencing of the 
transgene, an MOI of 10 was selected despite the lower infection efficiency. 
Growth properties of the target cells are also important for iPS cell generation. 
Transduction efficiency is significantly decreased when senescent cells are 
used for transduction. Therefore, fresh and pure stromal cells were transduced 
as early as possible for iPS cell production.  
7.3.4 Culturing and maintaining UT-iPS cells 
The generated UT-iPS were initially cultured and maintained in feeder-
dependent culture. Quality of the MEFs has been found to play an important 
role to help maintain successful culture of human pluripotent cells (Amit et al., 
2003). The quality of UT-iPS culture varied with different batches of MEFs since 
each batch varies in its capacity to support these cells. UT-iPS cells cultured 
onto low-quality MEFs showed excessive differentiation and poor colony 
morphology. The optimum plating density of MEFs is also critical to reduce the 
differentiation and maintain appropriate proliferation. We found that iPS cells 
plated on 50,000 cells/cm2 MEFs density produced healthy cultures with good 
colony morphology. UT-iPS were also cultured and maintained successfully in 
feeder free culture.  Human ES cells were cultured in feeder free conditions for 
the first time by Xu et al (Xu et al., 2001). This system allowed for long-term 
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maintenance of stem cells with low level of spontaneous differentiation even at 
high passages. Recently, several human ES and iPS cell lines have also been 
cultured in the absence of feeder cells (Amit et al., 2000; Sjogren-Jansson et 
al., 2005; Warren et al., 2012; Fukusumi et al., 2013). The move to feeder free 
culture has several advantages; first and foremost, it reduces the exposure of 
human ES and iPS cells to animal pathogens. In addition, it eliminates the need 
to prepare and preserve an additional cell type (MEFs), attains better 
visualization of iPS colonies, and excludes a source of potentially confounding 
cells especially during iPS cell differentiation. Regardless of the culture system, 
feeder dependent or independent, to preserve the passaging efficiency and 
pluripotency of the iPS culture, it is significant that the iPS cells are transferred 
as small fragments (200 to 300 cells/clump). Triturating the colonies down to 
very small fragments or single cells will significantly increase the differentiation 
and reduce the plating efficiencies. Colony fragments that are too large however 
result in poor attachment. Moreover, the period of time from colony scrapping to 
re-plating is also critical and should be kept to a minimum. Appropriate passage 
timing and plating densities are also essential to maintain a constant 
undifferentiated state and optimum attachment. Passaging cells too late will 
stimulate the differentiation and reduce the quality of the culture. In contrast, 
replating the cells too early may results in low plating efficiencies. In our hands, 
iPS cultures were passaged every 5 to 7 days, while passaging we tried to 
obtain clumps of the same, near-optimal size and spread them throughout the 
well. UT-iPS cells lines were maintained using a combination of both the 
mechanical and enzymatic transfer procedures which allows for mass 
production of undifferentiated iPS cells by manually excluding differentiated 
colonies prior to enzyme treatment (Oh et al., 2005; Schatten et al., 2005). 
Since the first descriptions of iPS cells in 2006, most reports have focused on 
the generation of iPS cells from a range of normal and diseased tissues. Only 
more recently researchers have started to further explore the differences in the 
ability for terminal tissue-specific differentiation between the iPS cell lines 
derived from different organs and found that not all iPS cells are the same in 
this respect (Kim et al., 2010; Polo et al., 2010; Ohi et al., 2011). Interestingly, 
several studies have demonstrated that de facto iPS cells may carry an 
“epigenetic memory” of their cell type of origin. Consequently, iPS cells with 
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source cell memory have higher tendency to differentiate back to their parental 
cell type than to other cell fates (Lee et al., 2012; Xu et al., 2012). Moreover, 
genetically identical iPS cell lines derived from different somatic cell types 
showed histone methylation patterns and transcription profiles unique to their 
tissue of origin (Polo et al., 2010). Whether retained DNA methylation marks, 
histone modifications, or a combination of both do contribute to iPS cell-somatic 
donor memory is still unclear (Kim et al., 2010; Ohi et al., 2011; Xu et al., 2012). 
Therefore, the functional differences and differentiation potential of UT-iPS cells 
to more efficiently generate bladder tissue cells compared with iPS cells derived 
from skin fibroblasts were further analysed.  
7.3.5 UT-iPS cells exhibit higher capacity for bladder tissues 
differentiation than skin-iPS cells 
We compared the differentiation potential of UT-iPS cells with skin-iPS cells in 
generating urothelial and smooth muscle stromal cells and our results 
demonstrated vast differences in their capabilities for bladder specific 
differentiation. UT-iPS cells have a greater propensity for bladder differentiation 
compared to skin-iPS cells under the same conditions. This observation serves 
to emphasise the importance of tissue specific iPS cells for the study of urinary 
tract differentiation, and is likely to be related to established mechanisms of 
epigenetic imprinting restricting differentiation potential. 
Although the epigenetic memory was observed in early passage iPS cells and 
can be gradually erased upon extended iPS cell culture (Kim et al., 2010; Polo 
et al., 2010), UT-iPS cells were used at passage numbers below 50 and it is 
therefore justifiable that these cells still retain some epigenetic signature of their 
somatic-cell provenance at this stage. Whether this source cell memory can be 
erased by continued passaging remains unknown and requires further 
investigation. This further underscores the need for understanding how this 
memory varies among different cell types and tissues.  
In urothelial and smooth muscle stromal cells differentiation of UT-iPS cells, U-
CM treatment appears more efficient in inducing UT-iPS cells differentiation into 
urothelium when comparing treatment with S-CM. In previous studies, U-CM 
was shown to be more efficient in inducing urothelial differentiation whilst S-CM 
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was more efficient at inducing smooth muscle stromal cell differentiation 
(Mudge and Klumpp, 2005); however, further studies of UT-iPS cells 
differentiation would be required to disentangle relative contributions to 
epithelial or stromal differentiation in our model. Nevertheless, our findings 
show that either U-CM and S-CM were able to guide UT-iPS cells to 
differentiate into both urothelial and SM cells consistent with evidence that 
stromal-epithelial interactions are necessary for their development and 
maintenance (Baskin et al., 1996).  
Moreover, a reciprocal cell-cell signalling relationship between the stromal and 
epithelial compartments during differentiation would be consistent with the 
simultaneous induction of both cell types as observed in our model. 
Contemporary evidence has shown that mesoderm (Wolffian duct) does not 
contribute to trigone development (Viana et al., 2007; Tanaka et al., 2010) and 
that endodermal derivatives of the urogenital tract could differentiate to form 
prostate and only mesodermal derivatives of the urogenital tract could 
differentiate to form seminal vesicle (Tanaka et al., 2010). However, this usual 
pattern of restricted differentiation depending on the germ layer origin of the 
epithelium can be overcome by iPS cell generation as both ureteric 
(mesodermal derivative) and bladder (endodermal derivative) were able to 
demonstrate bladder specific differentiation. This is consistent with de-
differentiation into a pluripotent ES cell-like state preceding gastrulation; where 
endoderm and mesoderm arise from the transient mesendoderm common 
precursor cell population.  
In addition, we know that organ-specific mesenchyme, from which we took 
conditioned media, can enforce lineage commitment and alter terminal 
differentiation of adult epithelia across endodermal and ectodermal boundaries 
(Taylor et al., 2009). This may also explain why there is plasticity in 
mesenchymal stem cells (MSCs), such as those derived from bone, that are 
able to undergo endodermal differentiation into bladder tissue (Anumanthan et 
al., 2008). Pre-clinical studies of MSCs in the urinary tract have shown 
considerable promise (Anumanthan et al., 2008; Tian et al., 2010b). However, 
in comparison to human ES cell derived progenitors, MSCs display substantially 
decreased tissue formation (Peppo et al., 2012) and furthermore the 
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regenerative capacities of MSCs can be enhanced by inducing the expression 
of iPS cell-related genes NANOG and OCT4 (Liu et al., 2009c). The exact 
contribution of MSCs to fully differentiated bladder regeneration requires further 
assessment and a direct comparison with the UT-iPS cells would be of interest. 
Interestingly, the expression of a-SMA was substantially higher than that of 
calponin and desmin. a-SMA is considered as an early marker of smooth 
muscle differentiation, while calponin and desmin are highly specific markers 
confined to fully differentiated contractile smooth muscle cells (Jack et al., 
2009). The expression of a-SMA has also been found to precede the 
expression of other smooth muscle markers, including calponin and desmin 
during the myofibrillar development in the early development of rat and chicken 
hearts (Ruzicka and Schwartz, 1988; Ya et al., 1997). Therefore, the presence 
of differences in the expression of these markers in differentiated UT-iPS cells 
might reveal differences in the developmental timing of myocyte maturation. 
Early investigations proved that various sources of stem cells (embryonic stem 
cells (ESCs), BM-derived SCs) have the ability to differentiate into bladder cells. 
Oottamasathien et al, showed that mouse ES cells can differentiate to bladder 
cells when associated with embryonic rat bladder mesenchyme and implanted 
under the kidney capsule for up to 42 days. The endodermal markers of Foxa1 
and Foxa2, but not uroplakin were first detected at day 7 after grafting. By 42 
days, optimized number of cells resulted in pure urothelial cells with mature 
bladder tissues derived from the ES cells that was evident by hematoxylin and 
eosin staining. Maturation was evident based on expression of uroplakin, a 
selective marker for urothelial cell differentiation and the basal cell marker p63, 
whereas smooth muscle α-actin (SMA); was used as a marker to identify 
smooth muscle cells (SMCs) (Oottamasathien et al., 2006; Oottamasathien et 
al., 2007). However, there are ethical and immunological debates about using 
this procedure in humans. In addition, the differences observed between murine 
ES cells and human ES cells regarding molecular and developmental properties 
may represent an obstacle for direct translation to humans. Utilizing the same 
model, Anumanthan and his colleagues used a recombinant xenograft of MSCs 
with EBLM to differentiate mouse MSCs toward mature bladder cells. 
Histological examination showed a bladder tissue structure with expression of 
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uroplakin, SMA and desmin (Oottamasathien et al., 2007). The primary 
limitation of using adult stem cell derived urothelium hinges on a poorly 
understood differentiation process that typically occurs through either 
transdifferentiation or cell fusion. Furthermore, adult cells have limited 
proliferation potential in vitro (Ning et al., 2011). While the murine model 
provided evidence of feasibility, only recently has the differentiation of human 
urothelium from pluripotent stem cells been reported. Osborn et al described the 
induction of human urothelium from ES cells and iPS cells using a 
developmentally directed culture system, where urothelium is induced through a 
definitive endoderm step. The system efficiently differentiated urothelium 
through a process that appeared to mimic development of the bladder 
epithelium during embryogenesis (Osborn et al., 2014). Osborn data also 
supported our finding human iPS cells be efficiently differentiated in vitro into 
urothelial cells in the absence of cell contact (Moad et al., 2013). 
Several studies have also addressed the question of true differentiation versus 
fusion of stem cells (Terada et al., 2002; Ying et al., 2002). In this study, using 
cell-free conditioned medium to treat the UT-iPS cells does confirm that they 
have undergone true differentiation. 
7.3.6 Establishment of UT-iPS transgenic cell line 
To identify the UT-iPS cells and their cell lineage in vitro and in vivo, UT-iPS 
cells were transduced with lentiviral vectors encoding for fluorescent marker 
gene. Lentiviral mediated gene transfer was selected for gene delivery into UT-
iPS cells since it provides stable transgene integration, efficient transduction 
(Gropp et al., 2003; Ma et al., 2003; Norrman et al., 2010), and less tendency 
for silencing during propagation and differentiation (Cherry et al., 2000), while 
other non-integrating viral systems, such as adenovirus can only provide 
transient expression of the transgene (Suzuki et al., 2008). Fluorescent proteins 
are genetically encoded which allows to monitor and track the cells easily, and 
make it possible to image certain type of cells in real time within living cells and 
in animal grafting experiments (Miyawaki et al., 2003; Verkhusha and Lukyanov, 
2004; Giepmans et al., 2006). Although the low viral transgene expression is a 
common phenomenon in human ES cells (Xia et al., 2007), several viral 
promoters have successfully been reported for efficient stable expression of 
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transgenes in human ES cells. We started with a lentivirus vector expressing 
mOrange under the control of the β-actin promoter. This lentiviral vector also 
carries blasticidin resistance, which was used to select for the transduced cells. 
However, mOrange (β-actin)- transduced UT-iPS cells lost most of their 
mOrange expression in subsequent culturing and during their in vitro 
differentiation as confirmed by fluorescent microscopy and flow cytometry and 
remained blasticidin-resistant. Similar and complementary results were reported 
previously using the same construct (Frame et al., 2010). It is well known that 
lentiviral silencing is usually associated with certain promoters (Xia et al., 2007; 
Mao et al., 2008). Although human ES cell lines expressing robust levels of 
EGFP both in undifferentiated and differentiated cells has been achieved using 
a human β-actin promoter-driven EGFP gene (Costa et al., 2005), the 
transgene expression in the transduced cells might be affected by potential 
alterations in activity of the promoter sequence of the fluorescent gene. Indeed 
promoter silencing associated with both the promoter-fluorescent gene 
combination and cell type have been reported previously (Tao et al., 2007; 
Frame et al., 2010). The observed difference in β-actin promoter activity may 
also be explained by the differences in lentiviral vector design. As a result of 
this, the constitutively active promoter EF1a was subsequently investigated. 
Previous studies reported long-term stable expression of most transgenes 
under the control of EF1a by lentiviral vectors in ES cells in vitro and in vivo 
(Chung et al., 2002; Hong et al., 2007; Kim et al., 2007; Liu et al., 2009b; Qin et 
al., 2010). UT-iPS cells were transduced with a lentiviral vector coding for 
mWasabi or citrine under the control of EF1a. mWasabi is a monomeric green 
fluorescent protein derived from mTFP1 and it is approximately 2-fold brighter 
than EGFP. We found that mWasabi and citrine expression under the control of 
EF1a promoter were stably maintained for more than 10 passages in 
undifferentiated UT-iPS cells with no obvious cytotoxic side effects. This is in 
line with previous data demonstrating constant, robust EF1a promoter activity in 
human ES cells for up to 60 days in culture (Ma et al., 2003). In addition, 
transgene expression is sustained during in vitro differentiation. Such 
genetically modified iPS cell lines will provide new tools for tracking cells 
transplanted into animal models and hence a better understanding of human 
development. However, the long term activity of EF1a promoter in differentiated 
UT-iPS cell lines has not been extensively studied. In addition, the behaviour of 
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this promoter during in vivo UT-iPS cell differentiation remains unknown. It is 
worth noting that differentiating iPS cells will result in heterogeneous cell 
populations at the fully differentiated stage, including different types of cells, 
therefore it is still unclear whether the EF1a promoter may exhibit various 
transcriptional activities in different cell lineages.  
7.4 Transduction of human urothelial cells 
The induction protocol used for UT-stromal cells was also applied to the primary 
culture of human urothelial cells. However, we undertook unsuccessful 
preliminary attempts at inducing urothelium. It is conceivable that epithelial cells 
per se are more amenable to reprogramming, perhaps because, unlike stromal 
cells, they may not need to undergo an initial MET to yield iPS cells. However, 
primary urothelial cells might not be healthy enough for reprogramming after the 
cell sorting and replating processes, taking into account that primary urothelial 
cells even without the stress of sorting are technically challenging cell cultures 
and often have limited life span in vitro. Although a few colonies that were 
positive for the TRA-1-60 and SSEA4 antigen were detected, these were non-
proliferative and the morphology was not similar to that of ES cells.  
Previous study reported early TRA-1-60 and SSEA-4 positive cells detected in 
human fibroblasts transduced with the four reprogramming factors (OCT4, 
SOX2, KLF4 and C-MYC) that were not on a trajectory to reach a fully 
reprogrammed state, but instead senesced, died or remained partially 
reprogrammed (Chan et al., 2009a). Consistently, a very recent paper from the 
Yamanaka lab (Tanabe et al., 2013) in which the fate of transduced cells was 
monitored during the reprogramming process demonstrated that although 20% 
of the transduced cells exhibited TRA-1-60 positive staining, about 99% of 
these nascent reprogrammed cells failed to reach the pluripotency state and 
turned back to be negative again during the subsequent culture. Small-molecule 
treatment has been suggested to induce these reversed cells to convert to the 
next reprogramming stage and subsequently to iPS cells more efficiently (Ichida 
et al., 2009; Esteban et al., 2010; Plath and Lowry, 2011).  
Further reduction of toxicity involving the optimisation of MOI, reduction of 
polybrene and timing of transfer to ES cell medium with MEFs may also be 
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required. Further experimentation was not pursued given that the stroma based 
UT-iPS cells demonstrated robust ability to differentiate into urothelium. 
Furthermore, a proof of principle in animal studies was already established 
where mouse ES cells were shown to undergo endodermal lineage 
transformation into mature urothelium (Oottamasathien et al., 2007). This 
phenomenon also provides the additional attraction of using an alternative, 
genetically normal, tissue source in urothelial malignancies and thus avoids the 
hazards of using diseased cells.  
7.5 Challenges of iPS cells 
Future challenges include developing viral- and transgene-free reprogramming 
approaches and xeno-free culture methods in building towards clinical 
translation.  
7.5.1 Gene delivery methods 
Since the first generation of iPS cells using retroviral transduction there has 
been remarkable progress toward reprogramming technologies, optimizing the 
delivery of the reprogramming factors into somatic cells, and improving 
reprogramming efficiency (Figure  7-2).  
7.5.2 Viral delivery system 
The basic method developed by Yamanaka and colleagues used constitutively 
active retroviral vectors in mouse (Takahashi and Yamanaka, 2006) as well as 
human fibroblasts (Takahashi et al., 2007; Lowry et al., 2008). Because they 
tend to be completely silenced and provide extended expression of the 
transgene, retroviruses are considered as effective gene transfer vehicles 
(Hotta and Ellis, 2008). However, subsequent mutations that contributed to 
neoplastic clone formation have been identified in retrovirus transduced cells 
(Nienhuis et al., 2006; Takahashi and Yamanaka, 2006). Later on, iPS cells 
from various cell types have been generated successfully using lentiviruses, a 
subclass of retroviruses. Unlike retroviruses, lentiviral vectors are able to target 
both dividing and nondividing cells which increases the rate of cell transduction 
(Yu et al., 2007; Sommer et al., 2009; Sun et al., 2009) and can be used with 
constitutive or inducible expression system (Brambrink et al., 2008; 
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Hockemeyer et al., 2008; Stadtfeld et al., 2008a), but they seem to be 
associated with inefficient proviral silencing (Robinton and Daley, 2012). These 
two systems have been shown to be robust, reproducible and very efficient at 
delivering genes. However, the risks of permanent transgene integration into 
the genome and the possible reactivation of the transgene expression leading 
to tumour formation pose serious clinical concerns (Ton-That et al., 1997; 
Stadtfeld et al., 2008a; Sommer et al., 2009; Anokye-Danso et al., 2011). 
Additionally, the protocol efficiency which uses retro/lentiviruses is low, with 
reported reprogramming rates of 0.001% to 1% (Maherali et al., 2007; Wernig et 
al., 2007). Since the most exciting prospect for the use of iPS cell technology is 
for human therapeutic applications, alternative methods to derive iPS cells free 
of transgenic sequences have been now demonstrated. Generally integration-
free iPS cell lines have been established using integrating vectors that can be 
subsequently excised from the genome, non-integrating viruses, and non-viral 
delivery system (Stadtfeld et al., 2008c; Zou et al., 2009).  
To reduce the tumour formation potential of iPS cells, the exogenous factors 
can be excised from genomic integration sites in iPS cells by Cre-loxP 
recombination and piggyBac (PB) transposition. Reprogramming factors flanked 
by loxP sites can be excised by transient expression of CRE recombinase. The 
Cre protein is a site-specific DNA recombinase that catalyzes the recombination 
of DNA between loxP sequences which contain binding sites for Cre (Shi et al., 
2008; Soldner et al., 2009). However, transgene excision leaves behind the 
entire long terminal repeat, which contains a loxP site and that could potentially 
lead to genomic instability and genome rearrangements.  
To overcome the multiple genomic integrations, a single polycistronic vector, 
containing the four reprogramming factors connected with 2A peptide linkers 
was established (Chang et al., 2009; Shao et al., 2009). However, a loxP site 
and vector DNA external to the loxP sites still remains in the genome after Cre-
mediated excision, retaining the possibility of interrupting promoters, coding 
sequences and regulatory elements.  
In contract, the PB transposon removes itself without leaving any remnants of 
exogenous DNA in the cell genome (Woltjen et al., 2009). Woltjen, Kaji, and 
colleagues reported successful and efficient generation of transgene-free 
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murine and human iPS cells using doxycycline-inducible transcription factors 
delivered by PB transposition which can be excised once pluripotent cell lines 
become established. The transduction efficiency using this approach was 
similar to the retroviral methods (Yusa et al., 2009).  
Adenovirus is a non-integrating vector that remains in an epichromosomal form 
in cells and provides high-level expression of exogenous genes. The first iPS 
cells free of exogenous gene integration were generated from mouse fibroblasts 
and liver cells using adenoviral vectors containing OCT4, SOX2, KLF4 and C-
MYC genes without permanent genetic integration and at an efficiency of about 
0.0005% (Stadtfeld et al., 2008c). Human fibroblasts have also been 
reprogrammed into iPS cells with adenoviral vectors (Zhou and Freed, 2009). 
However, the limited availability of primary cellular receptor required for binding 
and internalization decrease the efficiency of gene transfer (Freimuth et al., 
2008). In addition, repeated transfection might be required for efficient 
reprogramming of certain cells (Stadtfeld et al., 2008c).  
Fusaki et al, reported efficient generation of viral-free iPS cells from human 
fibroblast cells with Sendai virus (SeV) vectors (Fusaki et al., 2009). Sendai 
virus is an RNA virus which does not integrate into chromosomes of the target 
cells.  
7.5.3 Non-viral delivery system 
The transgene silencing after retrovirus transduction and successful 
reprogramming with a nonintegrating system indicated that transgene 
integration into the genome is not essential for direct reprogramming. Therefore 
researchers tried to generate iPS cells using non-viral delivery approaches.  
Plasmid vectors are a non-viral delivery system in which the encapsulated 
exogenes are carried on plasmids and transfected into the cells to be 
reprogrammed. Plasmids are episomally retained and usually exhibit short 
duration of gene expression. This approach was used for the first time by Okita 
et al (Okita et al., 2008) to transfect mouse embryonic fibroblast. No integration 
was identified within the iPS cells generated using the transient transfection 
nucleofection protocol. However, plasmid incorporation into the host genome 
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was detected at rates as low as approximately 5.5% using the serial 
transfection method. Compared with regular plasmid vectors which provide a 
short window of gene expression, episomal plasmid vectors show longer and 
more stable expression in target cells and can be controlled in transfected cells 
through drug selection to remove the untransduced cells (Nanbo et al., 2007). 
Nevertheless, the reprogramming efficiency of this strategy was extremely low 
(3–6 colonies per 106 somatic cells) comparing to that of viral systems (Kaji et 
al., 2009; Yu et al., 2009).  
However, all the previous strategies still target the cells with foreign genetic 
materials, which may still produce unpredicted alterations within the genome. 
Thus, reprogramming strategies entirely free of DNA-based vectors are a major 
future goal. In 2009, Zhou et al. and Kim et al. reported the possibility of 
obtaining mouse and human transgene-free iPS cells using cell-permeable 
recombinant proteins of the four factors (OCT4, SOX2, KLF4 and C-MYC) 
rather than forcing their transcription through transgenes (Kim et al., 2009a; 
Zhou et al., 2009). 5×104 mouse embryonic fibroblast cells were subjected to 
four rounds of protein supplementation, and treated with the histone 
deacytelase inhibitor, valproic acid (VPA). After 30–35 days in culture, three iPS 
cell clones that were morphologically similar to mouse ES cells were obtained. 
In addition, the generated protein-induced pluripotent stem (piPS) cells were 
shown to have global gene expression similar to that of mouse ES cells and 
demonstrated an ability to differentiate into cells of the three primary germ 
layers in vitro and in vivo. However, it is not clear if adult cells can be 
transduced successfully using recombinant cell-penetrating reprogramming 
proteins which have proven to be more refractory to reprogramming than 
embryonic cells. Moreover, due to the short half-life of the recombinant proteins, 
repeated protein transductions might be required for successful reprogramming 
(Gump and Dowdy, 2007; Lai et al., 2011).  
More recently, Warren and colleagues showed that they were able to efficiently 
generate iPS cell lines from multiple human differentiated cells using modified 
mRNA encoding reprogramming factors (Warren et al., 2010). Using mRNAs for 
reprogramming has many advantages over other methods including high 
efficiency as they are much smaller than DNA; high activity as they will be 
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translated into proteins by the host cell, and better ability to control the amount 
of each factor (Plews et al., 2010). However, mRNA provides only a short 
duration of gene expression (2–3 days), thus multiple transfections are required 
for complete reprogramming and innate immune response must be suppressed 
alongside mRNA transfection (Wang and Na, 2011).  
One major drawback to these approaches, however, is the very low 
reprogramming efficiency (0.01–0.1%), making them currently far from being 
technically mature. Finding that microRNA (miRNA)-deficient ES cells are 
defective in differentiation and proliferation highlighted the importance of 
miRNAs in the control of pluripotent stem cells.  
Recently, Judson et al. reported the first successful generation of iPS cells from 
mouse embryonic fibroblasts using miRNAs specific to ES cells (Judson et al., 
2009). Cells were exposed to a subset of the miR-290 cluster, known as the 
embryonic stem cell cycle (ESCC) regulating miRNA in the presence of OCT4, 
SOX2 and KLF4 factors. MicroR-294 was found to be the most effective miRNA 
and increased the reprogramming efficiency to 0.1–0.3%. MicroR-302 which is 
the human homologous miR-291/294/295 family is also abundantly present in 
mouse and human pluripotent cells but not in somatic cells, thus miR-302 can 
be potentially used to enhance the reprogramming efficiency of differentiated 
cells. The miR302/367 cluster has been found to be a direct target of OCT4 and 
SOX2 (Card et al., 2008). It was also found that the introduction of the miR-
302/miR-372 cluster improved the reprogramming efficiency through enhancing 
the kinetics of MET during reprogramming (Nie et al., 2012) confirming its 
critical role in self-renewal ability and the maintenance of pluripotency. As 
expected, the miR302/367 cluster possessed the ability to directly reprogram 
mouse and human somatic cells to an iPS cell phenotype without the 
expression of the known reprogramming factors (Anokye-Danso et al., 2011; 
Miyoshi et al., 2011). Similarly, Lin et al. reported successful generation of iPS 
cells from human hair follicle cells (hHFCs) by inducing miR-302 expression 
beyond 1.3-fold of the concentration in human ES cells (Lin et al., 2011b). 
Reprogramming by miRNAs produced iPS cells indistinguishable from those 
generated by transcription factors with respect to colony morphology, 
expression of stemness markers, differentiation potential, and germline 
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transmission (in mice). In addition, this reprogramming technique has been 
found to be highly efficient and rapid compared with that by the transcriptional 
factors and most importantly it requires neither using transcription factors nor 
manipulating the cell genomes. However, how exactly miRNAs can induce the 
whole network governing pluripotency and the practical use and robustness of 
this approach is yet to be revealed (Wang and Na, 2011).  
Stimulus-triggered acquisition of pluripotency (also known as STAP) is a new 
cellular reprogramming approach which describes the ability to reprogram the 
somatic cells by exposing these cells to harsh external stimuli such as a 
transient low-pH stressor without the need for nuclear transfer or the 
introduction of transcription factors. However, since this report was published, 
scientists in other prominent stem-cell laboratories have been unable to 
produce “STAP” cells using the protocols reported in Obokata’s publications 
(Obokata et al., 2014).  
 
Figure  7-2: Factor delivery methods for reprogramming somatic cells to iPS 
cells. Based on (Gonzalez et al., 2011). 
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7.6 Factors and strategies to enhance reprogramming 
To enhance the efficiency of DNA reprogramming several modifications have 
been tried such as adding small molecules and chemical compounds including 
vitamin C which has been found to significantly enhance the generation of both 
mouse and human iPS cells by suppressing p53 and minimizing the cellular 
senescence resulting from the stress of DNA damage (Esteban et al., 2010), 
and valproic acid, a histone deacetylase inhibitor which increased the 
reprogramming efficiency by more than a hundred fold (Huangfu et al., 2008a; 
Mikkelsen et al., 2008; Feng et al., 2009b). The efficiency of lentiviral 
transduction can also be enhanced using a drug inducible transgenic system, 
this system further permits temporal control over factor expression (Maherali et 
al., 2008; Stadtfeld et al., 2008b).  
A recent study by Liao et al. improved the efficiency of producing iPS cells from 
human differentiated cells using a combination of 6 transcription factors, OCT4, 
NANOG, SOX2, LIN28, C-MYC and KLF4 (Liao et al., 2008). Human newborn 
foreskin fibroblasts were transduced with the lentivirus carrying GFP (as 
negative control), a cocktail of lentivirus carrying 4 factors (OCT4, NANOG, 
SOX2, and LIN28), or 6 factors (OCT4, NANOG, SOX2, LIN28, C-MYC and 
KLF4). Colonies with human ES cell-like morphology were observed after 12 
days from transduction with 4 factors, and after only 7 days from transduction 
with 6 factors.  
More recently, deterministic reprogramming of mouse and human differentiated 
cells back to an undifferentiated state similar to ES cells at efficiencies nearing 
100% within seven days has been achieved by OSKM factors together with 
inhibiting Mbd3, a core member of the Mbd3/NuRD (nucleosome re-modelling 
and deacetylation) (Rais et al., 2013). In this study Mbd3/NuRD was found to 
supress iPS cells induction through silencing the OSKM target genes that are 
required to boost the reprogramming process. However, contrary to previous 
reports (Luo et al., 2013), depleting Mbd3 expression couldn’t induce the 
formation of iPS cell in somatic cells without exogenous overexpression of 
OSKM. It is worth exploring if depleting Mbd3 may improve iPS-generation 
efficiency in the human urinary tract cells. 
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Another major drawback with Yamanaka’s original transduction protocol 
however, was the use of C-MYC oncogene as a reprogramming factor. 
Although retrovirally delivered, C-MYC is strongly silenced in bona fide iPS 
cells, reactivation of the C-MYC transgene induced tumour formation in about 
20% of iPS - derived progeny (Okita et al., 2007).  
At the same time, Thomson and co-workers were successfully generating 
human iPS cells utilizing lentiviral vectors with OCT4, and SOX2 in combination 
with NANOG and LIN28 genes instead of C-MYC and KLF4 (Yu et al., 2007). 
The reprogrammed human somatic cells met all defining criteria for ES cells 
suggesting that different transcription factors can stimulate each other’s 
synthesis which in turn leads to a common pluripotent ground state, or, 
alternatively, different routes can lead to the pluripotency state (Stadtfeld and 
Hochedlinger, 2010).  
Nakagawa et al. examined whether iPS cells can be generated without the MYC 
transgene (Nakagawa et al., 2008). Mouse and human fibroblast were 
transduced with three factors devoid of MYC and cultured without selection for 
at least 2 or 3 weeks. NANOG-GFP expressing colonies appeared ~30 days 
after transduction and NANOG-selected iPS cells displayed human ES-cell 
markers, and differentiated into cell types from the three germ layers. 
Importantly, generated chimeric mice didn’t develop tumours indicating that C-
MYC is not essential for direct reprogramming of somatic cells into iPS cells 
albeit at the cost of reduced reprogramming efficiency and speed. Omitting C-
MYC also selected for high standard iPS cells, reduced the high number of 
background cells and significantly reduced the risk of tumourigenicity in 
chimeras (Nakagawa et al., 2008; Wernig et al., 2008b).  
In subsequent studies the number of genes required for reprogramming was 
further reduced. Both mouse (Kim et al., 2008) and human (Hester et al., 2009) 
neural stem cells (NSCs) which endogenously express high levels of SOX2 and 
C-MYC compared to ES cells have been reprogrammed into a pluripotent state 
using only OCT4/ KLF4 or OCT4/C-MYC, though at lower efficiency than with 
four factors. A single factor reprogramming of human and mouse neural stem 
cells with only OCT4 has been also reported (Kim et al., 2009b; Kim et al., 
2009c). Similarly, dermal papilla (DP) cells from mouse hair follicles which 
212 
 
express high endogenous levels SOX2, C-MYC, and KLF4 can be 
reprogrammed into iPS cells with the single transcription factor OCT4 (Tsai et 
al., 2011). 
Successful reprogramming has also been achieved using subtypes of 
transcription factors, albeit with a decrease in reprogramming efficiency, for 
example SOX1 and SOX3 can be used instead of SOX2, L-MYC and N-MYC 
instead of c-MYC, and KLF2 instead of KLF4 (Blelloch et al., 2007; Okita et al., 
2007; Lai et al., 2011). Direct reprogramming of somatic cells has been also 
achieved by replacing some of the reprogramming transcription factors with 
small molecules. For example, the histone deacetylase inhibitor, valproic acid 
enables efficient reprogramming of human fibroblasts without using KLF4 and 
C-MYC (Huangfu et al., 2008b). Feng at al. reported successful reprogramming 
of MEFs using orphan nuclear receptor, Esrrb in the presence of OCT4, SOX2 
and C-MYC (Feng et al., 2009a). Even OCT4, which was considered to be 
essential for reprograming, has been replaced with an orphan nuclear receptor 
gene, Nr5a2 in iPS cells generation in the presence of ectopic expression of 
SKM. However, Nr5a2 upregulates OCT4 and NANOG through direct binding to 
their promoters, indicating that its ability to promote reprogramming was still 
through the OCT4 route (Heng et al., 2010). Moreover, using chemical 
components as an alternative to transcription factors significantly decreased the 
number of generated iPS cell clones, suggesting that none of these compounds 
can completely substitute the function of a transcription factor (Stadtfeld and 
Hochedlinger, 2010). 
Another challenge before human iPS cells can be used for therapy is 
developing a serum-free, xeno-free, and chemically defined medium, suitable 
for derivation and maintenance of these cells. At first, scientists 
commonly used human ES cell medium containing foetal bovine serum (FBS) 
supplemented with conditioned secretory factors from MEFs (Thomson et al., 
1998), but later, more standardized and better-defined medium to overcome 
xenogeneic -related problems was described. Knock-out serum replacement 
with basic fibroblast growth factor (bFGF) has been successfully used to 
support feeder-based human iPS cell culture. This medium provides more 
standardized and better defined culture conditions compared with serum-
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containing medium. However, it is not an animal free medium as it contains 
lipid-rich bovine serum albumin (Koivisto et al., 2004; Chaudhry et al., 2008). 
Later on, Tenneille Ludwig and colleagues developed serum-free, xeno-free 
culture medium (termed TeSR1) with high levels of FGF-2, lithium chloride 
(LiCl), gamma-aminobutyric acid (GABA), TGF-beta, and pipeolic acid for use in 
feeder-free conditions (Ludwig et al., 2006).  
Currently, the majority of human ES and iPS cell lines are maintained on a 
feeder layer of MEFs because they provide robust growth of their colonies. 
However, since MEFs have complex, undefined, and xenogeneic properties, 
various human cell types have been substituted to support human ES and iPS 
cell growth (Chen et al., 2014). Great progress has been achieved by Richard el 
al. who replaced MEFs with human foetal and adult fibroblast feeders (Richards 
et al., 2002), and Mallon et al. who used human cells from adult tissues such as 
foreskin, uterine endometrium, and marrow-derived stromal cells to grow human 
ES cells (Mallon et al., 2006). However, the use of feeders is not suitable for 
clinical application. Hence, considerable effort has been made to develop 
complete xeno-free environment for derivation and maintenance of iPS cells.  
Xu et al. reported the first attempt to produced feeder-free cultures of human ES 
cells using Matrigel, an animal based extracellular matrix (ECM) preparation, or 
laminin substrates in medium conditioned by MEFs (Xu et al., 2001). Currently 
well-defined and xenogeneic- free extracellular components for the 
maintenance of human ES cells and iPS cells under feeder-free conditions are 
commercially available including CELLstart, StemAdhere, and Synthemax- R 
Surface (Chen et al., 2014).  
7.7 Conclusion and future directions 
In summary, iPS cells seem to meet virtually all the defining criteria of true 
pluripotent stem cells but without the ethical and immunological concerns that 
have limited progress with human ES cells. Furthermore, alternative 
approaches are now becoming established to produce virus/integration free iPS 
cell lines, thereby improving the prospects of clinical translation. Nevertheless, 
the field of iPS cells remains in its infancy and a better understanding of the 
reprogramming process and its effects on the cells is needed in order to 
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develop safer and more quick and efficient approaches for pluripotency 
induction.  
Development of a robust protocol for the differentiation and derivation of a pure 
pool of desired cells to be used in the development of cellular-based therapies 
is also required. Our study, for the first time, provides proof of principle for the 
direct reprogramming of adult human stromal cells derived from urinary tract to 
iPS cells (UT-iPS cells). These UT-iPS cells exhibited typical pluripotent stem 
cell characteristics and showed more propensity toward urothelial and smooth 
muscle stromal cell differentiation as compared to iPS cells obtained from 
human skin fibroblast. As such, UT-iPS cells provide a cellular platform toward 
the development of differentiation protocols and show great promise in clinical 
regenerative medicine and modelling urinary tract disease.  
To direct the differentiation of these cells in vivo to form bladder structures using 
the inductive signalling properties of appropriate mesenchyme would be a great 
step forward from this work as this will potentially reveal information about the 
process of bladder development and bladder stem cells, and also offers the 
ability to characterize these cells with respect to their potential use for 
regenerative medicine and other bio clinical applications such as disease 
modelling, and drug screening. 
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Abstract 
 
Background: Primary culture and animal and cell-line models of prostate and 
bladder development have limitations in describing human biology, and novel 
strategies that describe the full spectrum of differentiation from foetal through to 
ageing tissue are required. Recent advances in biology demonstrate that direct 
reprogramming of somatic cells into pluripotent embryonic stem cell (ESC)-like 
cells is possible. These cells, termed induced pluripotent stem cells (iPSCs), 
could theoretically generate adult prostate and bladder tissue, providing an 
alternative strategy to study differentiation. 
Objective: To generate human iPSCs derived from normal, ageing, human 
prostate (Pro-iPSC), and urinary tract (UT-iPSC) tissue and to assess their 
capacity for lineage-directed differentiation. 
Design, setting, and participants: Prostate and urinary tract stroma were 
transduced with POU class 5 homeobox 1 (POU5F1; formerly OCT4), SRY (sex 
determining region Y)-box 2 (SOX2), Kruppel-like factor 4 (gut) (KLF4), and v-
myc myelocytomatosis viral oncogene homolog (avian) (MYC, formerly C-MYC) 
genes to generate iPSCs. 
Outcome measurements and statistical analysis: The potential for differentiation 
into prostate and bladder lineages was compared with classical skin-derived 
iPSCs. The student t test was used. 
Results and limitations: Successful reprogramming of prostate tissue into Pro-
iPSCs and bladder and ureter into UT-iPSCs was demonstrated by 
characteristic ESC morphology, marker expression, and functional pluripotency 
in generating all three germ-layer lineages. In contrast to conventional skin- 
derived iPSCs, Pro-iPSCs showed a vastly increased ability to generate 
prostate epithelial-specific differentiation, as characterised by androgen 
receptor and prostate-specific antigen induction. Simi- larly, UT-iPSCs were 
shown to be more efficient than skin-derived iPSCs in undergoing bladder 
differentiation as demonstrated by expression of urothelial-specific markers: 
uroplakins, claudins, and cytokeratin; and stromal smooth muscle markers: a-
smooth-muscle actin, calponin, and desmin. These disparities are likely to 
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represent epigenetic differences between individual iPSC lines and highlight the 
importance of organ-specific iPSCs for tissue-specific studies. 
Conclusions: IPSCs provide an exciting new model to characterise mechanisms 
regulating prostate and bladder differentiation and to develop novel approaches 
to disease modelling. Regeneration of bladder cells also provides an 
exceptional opportunity for translational tissue engineering. 
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Abstract
Background: Primary culture and animal and cell-line models of prostate and bladder development
have limitations in describing human biology, and novel strategies that describe the full spectrum of
differentiation from foetal through to ageing tissue are required. Recent advances in biology
demonstrate that direct reprogramming of somatic cells into pluripotent embryonic stem cell
(ESC)-like cells is possible. These cells, termed induced pluripotent stem cells (iPSCs), could theoreti-
cally generate adult prostate and bladder tissue, providing an alternative strategy to study
differentiation.
Objective: To generate human iPSCs derived from normal, ageing, human prostate (Pro-iPSC), and
urinary tract (UT-iPSC) tissue and to assess their capacity for lineage-directed differentiation.
Design, setting, and participants: Prostate and urinary tract stroma were transduced with POU class
5 homeobox 1 (POU5F1; formerly OCT4), SRY (sex determining region Y)-box 2 (SOX2), Kruppel-like
factor 4 (gut) (KLF4), and v-myc myelocytomatosis viral oncogene homolog (avian) (MYC, formerly
C-MYC) genes to generate iPSCs.
Outcome measurements and statistical analysis: The potential for differentiation into prostate and
bladder lineages was compared with classical skin-derived iPSCs. The student t test was used.
Results and limitations: Successful reprogramming of prostate tissue into Pro-iPSCs and bladder and
ureter into UT-iPSCs was demonstrated by characteristic ESC morphology, marker expression, and
functional pluripotency in generating all three germ-layer lineages. In contrast to conventional skin-
derived iPSCs, Pro-iPSCs showed a vastly increased ability to generate prostate epithelial-specific
differentiation, as characterised by androgen receptor and prostate-specific antigen induction. Simi-
larly, UT-iPSCs were shown to be more efficient than skin-derived iPSCs in undergoing bladder
differentiation as demonstrated by expression of urothelial-specific markers: uroplakins, claudins,
and cytokeratin; and stromal smooth muscle markers: a-smooth-muscle actin, calponin, and desmin.
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Mechanisms involved in prostate and bladder development
and differentiation have been implicated in disease [1–3].
Established animal models of prostate and bladder devel-
opment are well characterised; however, despite providing
key insights for differentiation, there are limitations in
translating these findings to the human setting. Similarly,
there are constraints on studying cells lines that forcibly
maintain expression of immortalising genes. Approaches to
human primary cell culture can overcome some of these
issues, although this can be challenging due to the limited
life-span of cultures, biologic variability between patients,
limited material despite cell expansion, and changes in the
phenotype associated with in vitro culture adaptation
[4–6]. An alternative strategy is the use of embryonic stem
cells (ESCs) that can generate foetal and adult prostate and
bladder tissue [7,8], but this approach is limited by ethics
associated with the source of material. However, a recent
landmark discovery by Yamanaka and colleagues demon-
strated that somatic cells can be reset to an embryonic-like
state, termed induced pluripotent stem cells (iPSCs), by the
expression of defined factors [9,10]. Such cells offer an
unparalleled opportunity for regenerative therapies, dis-
ease modelling, and drug screening [11]. However, iPSCs
appear to retain epigenetic imprinting associated with their
tissue type of origin. This phenomenon results in restricted
terminal differentiation into other cell types [12–14].
In this study, we generated, for the first time, iPSCs
derived from human prostate (Pro-iPSCs) and urinary tract
cells (bladder and ureter) (UT-iPSCs). Furthermore, our data
showed that Pro-iPSCs and UT-iPSCs are more efficient in
differentiating into respective prostate and bladder lineages
relative to established skin fibroblast-derived iPSCs, con-
firming the importance of the organ of origin on the
differentiation potential of the reprogrammed cell.
2. Materials and methods
2.1. Cell culture
All surgical specimens were collected according to local ethical and
regulatory guidelines and included written, informed patient consent
(Freeman Hospital, Newcastle Upon Tyne, UK). Patient details from
which successful iPSC lines were established are summarised in Table 1.
Histologic examination confirmed the absence of dysplasia or malig-
nancy. Prostate primary culture was undertaken according to previously
optimised protocols to separate purified epithelial and stromal cellsTable 1 – Details of patients from whom induced pluripotent stem cel
Patent identifier Age, yr Sex 
12380 65 Female Uret
12459 66 Male Blad
for b
12491 48 Male Blad
disor
12502 54 Male Uret
12506 56 Male Blad
11901 66 Male Pros
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were established using a protocol described by Southgate et al. [17].
Detailed protocols for cell culture are provided in Supplement 1. The
homogeneity of the stromal cells that were subsequently transduced
were confirmed by real-time reverse transcription-polymerase chain
reaction (RT-PCR) using a panel of cell lineage markers (CD24 epithelial,
CD45 haematopoietic, von Willebrand factor endothelial, CD146
endothelial, a-smooth-muscle actin [SMA] stromal smooth muscle,
and Thy-1 cell surface antigen [CD90] stromal cells).
2.2. Lentivirus transduction
Pure cultures of 5  104 prostate, bladder, and ureter stromal cells were
transduced using a polycistronic lentiviral vector (POU class 5 homeobox
1 [POU5F1, formerly OCT4], SRY [sex determining region Y]-box 2 [SOX2],
Kruppel-like factor 4 (gut) [KLF4], and v-myc myelocytomatosis viral
oncogene homolog [avian] [MYC, formerly C-MYC]; Allele Biotech, San
Diego, CA, USA) at a multiplicity of infection of 10 in the presence of
polybrene (10 mg/ml) and transduction medium (RPMI1640 medium with
HEPES modification; Sigma-Aldrich Co, St. Louis, MO, USA) containing 10%
foetal calf serum (Sigma-Aldrich Co, St. Louis, MO, USA), L-glutamine
(2 mM), and 1% penicillin and streptomycin (Invitrogen Corp, Carlsbad, CA,
USA). On day 2, the transduction medium(including lentiviralvectors) was
replaced with standard stroma culture medium. On day 6, cells were
seeded onto gelatine-coated plates with a feeder layer of irradiated
CF-1 mouse embryonic fibroblasts (MEFs) (MTI-GlobalStem, Rockville,
MD, USA) in human ESC medium (Knockout Dulbecco’s modified Eagle’s
medium, 1 mM L-glutamine, 100 mMnonessential aminoacids, 20%serum
replacement, and 8 ng/ml fibroblast growth factor [FGF] 2 [Invitrogen Corp,
Carlsbad, CA, USA]). Additional details on optimisation of these protocols
are available in Supplement 1. After an additional week, cells were cultured
in MEF-conditioned ESC medium. ESC-like colonies were manually
selected based on morphology between 4 and 6 wk. The medium was
changed every 48 h. A similar protocol was applied to epithelial cells but
was unsuccessful in iPSCs generation; it is described in Supplement 1.
2.3. Characterisations by polymerase chain reaction, DNA
fingerprinting, karyotyping, immunofluorescence, and alkaline
phosphatase staining
RNA isolation and real time RT-PCR was normalised to glyceraldehyde
3-phosphate dehydrogenase according to protocols described in
Supplement 1. DNA fingerprinting was based on microsatellite markers
for short tandem repeats and karyotyping was determined by Giemsa
banding. Details about this and about alkaline phosphatase activity
detection and immunofluorescence are described in Supplement 1.
2.4. Assays of pluripotency
In vitro and in vivo differentiation assays, and embryoid body and
teratoma formation were undertaken using established protocols and
are detailed in Supplement 1.ls lines were established
Nature of tissue biopsy
er biopsy from radical nephrectomy for renal cell carcinoma
der biopsy from cystoprostatectomy undertaken as part of urinary diversion
enign functional disorder (secondary to urethral injury and bowel surgery)
der biopsy from cystoprostatectomy for benign, functional, neurologic
der
er biopsy from radical nephrectomy for renal cell carcinoma
der biopsy from cystoprostatectomy for benign functional neurologic disorder
tate biopsy from cystoprostatectomy for bladder cancer
rinary Tract Differentiation, Tissue Regeneration, and Disease:
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pluripotent stem cells in vitro
MEFs were removed for differentiation studies. For the induction of
prostate differentiation, Pro-iPSCs were cultured with primary prostate
stroma-conditioned medium. For bladder differentiation, UT-iPSCs were
cultured with conditioned medium for 14 d using a previously established
protocol [18]. Details of the conditioned medium from either cultured
human urothelial cells or stroma cells are described in Supplement 1.
Comparison of differentiation potential was drawn against conventional
human-skin iPSCs, which is a pre-established cell line [19].
2.6. Statistical analysis
All results are expressed as mean plus or minus the standard error, and
statistical differences assessed using the student t test with p values
0.05 considered significant.Fig. 1 – (A) Timeline for induced pluripotent stem cell (iPSC) generation. (B) Ex
embryonic stem cell (ESC)–like morphology. (C) Immunofluorescence of generat
specific embryonic antigen-4 (SSEA4), tumour rejection antigen (TRA)-1-81, TR
POU class 5 homeobox 1(POU5F1, formerly OCT4). Note mouse embryonic fibrob
marker expression. Nuclei were stained with 40 ,6-diamidino-2-phenylindole (bl
markers are shown in their expected distribution.
hESC = human embryonic stem cell; Pro-iPSC = prostate induced pluripotent st
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3.1. Generation of induced pluripotent stem cells from normal
ageing prostate and human urinary tract cells
Once primary cultures of prostate, bladder, and ureter
stromal cells were established, we examined the purity of
fibroblast lineage. Following passage, there was an inherent
culture-based selection for fibroblasts based on cell mor-
phology and lineage-marker expressions. Morphologically,
cells were consistent with primary, prostate stromal fibro-
blasts and were confirmed to be devoid of endothelial,
epithelial, and haematopoietic contamination following the
first passage (Supplemental Fig. S1A and S1B). Pure bladder
and ureter stromal cells expressing smooth muscle andample of established iPSC colonies growing on a feeder layer with human
ed iPSCs for the expression of specific human ESC surface markers: stage-
A-1-60, and nuclear transcription factors Nanog homeobox (NANOG) and
last (MEF) cells at the periphery of the colonies are negative for stem cell
ue) (scale bar = 100 mm), and specific cellular localisation of the stem cell
em cell; UT-iPSC = urinary tract induced pluripotent stem cell.
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at second passage, associated with typical stromal-cell
appearance (Supplemental Fig. S2A and S2B). Polycistronic
lentiviral vectors containing the four transcription factors
POU5F1, SOX2, KLF4, and MYC were transduced into pure
stromal cells. A schedule for human iPSC reprogramming is
summarised in Figure 1A. Seven days following lentiviral
transduction, fibroblasts demonstrated features of mesen-
chymal to epithelial transition, which is typical of early
reprogramming [20]. Mesenchymal to epithelial transition
was characterised by a change in the prostate fibroblast
morphology from spindle-shaped cells to classic, epitheloid,
cobblestone colonies, and was confirmed by marker expres-
sion showing upregulation of epithelial marker E-cadherin
and downregulation of mesenchymal markers snail homolog
1 and 2 (Drosophila) (dubbed Snail and Slug, respectively)
( p < 0.05) (Supplemental Fig. S1C). Four week to 5 wk after
transduction with the lentivirus, several small and tight cell
colonies were detected; however, they grew slowly and so
were not consistent with ESC-like cells (Supplemental
Fig. S2C). By week 6 after transduction, rapidly growing
colonies displaying morphology similar to that of humanFig. 2 – (A) Alkaline phosphatase staining of induced pluripotent stem cell (iPS
negative control cells with no staining. (B) Reverse transcription–polymerase c
transgene expression in iPSCs. Control represents stromal cells 6 d after transd
class 5 homeobox 1 (POU5F1, formerly OCT4), SRY (sex determining region Y)-bo
growth differentiation factor 3 (GDF3), DNA (cytosine-5-)-methyltransferase 3 
iPSCs. All values were calculated with respect to the value for H9 human embr
Pro-iPSC = prostate induced pluripotent stem cell; UT-iPSC = urinary tract indu
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edges composed of small cells with a high nucleus-
to-cytoplasm ratio) (Fig. 1B, Supplemental Fig. S1D and
S2D). Eleven prostate and 31 urinary tract ESC-like colonies
(17 bladder and 14 ureter) were successfully expanded and
stably maintained throughout culture passages (>50 pas-
sages, >10 mo). The overall efficiency in generating Pro-iPSCs
and UT-iPSCs was low (0.02–0.04% of all stromal cells
transfected), but was comparable to the reported efficiency of
iPSCs generated from human dermal fibroblasts [21].
Karyotyping confirmed a diploid 46,XY chromosome
arrangement (Supplemental Fig. S1E and S2E). Authentica-
tion of Pro-iPSCs and UT-iPSCs derivation from parental
stromal cells was confirmed using DNA fingerprinting
(Supplemental Fig. S1F and S2F).
3.2. Characterisation of generated induced pluripotent stem
cells
Immunofluorescence for human, ESC-specific, surface
markers—stage-specific embryonic antigen-4, tumour
rejection antigen (TRA)-1-81, and TRA-1-60, and alsoC) colonies. Note underlying mouse embryonic fibroblast cells act as
hain reaction (RT-PCR) analysis demonstrating silencing of exogenous
uction. (C) Real-time RT-PCR analysis for expression of endogenous POU
x 2 (SOX2), and other stem cell marker genes: Nanog homeobox (NANOG),
beta (DNMT3B) and ZFP42 zinc finger protein (ZFP42, formerly REX1) in
yonic stem cell, which was set to 1.
ced pluripotent stem cell; ENDO = endothelial.
rinary Tract Differentiation, Tissue Regeneration, and Disease:
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Fig. 3 – Pluripotency in prostate induced pluripotent stem cells
(Pro-iPSCs) and urinary tract induced pluripotent stem cells (UT-iPSCs).
(A) Immunofluorescence analysis of embyroid bodies derived from iPSCs
shows expression of the lineage markers bIII-tubulin (ectodermal
marker; red), CD31 (mesodermal marker; green), and a-fetoprotein
(endodermal marker). Nuclei were counterstained with 40 ,6-diamidino-
2-phenylindole (blue) (scale bar = 100 mm). (B) Left: Histologic section of
teratoma formed from Pro-iPSCs showing neuronal epithelial
differentiation. Right: UT-iPSCs representing all three embryonic germ
layers: ectoderm (neuronal rosette-like structures), mesoderm (muscle-
like tissue), and endoderm (intestinal epithelial-like cells).
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POU5F1—was confirmed (Fig. 1C). Additionally, alkaline
phosphatase activity, typical of an ESC phenotype, was
demonstrated in the induced cells (Fig. 2A). Exogenous
transgene silencing is associated with the generation of iPSCs,
where there is a critical switch to endogenous expression of
key ESC regulatory factors such as POU5F1, SOX2, and NANOG.
Real-time RT-PCR using primers specific for lentiviral
transcripts demonstrated that exogenous transgene expres-
sion had ceased in both Pro-iPSC and UT-iPSC clones (Fig. 2B).
Furthermore, endogenous expression of the pluripotency
markers POU5F1, SOX2, and NANOG, in addition to ESC
markers growth differentiation factor 3 (GDF3), DNA (cyto-
sine-5-)-methyltransferase 3 beta (DNMT3B), and ZFP42 zinc
finger protein (ZFP42, formerly REX1) in both Pro-iPSCs and
UT-iPSCs was consistent with expression levels in the control
human-ESC line H9 (Fig. 2C). The iPSC clones were identical in
terms of ESC-like morphology, proliferation, and gene-
expression signatures (data not shown).
3.3. Pluripotency of generated induced pluripotent stem cells
When cultured in suspension on low-adhesion plates in the
absence of basic FGF, both Pro-iPSCs and UT-iPSCs formed
embryoid bodies containing all three germ-layer deriva-
tives, as demonstrated by immunofluorescence of lineage-
specific markers bIII tubulin (ectoderm), CD31 (mesoderm),
and a-fetoprotein (endoderm) (Fig. 3A). Xenografts from the
in vivo teratoma-forming assay also confirmed ectoderm,
mesoderm, and endoderm lineage histology (Fig. 3B).
3.4. Prostate induced pluripotent stem cells differentiate into
androgen receptor and prostate-specific antigen–expressing cells
We compared the differentiation potential of Pro-iPSCs with
conventional skin-derived iPSCs (skin-iPSCs). Following
induced differentiation by prostate stromal-cell condi-
tioned medium for 3 wk, both Pro-iPSCs and skin-iPSCs
displayed epithelioid cell morphology. Transcripts of
epithelial marker CD24 were detected at comparable levels
to primary prostate epithelium (data not shown). When
characterised with the prostate differentiation markers
androgen receptor (AR) and prostate-specific antigen (PSA),
the prostate-specific phenotype was restricted to Pro-iPSCs
(Fig. 4). AR expression was present in the differentiated Pro-
iPSCs and the degree of immunofluorescence was at levels
comparable with mature prostate epithelium in early
primary culture (day 10), whereas only minimal levels of
AR were detected in skin-iPSCs (Fig. 4A). Functional AR was
confirmed by PSA transcript and protein expression at levels
in keeping with primary, cultured, prostate epithelia,
whereas no PSA expression was detected in the differentia-
tion medium-treated skin-iPSCs (Fig. 4B).
3.5. Urinary tract-induced pluripotent stem cells differentiate
into uroplakin-expressing cells
Lineage-specific differentiation of the UT-iPSCs into bladder
lineages was assessed using established coculture methodsPlease cite this article in press as: Moad M, et al. A Novel Model of U
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10.1016/j.eururo.2013.03.054[18]. In comparison to cells derived from skin-iPSCs, UT-
iPSCs were significantly more efficient at inducing bladder-
specific differentiation, as demonstrated by urothelial
differentiation-specific genes (UPIb, UPII, UPIIIa, and UPIIIb;
claudin 1 [CLD1], claudin 5 [CLD5] and keratin 7 [CK7]) and
markers specific for smooth-muscle cells (a-SMA, calponin,
and desmin) (Fig. 5A). Furthermore, the effect of condi-
tioned medium from urothelia was compared with that of
conditioned medium from stromal cells (Fig. 5B). Similar to
the embryogenesis of the urinary tract, where there is a
reciprocal differentiation of epithelial and mesenchymal
fractions [22], both urothelial and stromal differentiation
was concurrently induced using either urothelial- or
stromal-conditioned medium (Fig. 5A and 5B). UPIb proteinrinary Tract Differentiation, Tissue Regeneration, and Disease:
d Pluripotent Stem Cells. Eur Urol (2013), http://dx.doi.org/
Fig. 4 – Prostate-specific differentiation of prostate induced pluripotent stem cells (Pro-iPSCs). (A) Relative messenger RNA (mRNA) expression of androgen
receptor (AR) in Pro-iPSCs before and after differentiation (control levels in primary prostate stroma and epithelia shown) (n = 6). Right:
Immunofluorescence staining for AR (green) shown in Pro-iPSCs and skin-iPSCs. AR is induced in Pro-iPSCs only, with functional activity suggested by
nuclear AR localisations (blue 40 ,6-diamidino-2-phenylindole [DAPI] counterstain). (B) Relative mRNA expression of prostate-specific antigen (PSA) in
Pro-iPSCs before and after differentiation (control levels in primary prostate stroma and epithelia shown) (n = 3). Immunofluorescence staining for PSA
(green) shown in Pro-iPSCs and skin-iPSCs. PSA is induced in Pro-iPSCs only (blue DAPI counterstain).
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confirmed in differentiated cells derived from UT-iPSCs
after 2 wk in urothelial-conditioned medium (Fig. 5C).
4. Discussion
We report for the first time successful reprogramming of
normal, human, ageing prostate, bladder, and ureter
stromal fibroblasts to an ESC-like pluripotent state. These
cells were validated as de facto iPSCs by confirming their
ability for sustained self renewal, silencing of exogenous
transgenes, expression of ESC-specific genes, and pluripo-
tent differentiation into all three germ lineages. Further-
more, within the appropriate inductive environment,
prostate epithelial-specific differentiation with induced
functional AR, as characterised by PSA expression, was
demonstrated and UT-iPSC differentiation could be directed
into urothelial-specific lineages. These models allow for
enormous scope in future studies of differentiation, tissue
engineering, disease mechanisms, and drug development.
Since the first descriptions of iPSCs in 2006, most reports
have focused on the generation of iPSCs from a range of
normal and diseased tissues. In our work, we generated
multiple clones of UT-iPSCs from multiple donors and sites
(bladder and ureter), and multiple clones of Pro-iPSCsPlease cite this article in press as: Moad M, et al. A Novel Model of U
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10.1016/j.eururo.2013.03.054from a single donor. All clones were comparable to both
skin-iPSCs and ESCs in terms of ESC-marker expression and
pluripotency potential, supporting the generalisability of
these methods to urologic tissues. Researchers exploring
further differences in ability for terminal organ-specific
differentiation among the iPSC lines derived from different
organs have found that not all iPSCs are the same in this
respect [13]. We compared the differentiation potential of
Pro-iPSCs and UT-iPSCs with skin-iPSCs and our results
demonstrated vast differences in their capabilities for
prostate- and bladder-specific differentiation. These find-
ings are consistent with emerging evidence that epigenetic
imprinting, specific to the tissue type of iPSC origin, remains
intact throughout the mechanism of stem cell reprogram-
ming and may limit the potential for terminal differentia-
tion into all cell types [12–14]. Our data emphasise the
importance of the source from which iPSCs are generated as
a consideration for organ-specific development studies.
Although we confirmed prostate-specific differentiation,
additional work is required to determine whether Pro-iPSCs
can generate the full breadth of epithelial differentiation. In
addition, it would be of interest to investigate if these cells
differentiate through somatic stem cell phenotypes or
directly into basal and luminal cells, in keeping with an
alternative model that proposes that epithelial stem cellsrinary Tract Differentiation, Tissue Regeneration, and Disease:
d Pluripotent Stem Cells. Eur Urol (2013), http://dx.doi.org/
Fig. 5 – Expression of urothelial and smooth-muscle lineage-specific transcripts in differentiated cells derived from urinary tract induced pluripotent stem
cells (UT-iPSCs) and skin-iPSCs by reverse transcription-polymerase chain reaction on day 14. Messenger RNA levels are shown as a fold change relative to
control (undifferentiated cells) (n = 3). (A) Expression of urothelial-specific markers (UPIb, UPII, UPIIIa, UPIIIb, claudin 1 [CLD1], claudin 5 [CLD5], keratin
7 [CK7]) and smooth-muscle-specific markers (a-smooth muscle actin [a-SMA], calponin, desmin) induced with conditioned medium from urothelium.
(B) Expression of urothelial- and smooth-muscle–specific markers induced with conditioned medium from stroma. (C) Immunofluorescence of
differentiated cells derived from UT-iPSCs treated with conditioned medium, at day 14, showing (left) bright field; (centre) positive staining for UPIb (red)
juxtaposed with an area of UPIb-negative staining, with 40 ,6-diamidino-2-phenylindole nuclear counterstain (blue); and high magnification of UPIb
immunostaining (scale bar = 100 mm).
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of the prostate (urogenital sinus epithelium) [23]. Also of
interest would be further in vivo study of prostate epithelial
development and organisation from iPSCs, especially given
the considerable debate about the nature of the somatic stem
cell in prostate epithelium. Recent evidence has shown that
in early, postnatal, mouse prostate development, epithelial
homeostasis is maintained by basal multipotent stem cells
that differentiate into basal, luminal, and neuroendocrine
cells, as well as by unipotent basal and luminal progenitors
[24]. In contrast, in situ assays in the human adult setting
have revealed that epithelial hierarchical organisation is
based on a common stem cell [25]. The Pro-iPSC model is well
placed to explore these differences with lineage trackingPlease cite this article in press as: Moad M, et al. A Novel Model of U
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10.1016/j.eururo.2013.03.054studies. Furthermore, the generation of ESC-like Pro-iPSCs
are of particular interest to the study of prostate disease,
where benign prostatic hyperplasia has been associated with
models of embryonic reawakening [26] and prostate cancer
can be associated with ESC-marker expressions [27].
Atala and colleagues reported the first human clinical trial
with engraftment of both urothelial and smooth-muscle
stromal cells into acellular biomaterials for bladder engi-
neering and reconstruction [28]. However, these strategies
rely on ex vivo cell culture to generate sufficient quantities
and quality of autologous cells. Although even small biopsies
of normal urothelium can be readily expanded before
undergoing senescence, this is significantly restricted in
diseased tissue [29]. We were unsuccessful in preliminaryrinary Tract Differentiation, Tissue Regeneration, and Disease:
d Pluripotent Stem Cells. Eur Urol (2013), http://dx.doi.org/
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was not pursued given that the stroma-based UT-iPSCs
demonstrated ability to differentiate into urothelium. In
clinical applications for regenerative medicine, this phenom-
enon also provides the additional attraction of using an
alternative, genetically normal tissue source in urothelial
malignancies for reconstruction. However, concerns about
induction of malignancies from iPSCs persist and are being
cautiously tackled with refinements in induction methods
that include virus-free and transgene-free reprogramming
and xeno-free approaches [30]. Alternative approaches are
now becoming established to realise this ambition, including
vector-free human-iPSC generation using episomal-factor
delivery, and feeder-free and albumin-free culture [31]. As
such, UT-iPSCs show great promise in clinical regenerative
medicine and modelling urinary tract disease.
5. Conclusions
Human prostate and urinary tract tissue can be used to
generate iPSCs that can be differentiated back into their
parent organ lineages. The generation of Pro-iPSCs and
UT-iPSCs provides a convenient ready-to-access model that
offers considerable potential for studies of normal and
diseased prostate and bladder biology.
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